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OUTLINE 
 
This thesis describes the applications of NMR-linked metabolomics analysis to urine 
and plasma samples collected from human Niemann Pick, type C1, (NP-C1) patients and their 
corresponding controls, together with the analysis of hepatic tissue from a mouse model of 
this disease, in order to explore metabolic alterations arising from the disease process, and 
also to seek valuable biomarkers for the purpose of diagnosing and monitoring its 
progression.  
The first Chapter (Chapter 1) provides an introduction to the main techniques 
employed in this work. A summary of NMR theory has been included in order to explain how 
this analytical technique operates, its applicability to the field of biofluid and tissue samples 
analysis, and how useful it is as a diagnostic tool. The field of metabolomics will also be 
described, together with the historical evolution of the methodologies employed. Chapter 1 
is also focused on the disease of study, Niemann-Pick, type C1 (NP-C1). The biochemical 
processes underlying this disease, the pathophysiological manifestations experienced by 
afflicted patients (with special reference to liver dysfunction and damage), together with the 
current status of treatment, specifically that involving the pharmacological agent miglustat, 
and disease diagnosis will be also explained. 
Chapter 2 describes the resolution of the urinary 1H NMR profile of NP-C1 patients, 
which is of major utility in the metabolomics-linked data analysis performed. The 
information extracted therefrom was subjected to differing multivariate analysis (MVA) 
strategies in order to classify these patients according to their disease status. Indeed, ROC 
curve analysis was employed for the purpose of assessing the classification success rate of 
 
 
xi 
 
the models developed for this urinary dataset in order to seek valuable biomarkers for this 
lysosomal storage disease. NMR analysis of urine samples from NP-C1 patients receiving 
therapies such as miglustat was also explored in order to detect this agent in their urinary 1H 
NMR profiles; accordingly, the solution structure of this drug was also investigated  by NMR 
analysis.  
Chapter 3 outlines the 1H NMR-linked metabolomics analysis performed on blood 
plasma samples collected from NP-C1 patients, healthy individuals, heterozygous disease 
carriers, together with NP-C1 patients undergoing miglustat treatment. The Random Forests 
(RFs) strategy was employed to classify these samples based on their classifications. A brief 
discussion regarding the methodology employed for the acquisition of 1H NMR spectra on 
these samples is also included. Finally, comparisons between the 1H NMR plasma profiles 
acquired from all the different patients/participants in the study are conducted, along with 
an evaluation of plasma metabolites as possible NP-C1 disease biomarkers. 
Chapter 4 describes the NMR analysis performed on liver samples collected during 
the development of NP-C1 in a mouse model of the disease, since this organ plays a crucial 
role in this disorder. The dataset extracted from the multicomponent 1H NMR analysis of 
aqueous extracts of these samples were analysed by RFs in order to extract valuable 
information regarding the disease classification of these hepatic tissue extracts. Additionally, 
the correlation of such metabolic changes to the progression of the disease was investigated, 
in addition to the redox status of the hepatic tissue. 
In Chapter 5, the ability of a newly-developed statistical MVA method, Correlated 
Component Regression, to successfully perform in a metabolomics context was evaluated, 
along with its dependence on the number of variables and components employed to build 
 
 
xii 
 
such classification models, specifically those arising from the urinary and hepatic NP-C1 
datasets. Both datasets will also serve to compare the variables ranking obtained after a 
cross-validated RFs analysis to a Recursive Feature Elimination (RFE) variant of the same 
method for variable selection. 
In Chapter 6, all the metabolic pathways and biochemical processes that can be 
affected in NP-C1 disease process are discussed according to the outcomes obtained in the 
previous sections, and will be compared and contrasted with corresponding information 
available in the literature. Furthermore, some metabolites will be proposed as valuable 
biomarkers for the diagnosis and stratificational prognosis of NP-C1 disease. 
In Chapter 7 the conclusions arising from this work will be discussed, including the 
utility of the metabolites selected as discriminatory urinary and blood plasma biomarker 
features for the diagnosis of NP-C1, together with outcomes from the NMR analysis of liver 
tissue samples. The classificational abilities of the RFs-Recursive Feature Elimination and 
CCR-LDA MVA strategies in a metabolomics context is also delineated. 
 
 
 
 
 
 
 
 
 
xiii 
 
ABSTRACT 
 
NMR-linked metabolomics analysis was employed to investigate urinary and human 
plasma profiles collected from Niemann Pick type C1 disease patients (NP-C1), in addition to 
aqueous extracts of liver samples of an NP-C1 mouse model. NP-C1 is a lysosomal storage 
disorder caused by mutations in the lysosomal proteins NPC1 and NPC2, which are involved 
in lysosomal cholesterol trafficking. NP-C1 disease is a fatal genetic disorder, characterised 
by neurodegeneration and hepatic damage. Miglustat (MGS) is the only approved drug for 
this disease, and consequently, plasma and urine samples collected from MGS-treated 
patients were also investigated. 
The ability of 1H NMR analysis to detect a wide range of metabolites simultaneously 
served to characterize the metabolic profiles of urine, plasma and hepatic tissue samples 
investigated in order to perform linked multivariate analysis (MVA). Additionally, MGS was 
identified in urine samples collected from NP-C1 treated patients. MVA employing both 
parametric and machine learning-based techniques was conducted to classify samples 
according to their disease status, and also to seek biomarkers that could aid in the diagnosis 
and/or prognosis of the disease. Moreover, a new technique was introduced in a 
metabolomics context, Correlated Component Regression (CCR), and the suitability of 
Random Forests (RFs) for variable selection was also explored.  
We were able to differentiate urine samples collected from NP-C1 patients from 
those collected from heterozygous controls, and also propose several metabolites as NP-C1 
urinary biomarkers such as bile acids, 2-hydroxy-3-methylbutyrate, 3-aminoisobutyrate, 5-
aminovalerate, trimethylamine, methanol, creatine and quinolinate. The 1H NMR linked 
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metabolomics study of plasma samples revealed major distinctions among the groups 
investigated, metabolic alterations ascribable to the disease pathology were mainly 
observed as changes in the lipoprotein profiles of NP-C1 patients. Hepatic tissue extracts 
analysed revealed major disturbances in amino acid metabolism, along with impairments in 
the NAD+/NADH production and redox status. Gut microbiota and bile acid metabolism were 
also highlighted as features altered in NP-C1 disease. 
CCR linked to Linear Discriminant Analysis was evaluated as a new tool for 
metabolomics analysis, giving accurate results when compared to alternative techniques 
tested. Additionally, the suitability of Random Forests and associated recursive feature 
elimination for variable selection in metabolomics studies was contrasted, suggesting that 
those strategies relying on a variable ranking to select the top features for discrimination are 
more suitable for metabolomics investigations than those that iteratively remove a 
percentage of the least effective features until the classification performance decays. 
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CHAPTER 1  
 
INTRODUCTION 
 
 
1.1. NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY (NMR) 
NMR is a spectroscopic technique based on the magnetic properties of nuclei. The 
effect of the magnetic field on the nuclei was first discovered by Rabi et al. in 1939 (1), when 
he performed an experiment based on sending a stream of hydrogen atoms through an 
homogeneous magnetic field which was additionally subjected to a radiofrequency field; 
these researchers found that some energy was absorbed by the molecules at a defined 
frequency, and this absorption caused a small-but-detectable deflection of the beam (1). 
This was the first observation of NMR, and Rabi received the Nobel Prize in 1944 based on 
his contribution towards the birth and development of this technique.  
Nuclear spin (I) is an intrinsic form of angular momentum (p) possessed by atomic 
nuclei which contain an odd number of protons or neutrons. The value of I is characteristic 
for each isotope.  
 
𝑝 = 𝐼
ℎ
2𝜋
                       (1) 
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A proton has a spin associated about an axis, which is a form of angular momentum, 
p. This spin presents an associated magnetic moment, μ. The correlation between both 
parameters is given by the gyromagnetic ratio, γ. 
 
𝛾 =
𝜇
𝑝
                                                             (2) 
 
Without a magnetic field, nuclear spin are orientated randomly; however, when the 
sample is placed in an external magnetic field, nuclei with positive spin are orientated in the 
same direction as this magnetic field, in the minimum energy state. However, nuclei with 
negative spin are orientated in the opposite direction, and this anti-parallel orientation has 
the higher energy. This effect on the orientation of nuclei in a magnetic field is known as the 
Zeeman Effect. 
When a bulk sample of hydrogen nuclei (protons) is placed in a magnetic field, it is 
expected that such particles are distributed equivalently, following the Boltzmann 
distribution, in both low and high energy states, through their parallel and anti-parallel spin 
orientations. The allowed orientations (m) are determined by the relation 2I + 1, and which 
is described by the magnetic quantum number, which takes values from -I to +I. For instance, 
in the proton case where I = 1/2, then m assumes values of -1/2 and +1/2. However, after a 
certain time (known as relaxation time), this sample of protons will attain thermal 
equilibrium with respect to the magnetic field (2).  
It is possible to induce the movement from the lower energy state to the higher 
energy state by applying radiation in the radiofrequency region to the sample. The energy of 
this transition, and hence, the frequency associated with it, and which is absorbed by the 
nuclei to accomplish the transition to the higher energy state, is given by the Bohr condition: 
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𝜈 =
𝛾𝐵0
2𝜋
                       (3) 
 
The nucleus under the magnetic field B0 along the z-axis (in this case) draws a 
precession movement around this axis [Figure 1(b)] since the alignment with Bo cannot be 
completely achieved. The angle has a defined value since it is quantizated (cos θ = m/I). The 
angular velocity of this precession movement is given by the Larmor equation: 
 
𝜔0 = 𝛾𝐵0                       (4) 
 
 This radiation has the same energy as the differing orientations, which is the 
resonance frequency of the system, known as Larmor frequency. In order to detect this 
effect, a vector M0 (magnetization vector) must be rotated away from z-axis towards the x,y-
plane. In view of the strong B0 applied to the sample, the only means to displace M0 is to 
supply an RF pulse orthogonal to B0 (along the x-axis) oscillating at the Larmor frequency of 
our nuclei, i.e. achieving resonance (3). This pulse is known as a 90o pulse [Figure 1(c)], since 
it rotates the magnetization 90o. Once the magnetization has been transferred to the x,y-
plane, and therefore nuclei are precessing about it, the electrical current generated can be 
detected by a receiver coil.  
Resonance causes transitions between both energy states [Figure 1(a)], and 
therefore nuclei can move to the maximum energy state. These two orientations are termed 
α (m = ½) and β (m = -½) respectively. Since more protons will have the lower-energy parallel 
orientation, a radio signal at the resonance frequency will be absorbed, and hence generate 
more upward transitions. When nuclei return to their minimum energy state, they are 
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required to lose that energy since it is a non-equilibrium state; subsequently, they emit the 
electromagnetic signal, termed Free Induction Decay (FID), which is detected by the receiver 
coil. The loss of this energy is conditioned by two parameters, T1 and T2. T1 is the spin-lattice 
or longitudinal relaxation time which leads to the recovery of Mz (achievement of thermal 
equilibrium); and T2 is the spin-spin or transverse relaxation time which involves the decay 
of the Mxy magnetization. 
 
 
Figure 1.1. (a) Energetic sub-levels present when a nucleus with non-zero spin (1/2 in this 
case) is placed in a magnetic field. (b) Precession movement of nuclei around the z-axis at 
which B0 has been applied. (c) Direction of the magnetization vector My in the rotating frame 
system. Abbreviations: RF, RadioFrequency pulse emitted along x-axis. 
 
In order to simplify the explanation of the pulse sequences employed in this work, 
the ‛vector model’ proposed by Block (4) will serve as a reference: after applying B1, M0 
moves towards B1, and both M0 and B1 are precessing around B0, originating a system that is 
complicated to represent. Furthermore, the rotating frame is introduced for purposes of 
clarity; this representation takes the frame of reference to precess at a frequency ωRF, hence 
B1 seems static and M0 precess around B0 at an offset frequency ω0 - ωRF.  (3). 
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The subsequent Fourier Transform (FT) of the FID provides a normal NMR spectrum 
with absorption signals at frequencies that represent the energy difference between the 
basal and excited states (2). This operation was implemented in 1966 by Anderson and Nerst 
(5), and was based in the previous discoveries made by Lowe and Norberg in 1957 (6). In 
summary, this transformation converts a signal described as a function of time into one 
within the frequency domain.  
In nuclear magnetism, not only are the nuclei involved, but also the electrons 
surrounding them, and these electronic effects are responsible for the differences in the 
locations of the resonances in conventional spectra. Nuclei’s behaviours in the magnetic field 
can be influenced by different effects, providing information such as: 
 
Environment and atoms linked to each nucleus (chemical shift, δ): In molecules, the 
nuclei are magnetically-deshielded or -shielded; the effective field at the position of nuclei is 
different from the externally-applied field. This phenomenon is attributable to the 
distribution of ‛electron density’ within the molecule, mainly around the protons and bonds 
involving these. Those groups with more electronic density around themselves experience 
an effective magnetic field lower than the one originally applied, this is the case for the 
methyl group at the terminus of a hydrocarbon chain, for example. Contrarily, those groups 
with less electronic density experience a more intense magnetic field (≤ B0, though), so that 
they are deshielded, such as those adjacent to carbonyl groups. The chemical shifts are 
therefore considerably affected by substituents which specifically influence this electron 
distribution; for instance, electronegative groups will pull away the electrons of 
neighbouring groups towards themselves, generating a deshielding effect, and therefore 
giving rise to a more downfield-shifted signal. 
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Number of nuclei (peak integral): The relative intensity from a resonance signal can 
be correlated with the number of nuclei that generate that signal. It is therefore possible to 
quantitatively estimate the proportions of different protons within the molecule, and this 
involves determinations of the area under the resonance peak. 
 
Number and placement of nuclei (multiplicity): In view of the electronic distributions 
in a bond, two linked nuclei retain the spin information of each other. The energy difference 
between the two energy levels is modified by the other nuclei, and therefore if electrons of 
one nucleus are in the excited state (higher energy level), the energy difference of 
contiguous nuclei will be increased, and vice-versa. Furthermore, two different energy sub-
levels will appear for each case, both of them higher or lower than the initial state. This 
phenomenon is known as spin-spin coupling, and consequently, the splitting of resonances 
is observed. The separation between the different multiplet lines of the same resonance 
signal is known as the coupling constant, J. It is calculated as the distance in Hz between 
these resonance lines.  
 
1.1.1. Water suppression experiments 
A simple pulse sequence involves the application of a 90o pulse (this value can be 
diminished to speed up the experiment) followed by the data acquisition, in which the FID is 
recorded. However, in NMR-linked metabolomics studies, the presence of water in the 
samples investigated is a common issue, since serum, urine, cerebrospinal fluid (CSF), etc., 
are all water-based biofluids. The relative concentration of metabolites in these fluids is 
minimal when compared to that of water, and therefore, the signal arising from H2O 
dominates the majority of the 1H single pulse spectra. In order to overcome this issue, water 
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suppression experiments are employed. The pulse sequences utilised in these experiments 
remove (partially) the water signal through different approaches. Two of the most commonly 
employed techniques used in metabolomics are NOEPR (Nuclear Overhauser Effect pulse 
train with presaturation during relaxation and mixing time) (7), and PRESAT (Presaturation) 
(8). Single-pulse spectra without suppression of the solvent signal present the main issue of 
signal overlap, and also overloading of the receiver, generating baseline distortions (wiggles) 
if the receiver gain value is very high, or inadequately digitized signals if this value is set very 
low to allow the acquisition of the massive solvent peak (9).  
 
PRESAT: This is a two-pulse experiment that utilizes a relatively long (seconds), low 
power RF pulse to selectively saturate (the solvent) at a specific frequency by irradiating 
during the relaxation delay (RD), and with a non-selective pulse to excite the full spectrum 
of resonances (8). The long power pulse is of the order of the solvent T1, so that it does not 
allow it to relax, and consequently its signal is suppressed. As noted above, this presaturation 
pulse is relatively long, so that the hydrogen atoms of -OH, -NH and -NH2 groups that 
chemically exchange with water are also saturated, and therefore they are unobservable or 
attenuated (for instance, the urea signal detectable in urine) (10). The pulse sequence works 
as follows: Presat (RD) - 90ox. It should be noted that the duration of a pulse is inversely 
proportional to the width of the area excited, and hence the longer the pulse, the narrower 
the spectral bandwidth (11). 
 
 NOEPR: This method is usually employed in conjunction with PRESAT, so that 
suppression of the solvent signal is performed during both the recycle delay and mixing time 
in a pulse sequence structured similarly to that of a NOESY (2D experiment employed to 
 
 
8 
 
observe connections through space). The structure of the pulse sequence is RD-[90°x - t1 - 
90°x - tm - 90°x]. RD is the relaxation delay, during which the water resonance is selectively 
irradiated (presaturation); t1 is a short delay, and tm is the mixing time in which the water 
resonance is again selectively irradiated. The mixing time is that in which the cross-
polarization takes place, transferring magnetization to another atom; this process is a 
function of the mixing time increment in a 2D-NOESY experiment. Nevertheless, in this case 
there is no such increment, and therefore no indirect dimension is detected.  
 
1.1.2. CPMG pulse sequence 
 In the NMR-linked metabolomics analysis of plasma samples, the investigators face 
the problem of poor ‛wiggly’ baselines attributable to protein signals, and broad envelope 
regions arising from the -CH3 groups of triacylglycerols, proteins, cholesterol and 
phospholipids at ca. 0.80 ppm. This effect arises from the small T2 values of these large 
biomolecules. Two alternatives are proposed in order to solve this issue, i.e. the physical 
filtering of larger biomolecules through ultrafiltration, or protein precipitation using organic 
solvents, or alternatively applying an NMR pulse sequence that acts as a T2 filter, known as 
the CPMG pulse sequence (Carr-Purcell-Meiboom-Gill), which attenuates signals from 
macromolecules which have short T2 relaxation times. Small metabolites experience rapid 
molecular motion, e.g. tumbling, contrarily to macromolecules such as proteins, which show 
slow motion, and consequently have shorter T2 (spin-spin relaxation time) values, that gives 
rise to broad resonances in spectra acquired. 
 Immediately after applying a 90ox pulse, the maximum My magnetization is achieved 
and this decays over time, following T2. This is the loss of coherence of the total My, and it is 
caused by the spin-spin relaxation, so that nuclei initially structured along My start fanning 
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out. The different effective magnetic field that each nucleus experiences leads them to 
precess at different Larmor frequencies, so they spread out with time, a process  guided by 
the T2 value. Another 180ox pulse can then be applied after a certain time (τ), refocusing the 
individual My  of nuclei and therefore obtaining a coherent magnetization, known as an echo, 
at M-y after τ. This is known as the spin-echo pulse sequence developed by Carr and Purcell 
(12) following the work on T2 determination by Hahn in 1950 (13); it can be depicted as 90ox 
- τ - 180ox - τ - 1st echo - τ - 180ox - τ - 2nd echo - … (τ - 180ox - τ)n, in which the intensity of each 
echo decreases exponentially with a time constant equivalent to T2 (14). As a result of the 
recovery of coherence after the 180o pulse, the echoes are formed along the -y and y-axes. 
Meiboom and Gill noted that if the 180o pulse does not exactly rotate the magnetization 
180o, then the vector moves away from the x,y-plane in an accumulative manner, and then 
the decay of the echo intensity will not correspond to T2 (14). These authors addressed the 
problem by replacing the rotation of the magnetisation around the x-axis (180ox) with that 
around the y-axis (180oy). With this modification, an amplitude deviation of the 180o pulses 
will not be cumulative, and the echo is generated at an even number of 180oy pulses always 
along the positive y-axis. These modifications introduced by these four researchers to the 
original Hahn spin-echo pulse sequence gave rise to the Carr-Purcell-Meiboom-Gill pulse 
sequence, termed CPMG, which is widely employed in the NMR analysis of plasma samples 
to remove the broad signals attributable to macromolecules (Figure 1.2). As noted above, 
large molecules have shorter T2 times, and hence during the τ delay the magnetization vector 
will have fanned-out. Small molecules with larger T2 times will only commence fanning-out 
after the 90o pulse, and therefore will be refocused after the 180oy pulse and detected in 
view of their orientation in the x,y-plane (15).  
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Figure 1.2. Stack plot of a 1D plasma spectrum acquired through (a) a NOEPR pulse sequence, 
and (b) a CPMG pulse sequence with water suppression: broad signals arising from lipids are 
diminished, and the wiggly baseline caused by protein signals is corrected.    
 
1.1.3. Two-dimensional NMR 
 When studying complex mixtures (urine, plasma, etc.) or macromolecules (proteins, 
polysaccharides, etc.) 1D NMR may not offer enough clear information about the structure, 
and consequently the identity, of biomolecules investigated. Instead of acquiring a spectrum 
displaying intensity vs. frequency in only one dimension, by 2D spectroscopic experiments 
we obtain a 2D plot showing intensity as a function of two frequencies, usually known as F1 
and F2. The position of each peak is defined by 2 coordinates (F1, F2) showing a signal (‛cross-
peak’) away from the main diagonal if two different resonances  are coupled within the 
molecule; or on the diagonal, centred around the same F1 and F2 frequency co-ordinates 
(‛diagonal-peak’), i.e. the own-connection of a resonance signal. The intensity of these ‛cross-
peaks’ is represented by a contour plot, depicting contour lines drawn at suitable intervals, 
and similar to a topographical map (3).  2D experiments are composed of different phases: 
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preparation, evolution (t1, indirect detection of an additional dimension), mixing 
(transference of coherence amongst spins), and detection (t2).  
 
COrrelation SpectroscopY (COSY): This 2D NMR technique shows how proton-
containing functions within molecules are connected to each other in spectra (16). These 
experiments are applied to identify molecules through the study of 1H-1H couplings arising 
from their structure. In this type of experiment, magnetization is transferred by scalar 
coupling. Protons that are more than three chemical bonds away do not generate cross 
peaks because the 4J coupling constants are very close to 0. Therefore, only signals of protons 
which are two or three bonds apart are visible in a COSY spectrum. 
The common pulse sequence is 90ox - t1 - 90ox - t2, where t1 is the evolution phase and 
t2 the detection one. After the first pulse, in a two proton coupling system (A, X), four 
different vectors will rotate along the x,y-plane, each of those with a different frequency, 
and consequently, fanning out at different velocities from the y-axis. Then, the second pulse 
rotates the y component vectors to the -z-axis (which is not detected) and maintains the x 
component. Associated with this step, there is transference of magnetization determined by 
the spin system situation at t1, which depends in turn on the Larmor frequencies of each 
proton A (νA) and X (νX). The x-components of magnetization vectors give an FID, which after 
FT with respect to t2 gives a 4 line spectrum containing signals at the frequencies: A1, νA + ½ 
J (A, X); A2, νA - ½ J (A, X); X1, νX + ½ J (A, X) and X2, νX - ½ J (A, X), which in turn are associated 
with the transitions depicted in Figure 1.3. The second FT along t1 yields the 2D spectrum 
with 4 groups of 4 signals, two centred around νA, νA and νX, νX (diagonal peaks), and 2 around 
νA, νX and νX, νA (cross-peaks) (17). t1 is sequentially-incremented from 0 in Δ intervals, giving 
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for each value for t1 an FID acquired at t2, so that a matrix is composed of rows containing t2 
data for t1 = 0 in the first row, with the second row containing t2 data for t1 = Δ, etc. This 
whole process is repeated until sufficient data is acquired, typically 50 to 500 increments of 
t1 (3). 
 
 
Figure 1.3. Energy levels scheme and transitions for a two spin AX system conformed for two 
1H nuclei. 
 
TOtal Correlation SpectroscopY (TOCSY): In a TOCSY experiment (18, 19) 
magnetization is transferred over a complete spin system within the molecule by successive 
scalar couplings. The TOCSY experiment involves all protons of a spin system, even if they 
are not directly connected. 
This experiment is similar to the COSY technique, but in this case we can observe the 
whole coupling system, and the second 90o pulse is substituted for a spin-lock stage (90o - t1 
- spin-lock - FID) which is equivalent to the mixing period. This stage consists of a low energy 
pulse or a series of short pulses in the y-axis direction that locks the My. In order to lock all 
the nuclei with regard to their difference Larmor frequencies defined by their nuclear 
environments, the spin lock pulse must be tuned in strength and duration. Moreover, the 
mixing time (tm) is directly correlated to the spin-system observation; the longer the tm, the 
further the whole spin system is extended. The goal of the spin lock stage is to reduce the 
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chemical shift differences (spin locking field << B0), and therefore, those arising from the 
scalar coupling will dominate the process (17). This is ascribable to the much lower energy 
of B1 when expressed relative to B0. In order to achieve the transference of energy between 
nuclei, the Hartman-Hahn condition (20) is required to be accomplished, i.e. different sets of 
nuclei all precessing at the same frequency (ν) in order to allow the transfer of energy (cross 
polarisation), a condition which is relatively easier to reach in homonuclear systems since all 
nuclei have the same γ value (21). The spin-locking field guides the relaxation across My, 
yielding a new relaxation time T1ρ, which differs from T1 and T2, but is very similar to T2 when 
T1 ≈ T2.  
  
 Heteronuclear Single Quantum Coherence (HSQC): This experiment reveals the 
connections through a direct bond between 1H and a heteronucleus (i.e., one which differs 
from 1H), particularly 13C in a metabolomics context, as cross-peaks in a 2D spectrum. This 
experiment was first described by Bodenhausen and Ruben in 1980 (22), who investigated 
15N NMR spectra. The pulse sequence is depicted below:  
 
 
(1H) 90ox - τ - 180ox - τ - 90oy - t1/2 - 180oy - t1/2 - 90ox - τ - 180ox - τ - FID 
(13C)           τ - 180oy - τ - 90ox -             t1     - 90ox - τ - 180ox - τ - Decouple 
 
 The first part of the pulse sequence (preparation) is the same as INEPT (Insensitive 
Nuclei Enhanced by Polarization Transfer), an experiment employed to enhance the intensity 
of 13C resonances through the transfer of polarization from directly attached 1H. Then the 
system evolves over t1, which is changed incrementally, and finally the 13C polarization is 
Detection Mixing Evolution Preparation 
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transferred back to 1H by a reverse INEPT, and its resonance signal subsequently recorded 
(17). Polarization transfer occurs when the excitation of one transition of a nucleus modifies 
the overall spin population distribution. 
 Initially, 1H nuclei are flipped towards the y-axis, and then those coupled to either Cα 
or Cβ start rotating about this axis at different frequencies during a time τ. After the 180ox 
pulse, both vectors (MHCα and MHCβ) are oriented oppositely, i.e., about -y-axis. If the system 
is left to freely evolve, then an echo would be formed along -y, as noted above, but since 
180ox is also applied in the 13C channel, the populations of both levels are inverted, and move 
towards the -x and x-axis in the opposite directions from which they started, generating a 
180o angle between MHCα and MHCβ after τ. Subsequently, the 90oy pulse places the vectors 
along -z and z-axis, with MHCβ in the starting position (z-axis) again, and MHCα facing the 
opposite one (-z-axis) aligned with MC. The 90ox to 13C permits polarization transfer from 
proton to carbon. After these 90o pulses, the preparation period ends. MCHβ and MCHα start 
refocusing on the x-axis to form an echo for a t1/2 period, although the 180ox applied to the 
adjacent proton inverts proton magnetization along z-axis where they were residing, and 
consequently MCHβ and MCHα start fanning out for another t1/2 time, until they form a 180o 
angle (antiphase) along the y-axis. This procedure is repeated many times with different t1 
increments in order to permit the acquisition of the indirect dimension during this evolution 
time. After t1, with the two 90ox pulses in both the 13C and 1H channel, the transfer back of 
polarization from 13C to the 1H nucleus is achieved. At this point, transverse magnetization is 
attributable to the evolution of protons according to heteronuclear coupling, and therefore 
this mixing period corresponds to a reverse INEPT. Subsequent 180ox pulses interchange the 
vectors for MHCα and MHCβ until they are phased, for both MCHβ and MCHα. This last phase 
allows observation of the frequency of the more insensitive 13C nucleus as 1H magnetisation. 
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The resulting spectrum shows the 1H resonances on F1, and the 13C ones on F2, and 
as both spectra are different, there are not diagonal peaks; only cross-peaks reveal direct 
connections between 1H and 13C. 
 
1.2. METABOLOMICS 
 Metabolomics is the systematic study of the unique ‛chemical fingerprints’ arising 
from specific cellular processes, diseases, environmental conditions, mutations, etc. It has 
been defined as ‛the quantitative measurement of the multi-parametric metabolic response 
of living systems to pathophysiological stimuli or genetic modification’ (23). 
The metabolic connections amongst these cellular processes, and particular biofluid 
profiles arising therefrom have been noted since the beginning of Medicine as a discipline, 
in addition to the possibility of extracting valuable information regarding a disease and/or 
its status.  
The colour, smell, and taste of urine, for example, were used as diagnostics from 
ancient China and India, where clinicians began using ants to detect the sugar content in 
urine, as well as tasting it (24). In Greece, since 450 BC Hippocrates developed the theory 
that the physical state of a person was correlated with the excess or lack of his/her body 
fluids. Galen (AD 131–200) continued with the theory that the health or temperament of a 
person was conditioned by the state of the 4 humours: black bile, yellow bile, phlegm and 
blood (25). This theory remained until nearly the 18th century. In that age, doctors tended 
to purge, bleed or apply pro-emetic techniques in order to equilibrate patient humours and 
heal them. In the middle ages, urine was used as a biofluid with a great value in diagnosis 
through its smell, taste and colour (Figure 1.4) (26).  
 
 
 
16 
 
 
Figure 1.4. 16th Century diagnostic urine wheel: this urine wheel was published in 1506 by 
Ullrich Pinder, in his book Epiphanie Medicorum. It describes the possible colours, smells and 
tastes of urine, and their use as a diagnostic tools (26). 
 
In the 1940s, Roger Williams working at Texas University, explored the ability of a 
simple method, such as paper chromatography, in order to investigate whether a metabolic 
profile can be obtained through the analysis of saliva and urine, this work being the first 
proposal for the existence of a metabolic pattern derived from biofluid analysis (27). He 
demonstrated that the taste thresholds and the excretion patterns of a variety of molecules 
presented inter-individual variability (Figure 1.5), but were homogeneous for each individual 
(27). 
The technological improvements accomplished in the 1960s and 1970s (first 
quadrupole GC/MS instrument) allowed investigators to carry out a detailed quantitative 
analysis of metabolic profiles. Accordingly, the Horning group in the 1970s demonstrated 
how gas chromatography-mass spectrometry (GC-MS) could be employed to investigate a 
wide range of compounds present in human urine and tissue extracts; they also created the 
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term ‘metabolic profile’ (28-30). The investigations conducted by the Horning group, 
together with  that of Linus Pauling and Arthur B. Robinson led to the development of GC-
MS methods to detect and identify metabolites present in urine (31). 
 
 
Figure 1.5. Polar co-ordinates of the metabolic patterns of 4 subjects studied by R. Williams 
in 1940: data were obtained by measurements of taste thresholds (numbers 1-17), and 
urinary metabolites (numbers 18-31). The lengths of the lines are indicative of the amounts 
of compounds determined (27). 
 
The establishment of metabolic profile determinations in biological samples using 
high-resolution NMR analysis provides a detailed and specific view into cellular metabolic 
processes under normal and altered (disease-related) conditions. Indeed, continuing the 
work performed on GC-MS for biofluid profiling in previous years, McConnell, M. L. et al. 
published their work on pattern recognition using this technique (32).  
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In 1974, the NMR analysis of tissue began its development with investigations 
conducted by Hoult et al. focused on the 31P NMR analysis of intact biological samples (Figure 
1.6). They analysed muscle tissue in order to explore the complexation of ATP with 
magnesium (33); this is known to be the first NMR analysis applied to a biopsy. One year 
later, an NMR analysis of intact frog muscle was also reported by Bárány and co-workers 
(34). Therefore, these studies of organs and tissues by NMR analysis that led to the 
development of modern in vivo NMR spectroscopy (35) commenced 40 years ago.  
 
 
Figure 1.6. Experiment performed by Hoult et al. involving 31P-NMR analysis (129 MHz) of 
muscle: intact muscle from the hind leg of a rat. Peak assignments: I, sugar phosphate and 
phospholipids; II, inorganic phosphate; III, creatine phosphate; IV, γ-ATP; V, α-ATP; VI, β-ATP 
(33). 
 
In the late 1970’s 1H NMR analysis started to be proposed as a non-invasive technique 
for the metabolic profiling of biofluids and tissue by D. Rabenstein and co-workers (36, 37). 
A few years later, in the middle 1980s, Jeremy Nicholson and Peter Sadler at Birkbeck College 
(University of London, UK), and later at Imperial College (London, UK) demonstrated how 1H 
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NMR spectroscopy could be utilised as a valuable diagnostic tool, and applied this technique 
to establish a diabetic metabolic profile and subsequently developed the study of NMR 
spectroscopy linked to pattern recognition in the mid- to late 1980s (38). This work 
performed by Nicholson and co-workers on plasma analysis by 1H NMR was based on the 
application of the newly-introduced pulse sequences utilised to supress the broad signals 
arising from the macromolecules such as proteins and lipids by Daniels et al. in 1976 (39), 
and in the previous investigations conducted by Bock in 1982 (40), in which this author 
analysed blood plasma by NMR for the first time, exploring the 1H NMR plasma spectral 
change in patients suffering from lactic acidosis, those undergoing phenobarbital treatment, 
and also investigating the detection of ethanol resonances in his own plasma profile 
following vodka consumption.   
In 1985, Arús et al. were the first investigators to assign the 1H NMR resonances in 
spectra of excised rat brain (41). In frog, rat and human skeletal muscle, the 1H resonances 
found were virtually the same as those detected in rat brain. Furthermore, the =N-CH3 
resonance signal of creatine at 3.02 ppm was proposed to be used as internal reference for 
chemical shift values (42).  
Interestingly, all this early metabolomics research work was devoid of a name to 
define the class of research performed, so that the first paper using the word metabolome 
was Oliver S. G. et al. (Trends. Biotechnol. 1998. 16:373). 
In 2005, the Siudzak group at The Scripps Research Institute (CA, USA) developed the 
first Metabolomics web database (METLIN), which contained over 10,000 metabolites and 
tandem MS data. On 23th of January of 2007, the Human Metabolome Project, led by David 
Wishart (University of Alberta, Canada), completed the first draft of the human metabolome, 
and this database primarily contained approximately 2,500 metabolites, 1,200 drugs and 
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3,500 food components (43). An additional database available that contains NMR spectra of 
metabolites is the Biological Magnetic Resonance Data Bank (BMRB) run by the University of 
Wisconsin, which also hosts spectra from peptides, proteins and nucleic acids (44). 
Moreover, the Spectral Database for Organic Compounds (SDBS), created by the National 
Institute of Advanced Industrial Science and Technology (Japan) contains not only NMR 
spectra, but also MS, Electron Spin Resonance (ESR), Infra-Red (IR) and Raman ones. These 
databases have incredibly aided  the identification of metabolites, and the information 
contained therein has been updated and enlarged with recently published works regarding 
the identification and resolution of the majority of resonances  present in urinary (45), blood 
serum (46) and salivary (47) 1H NMR profiles. 
The future of NMR-linked metabolomics is moving towards both the automation of 
all the analytical steps performed after spectral acquisition, and also the standardization of 
experimental conditions. Accordingly, automated assignment web-based software has been 
developed, i.e. COLMAR (48), and software developed by the Wishart group allows the 
automatic resonance signal deconvolution for quantitative Metabolomics, BAYESIL (49). The 
next step in a metabolomics investigation after the completion of all resonance assignments 
is multivariate analysis, and this can be performed by the web-based tool MetaboAnalyst 3.0 
(50) that allows researchers to analyse datasets through a wide battery of multivariate and 
univariate analysis techniques, and also includes modules for time-series and pathway 
analyses. The standardization of NMR-linked Metabolomics investigations is a major concern 
for the scientific community, mainly in the field of urine NMR analysis as a diagnostic tool 
(51), since plasma analysis investigations are still being subjected to new developments, both 
in terms of signals assignments [mainly lipoprotein subclass identification (52)] and the 
dichotomy between physically (ultrafiltration, organic solvent precipitation) (53) or NMR-
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based suppression of the broad signals attributable to macromolecules present in this 
biofluid. Nevertheless, Nicholson and co-workers have reported a set of protocols for human 
urine, serum, and plasma NMR-linked metabolomics analysis in order to provide 
standardized steps in metabolomics investigations (54). This effort for standardizing the 
experimental procedures in NMR-linked urinary metabolomics analysis includes all the steps 
involved in such investigations, from sample collection and preparation to the manner in 
which investigators should report their results (55). In order to accomplish this ambitious 
objective, the Metabolomics Society released the Metabolomics Standards Initiative in 2007 
(56). In 2012, a further initiative known as the coordination of standards in metabolomics 
(COSMOS) was set up to bring together metabolomics researchers to develop guidelines and 
standard workflows for metabolomics applications (www.cosmosfp7.eu). Additionally, the 
standardization of urinary metabolite quantification serves as a further step, since it would 
translate the investigations from laboratory to clinic, since proposing metabolites as 
biomarkers irremediably requires the provision of accurate threshold metabolite values in 
order to distinguish healthy from diseased patients in a diagnostic test (57). 
In the NMR-linked metabolomics field, the major instrumental advances are driven 
towards a decrease in the spectral acquisition duration for homo- and heteronuclear 2D 
spectroscopy in order to facilitate the assignment of resonances within reduced time 
periods. Throughout the last five years, the development of ultrafast NMR experiments has 
allowed the acquisition of 2D NMR spectra in a single scan (58), which may permit the 
development of high-throughput 2D NMR-based metabolomics studies (59). Moreover, Rai 
and Sinha (2012) reported a new J-compensated HSQC pulse sequence which reduces the 
data collection time 22 times, and which does not show any deficiency in the quantification 
of low abundance metabolites (60). 
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1.3. MULTIVARIATE STATISTICAL ANALYSIS TECHNIQUES 
1.3.1. Principal Component Analysis (PCA) 
The PCA technique is attributable to Hotelling (61), although its origins are in the 
orthogonal least-squares adjustments introduced by K. Pearson, who first proposed it over 
100 years ago (62). By applying PCA, we seek to maximize the percentage of variance 
explained using linear combinations of ‛predictor’ variables, the so-called components. PCA 
is an unsupervised technique, since these components are selected without any assumption 
about the group classification and hence clusterings that might underlie the dataset; 
therefore, no grouping of observations is assumed. The information lies in the correlation 
structure, and both clustering tendency and outliers can be detected. 
A dataset with K-variables can be geometrically represented by a plane of K-
dimensions. The goal of PCA is to reduce the number of dimensions, together with an 
explanation, with those few dimensions, of the maximum variation of the dataset (Figure 
1.7).    
Each sample/observation is represented in the PCA space as a point with K-
coordinates. The samples in that space have to be centred first, by subtracting the mean, 
and PCA then draws a line through the K-dimensions that best approximate the data 
(ordinary least squares technique), which would represent the first component. It is usually 
convenient to standardize the variables prior to principal component analysis computations, 
since those variables which present a higher contribution towards the total variance 
dominate computation of the first PC. This first PC is obtained as a linear combination of the 
variables with the aim of achieving maximal variance; then, the second PC is obtained as a 
linear combination of the original variables, with the same purpose of achieving maximal 
variance, in an orthogonal direction to the first PC, and so on (63).  
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Figure 1.7. PCA representation in a 3D space: the 4 groups depicted in the 3D space (left) are 
represented by PCA in a 2D space (right) in which PC1 and PC2 explain the maximum variance 
achievable. 
 
  The projections of the samples/observations in the new plane with A-dimensions (A, 
number of principal components) are the scores T (Figure 1.8). The proximity between 
objects/samples indicates the presence of similar properties amongst those samples, and 
vice-versa.  
The weights of the variables in the PCs are known as loadings (P). They express how 
the original variables are linearly combined to form the scores, and how the variables are 
related to the components. The residual matrix represents the distance between each point 
in K-dimensions, and its projections in the new dimension-reduced plane, and therefore it is 
the variation unexplained by the PCs (10). 
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Figure 1.8: Matrix representation of a PCA model: X, original dataset; P, loadings matrix; T, 
scores matrix; E, residual matrix. 
 
 In some situations, loadings of some variables might have medium correlation values 
to the factors, which may lead to a difficult interpretation of the results. In order to facilitate 
this interpretation, the factors can be rotated to make the correlations of the variables to 
the factors more polarized. Rotation can be either orthogonal or oblique, the former being 
the most widely employed since the factors arising from the components’ rotation remain 
orthogonal, as are the PCs from which they are generated. Through a rotation of the 
components [linear combination of the original factors such that the variance of the squared 
loadings is maximized (64)], the explained variance changes from the PCs to the new 
rotation-derived factors, but the total amount of explained variance remains the same, i.e. 
the only change is the partition of the variance into factors. Varimax (65) is the most widely 
used rotation technique, and it attempts to reduce the number of variables with higher 
loadings within a factor, and also the number of variables associated with several factors 
simultaneously (64). 
 
1.3.2. Linear Discriminant Analysis (LDA) 
Linear discriminant analysis (LDA) is a statistical method which seeks a linear 
combination of the variables in order to achieve the best discrimination between the initial 
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groups investigated (66). Moreover, it can be employed to define decision rules in order to 
classify a new sample, the class of which is unknown.   
This method finds the linear combination of the features that maximizes the ratio of 
‛between-class’ variance to the ‛within-class’ variance in any particular dataset, thereby 
guaranteeing maximal separation (67). 
 If the dataset is represented by the matrix X = (x1, x2,…xn), where n is the number of 
observations, xi being an observation described by q features, then μk is the mean of a class 
Ck and μ is the overall mean of all the observations: 
 
𝑆𝐵 =  ∑ (μ𝑘 −  μ)(μ𝑘 −  μ)
𝑡
𝑘                      (5) 
𝑆𝑤 =  ∑ ∑ (μ𝑖 −  μ)(μ𝑖 −  μ)
𝑡
𝑥𝑖𝜖𝐶𝑘𝑘         (6) 
 
SB and SW represent the ‛between-class’ and ‛within-class’ scatter matrices 
respectively. The sum of both gives the covariance matrix for the whole dataset. 
The aim is to seek and find a projection of the dataset, in the d dimensional plane, 
where it achieves a maximum separation between the mean values of projected classes, and 
minimum variance within each projected class so that wtSB w is maximized and wtSW w is 
minimized. This dual objective can be reached through the vector wopt, which attemps to 
maximize the following function: 
 
𝐽(𝑤) =  
𝑤𝑡𝑆𝑏𝑤
𝑤𝑡𝑆𝑤𝑤
                              (7) 
 
 This LDA approach is similar to PCA, but in this case we not only seek to find the 
components that maximize the variance, but additionally, we attempt to achieve a maximal 
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separation between classes, differentiating between variability ‛between-groups’ (SB) and 
‛within-groups’ (SW). If the structure underlying the dataset reveals that SB >>> SW, then PCA 
also performs well for classification purposes.  
 
1.3.3. Partial Redundancy Analysis (pRDA) 
RDA is a technique that combines regression and PCA in order to model multivariate 
response data (68). Indeed, RDA (69) with a single ‛response’ variable is equivalent to 
multiple linear regression modelling.  The operation of this method can be viewed as a 
multivariate linear regression of Y (response variables matrix, n x p) on X (explanatory 
variables matrix, n x m), yielding a matrix of fitted values, known as  ?̂?. Subsequently, a PCA 
on ?̂? is performed in order to obtain a matrix of the canonical axes (similar to the scores 
matrix in a PCA). 
Permutation tests are usually employed to check if the linear combinations of X are 
truly explaining Y, and consequently the R2 value, a parameter that represents how well a 
model fits the original data (with a score of 0 indicating an absolute lack of fitting, and 1.00 
a perfect fitting of the data), together with the p-value obtained when the observed case is 
tested against those obtained after randomly permuting the yi variables within the Y matrix, 
perhaps several thousand or more times. 
Partial Redundancy Analysis (pRDA) is method first proposed by Davies & Tso in 1982 
(70), in which an additional matrix of covariables W, influences the response variables Y. This 
approach is applied to control the known effects of a covariable, when analysing the effect 
of a set of variables X on Y (71). Another application of this model is to isolate the effect of a 
single explanatory variable or factor. 
 
 
 
27 
 
1.3.4. Correlated Component Regression (CCR) 
Correlated Component Regression (CCR) is an ensemble dimension reduction 
regression technique that provides reliable predictions even with near multicollinear data 
(72). Correlation amongst variables, known as multicollinearity, is a common problem 
encountered when dealing with large datasets, and consequently, traditional regression 
techniques may estimate unstable coefficients (73). Situations where the number of 
predictor variables P approaches or exceeds the sample size N give rise to major problems, 
and such instability is often accompanied by perfect or near perfect predictions of the 
regression model developed. However, this seemingly good predictive performance is 
usually associated with overfitting, and is not accurate when new samples are employed to 
test the model (72). 
CCR proposes the prediction of the dependent variable based on K correlated 
components. If K = 1, CCR is equivalent to the corresponding Naïve Bayes solution 
(probabilistic classifier based on the application of Bayes' theorem with independence 
assumptions) (74). It is further suggested that for K > 1, CCR represents a natural extension 
of a Naïve Bayes model applied to multiple dimensions (74).  
 
Estimation of components: CCR utilizes K < P correlated components in place of the 
P predictors to estimate the response variable (75). Each component Sk is an exact linear 
combination of the variables, X = (X1, X2,…XP). The first component S1 captures the effects of 
those predictors that have direct effects on the outcome (72). Unlike PCA, the objective is 
not to explain the correlation/covariance matrix through the weights of the components 
(percentage of variance explained), but to compute the weights with the aim of maximizing 
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the ability to predict the outcome (75). The CCR-linear model (CCR-LM) algorithm proceeds 
as follows:  
Estimate the loading λg(1), on S1, for each predictor g = 1, 2,…P, as the simple 
regression coefficient of the regression of Y on Xg . Component S1 captures the direct effects 
of X for the regression y on X as a weighted average of the one predictor model. 
 
𝜆𝑔
(1)
=
𝐶𝑜𝑣 (𝑌,𝑋𝑔)
𝑉𝑎𝑟(𝑋𝑔 )
                      (8) 
𝑆1 = ∑ 𝜆𝑔
(1)𝑃
𝑔=1 𝑋𝑔                      (9) 
 
The first component S1 is computed as a linear combination of X using 𝜆𝑔
(1)
 as weights. 
Similarly, predictions for the 2-component CCR model are obtained from the simple OLS 
regression of Y on S1 and S2. Components are related to each other, and they are not 
orthogonal as in other techniques (PCA, Partial Least Squares); this correlation allows the 
mutual enhancement of the predictive abilities of the whole set of components, so that S2 
improves the performance of predictor S1, S3 improves that for S2, and so forth, with the aim 
to achieve the desired effect of removing ‘extraneous variation’. 
Component Sk′ for k′ > 1, is defined as a weighted average of all 1-predictor partial 
effects, where the partial effect for predictor g is computed as the partial regression 
coefficient in the OLS regression of Y on Xg, and also on all previously computed components 
Sk,k = 1,… k’ -1  (75). 
 
𝑌 =  𝛼 + 𝛾1.𝑔
(2)
  𝑆1 +  𝜆𝑔
(2)
 𝑋𝑔 + 𝜀𝑔
(2)
                    (10) 
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 With the aim of representing the model developed in a simpler fashion by regression 
coefficients, the CCR model can be expressed as follows: 
 
?̂? =  𝛼 
(𝑘) + ∑ 𝑏𝑘
(𝑘)𝑘
𝑘=1 𝑆𝑘
 =  𝛼 
(𝑘) + ∑ 𝑏𝑘
(𝑘) ∑ 𝜆𝑔
(𝑘)𝑃
𝑔=1 𝑋𝑔
 =𝑘𝑘=1   
 
𝛼 
(𝑘) + ∑ 𝛽𝑔
 𝑃
𝑔=1 𝑋𝑔
               (11) 
 
 Therefore, the regression coefficient 𝛽𝑔  is the weighted sum of the loadings, where 
the weights are the regression coefficients for the components (75): 
 
𝛽𝑔 = ∑ 𝑏𝑏
(𝑘)
𝜆𝑔
(𝑘)
 𝑘𝑘=1                     (12) 
 
M-fold Cross Validation (CV): The purpose of CV is to improve the performance of 
the classification model by assigning a fraction of the original sample size to a training set 
and the remaining to a ‛test set’. The first of these contains the samples employed to develop 
the model, whilst the second one is employed to check how effective the model is when 
these samples are tested in order to predict their classification status.    
CCR employs M-fold validation, and runs this procedure several times iteratively. 
Each round provides one set of CV performance statistics. One round of M-fold validation 
randomly divides a sample of n cases into M mutually-exclusive sub-groups, known as folds, 
and obtains a similar number of samples within each fold. 
The first fold is the ‛test sample’, and the remaining folds are used as ‛training 
samples’ employed to estimate the model performance. The Q2 statistic is typically used to 
evaluate the performance of the model in the validation fold. Q2 is the cross-validated R2 
value and is computed utilising the Predictive Error Sum of Squares (PRESS) and the Total 
Sum of Squares (TSS) (Equation 9). 𝑄2 values are always ≤1, and it can indeed assume 
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negative values when PRESS > TSS, revealing that the model performs worse when it is 
evaluated with the ‛test set’ than the mean response of the ‛training set’ (76): 
 
𝑄2 = 1 −  
𝑃𝑅𝐸𝑆𝑆
𝑇𝑆𝑆
= 1 − 
∑ (𝑦𝑖− 𝑦?̂?)
2𝑛
𝑖=1
∑ (𝑦𝑖− ?̅?)2
𝑛
𝑖=1
                    (13)
   
This result on fold 1 is then stored, and the process is repeated for the second fold. 
The model’s predictive performance is then tested on this 2nd validation fold, and the results 
aggregated with the previous CV performance (from fold 1). The process is then repeated 
for the remaining folds. 
 
Step-Down Procedure: This approach works in conjunction with M-fold cross-
validation. For a particular value of K (number of correlated components), a model with all 
possible predictors is initially estimated. Subsequently, the least important predictors are 
left out based on their standardised effect (Equation 14), and the Q2 value for the new model 
is obtained using the original set of predictors minus the ‛worst’ (75). This process then 
repeats until we have Q2 values for every possible model (75).  
 
𝛽𝑔
∗ = ( 
𝜎𝑔
𝜎𝑦
 ) 𝛽𝑔
                                  (14) 
 
CCR uses a step-down variable selection algorithm in order to remove irrelevant 
predictors, which commences using all the variables for developing the model; subsequently, 
it eliminates those variables with the smallest standardised coefficients one by one, re-
estimating the model at each step (72).  
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1.3.5. ROC curve analysis  
ROC (Receiver Operating Characteristic) curve analysis represents a relative balance 
between the benefits (true positives) and costs (false positives) of MVA models (77), and is 
widely considered to be the most objective and statistically-valid method for biomarker 
performance evaluation (50). ROC curves are often summarized into a single metric known 
as the area under the ROC curve (AUC) depicted in a 2D plot in which the True Positive Rate 
(TPR) is plotted on the y-axis, and False Positive Rate (FPR) is plotted on the x-axis. 
 
TRUE CLASS   
DISEASE HEALTHY   
True positives (TP) False positives (FP) DISEASE PREDICTED 
CLASS False negatives (FN) True negatives (TN) HEALTHY 
Table 1.1. General confusion matrix 
 
𝑇𝑃𝑅 (𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦) =  
𝑇𝑃
𝑇𝑃+𝐹𝑁
                               (15) 
𝑇𝑁𝑅 (𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦) =  
𝑇𝑁
𝑇𝑁+𝐹𝑃
                               (16) 
𝐴𝐶𝐶 (𝑎𝑐𝑐𝑢𝑟𝑎𝑐𝑦) =  
𝑇𝑃+𝑇𝑁
𝑇𝑁+𝑇𝑃+𝐹𝑃+𝐹𝑁
                  (17) 
 
Sensitivity is the ability of the model to classify diseased patients as diseased (or 
controls as control), and specificity is the ability of the model developed to correctly classify 
control (non-diseased) participants. Both terms are major parameters utilised to assess the 
performance of a diagnostic/classification rule. Indeed, the AUC is conditioned by both 
values, which inform us about the suitability of the model proposed, i.e. AUC values are 
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considered excellent if they lie between 0.90 - 1.00, good for 0.80 - 0.90, fair for 0.70 - 0.80, 
poor for 0.60 - 0.70 and of no value for ≤0.6) (78). 
 
1.4. ARTIFICIAL INTELLIGENCE BASED TECHNIQUES 
1.4.1. Random Forests (RFs) 
Random Forests is a prediction/classification model technique consisting of an 
ensemble of classification and regression tree-structured classifiers (79).  
Decision trees are classifiers which use a single feature at each non-terminal node, 
so that a sample is classified to the left or the right branch at that specific node if its value 
for that feature is greater or less than the threshold specified at that node. At each split, the 
data is partitioned in two mutually-exclusive groups, and attempts to achieve as much 
homogeneity as possible in each group; subsequently, the splitting is repeated for each 
group in order to improve this homogeneity within them, but with the constraint of having 
a tree relatively small and easy to interpret (80). Once the tree is unable to continue the 
splitting of samples into different groups, the process completes. The tree can then be 
‛pruned’ back to the desired size. 
 In 1984, Brieman, Olshen, Friedman and Stone published the book ‛Classification and 
Regression Trees’, and developed the CART software (81). This book presented the 
applicability of RFs and its successful performance when attempting to solve a range of 
problems that one of the researchers faced when he was working at the UC San Diego 
Medical School.  
RFs uses an ensemble of classification trees; each of these trees is grown by random 
feature selection from a ‛bootstrap’ sample [‛training set’ sub-samples with replacements 
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obtained from the original dataset (82)] at each branch (83). Class prediction is based on the 
average classification performance of the aggregate of trees. The process of building up a 
tree consists of selecting a bootstrap sample of 63.2% (on average) from the original whole 
sample set, and then a random group of variables are chosen for splitting at a particular 
node. The remaining 36.8% sub-set is then employed to obtain an unbiased estimate of the 
classification error (out-of-bag error, OOBE error) (84). Since the OOB observations are not 
used for fitting the trees, this is a cross-validated accuracy estimate, and hence it represents 
an unbiased estimation of the generalization error (79). Variable importance is evaluated via 
measurements of the increase of the OOB error value when it is permuted (79). The OOB 
error estimate ranges from 0 (if the model is able to predict with a 100% in accuracy the class 
of the test set) to a value of 1.00 (no sample from the test set was correctly classified). 
 
1.4.2. Support Vector Machines (SVMs) 
 Support Vector Machines were originally developed in 1982 by Vapnik (85), and the 
most relevant outcome appeared in 1992 with the seminal Boser, Guyon and Vapnik paper: 
‛A training algorithm for optimal margin classifiers’, in which this technique was formally 
proposed (86). 
SVMs is a classification algorithm that operates by finding the decision surface that 
can more clearly separate samples from different classes, and hence has the largest distance 
between borderline samples (support vectors). Separation is then achieved by identifying 
these support vectors for the respective classes, identifying the separating hyperplane (space 
of K-1 dimensions constructed in a K-dimensional space, where K > 3) in between, so that 
these points are the most influential ones over the parameters selected to ‛draw’ this 
hyperplane in such a manner that moving a support vector moves the hyperplane. However, 
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the remaining samples do not have any influence in the process of seeking of this 
hyperplane. Therefore, the algorithm generates the weights, and only considers the support 
vectors to define their values, and hence the boundary. Nevertheless, if this decision surface 
does not exist, then the dataset has to be mapped onto a higher dimensional space where 
this decision surface exists. This transformation is known as the Kernel trick.  
If the training set xi ∈ Rn, i= 1... m where each of the xi (samples) belong to one of the 
two categories yi, indicated by either -1 or 1, SVMs finds a hyperplane with the parameters 
(w,b), using the following convex optimization problem to obtain them (86): 
 
min
𝑤,𝑏,𝜖
1
2
𝑤𝑡𝑤 + 𝑐 ∑ 𝜖𝑖
𝑁
𝑖=1                      (18) 
subject to 𝑦𝑖(𝑤
𝑡𝑥𝑖 + 𝑏) ≥ 1 − 𝜖𝑖 , where  𝜖𝑖 ≥ 1, for i = 1,…N 
 
In Equation 18, c works as a regularization parameter which acts as a ‛slack’ constant, 
and which is a ‛trade-off’ between the ability of the system to model accurately using the 
training set, and its predictive performance (87). If c is small, then the margin is large, so 
constraints are easily ignored; however, if c is large, then the margin is narrow, and therefore 
constraints are hard to ignore, so that c controls the margin width. 𝜖𝑖 is a measure of 
misclassification rate and is also known as the ‛slack variable’. The function of this term is to 
reduce the overfitting problem, enhancing the performance of SVMs, but also allowing a 
fraction of training sample objects to be within the margin or even misclassified in order to 
not introduce more complexity within the model (i.e., a ‛soft’ margin classifier). 
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1.4.3. Genetic Algorithms (GAs) 
 GAs are randomized search and optimization algorithms inspired by Darwin’s theory 
of evolution that were introduced by Holland in 1975 (88). GAs function as a simulation of 
an evolutionary process, in which a population of solutions evolve over a sequence of 
generations (89) (Figure 1.9). Each chromosome represents a potential solution, and the 
fitness value associated with each chromosome indicates its relevance to obtain the best 
possible solution (90).   
 
 Encoding and Initial Population: A chromosome is a string of ‘bits’ with a length 
determined by the total number of variables. The presence/absence of a variable in the 
chromosome is given by the value 1 or 0 in the corresponding i-th place within the 
chromosome; this assignment is generated randomly. Consequently, each chromosome 
represents a different sub-set of features. 
 
 Selection, Crossover and Mutation: The selection process involves the principle of 
‛Survival of the fittest’, i.e. improved solutions are selected to get through to the next 
generation; notwithstanding, ‛bad’ solutions are discarded. The ‛good & bad’ criteria are 
given by the fitness function.  
 Crossover causes a structured yet randomized exchange of genetic information 
amongst solutions/chromosomes, with the aim that effective solutions could be crossed with 
other high-performance ones in order to generate improved models. This process is applied 
with a probability, called crossover rate, i.e. the probability that a chromosome (solution) 
experiences cross-over during its reproduction process. A crossover rate of 1.00 indicates 
that all the chromosomes experience crossover, so no unchanged solutions go through to 
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the next generation. For instance, a value of 0.75 indicates that a chromosome may go 
through to the next generation unchanged with a probability of 0.25. 
 Mutation works by modifying the value of each gene with a certain probability. This 
operator then restores missed or unexplored genetic material stored in the population in 
order to prevent the premature convergence of the GAs to sub-optimal solutions (89). 
 
Fitness function: The fitness function is a measure of the ‘goodness’ of a solution, 
and can be used to rank chromosomes/solutions against the other chromosomes. It can also 
be employed to assess feature sub-set selection, in order to simplify the model using less 
features, achieving at least the same level of success when classifying samples according to 
their correct class. In a classification problem context, the fitness is equivalent to evaluations 
of the predictive ability of the model using a sub-set of genes (variables). 
 
 
Figure 1.9. Schematic representation of a GAs procedure for a classification problem: 
variables (xi…xn) are coded in chromosomes as 1 or 0 if they are or are not included in the 
model respectively. The whole process moves on for N number of generations, or until the 
fitness value is attained. 
 
 
37 
 
1.5. NIEMANN PICK TYPE C1 DISEASE 
1.5.1. Description 
Niemann-Pick type C (NP-C) disease is a neurodegenerative lysosomal storage 
disorder caused by mutations in the NPC1 and NPC2 genes, the hereditability of which is 
autosomic recessive (91).  Approximately 95% of patients have mutations in the NPC1 gene 
(mapped at 18q11) which encodes a large membrane glycoprotein located in late 
endosomes (92) . The remaining 5% have mutations in the NPC2 gene (mapped at 14q24.3) 
which encodes a small soluble lysosomal protein that binds cholesterol in the lumen of this 
organelle (92). Patients with NP-C1 and NP-C2 diseases are indistinguishable, both clinically 
and in terms of the standard biochemical tests for NP-C diagnosis (93). 
In 1984, Pentchev and colleagues made the highly significant discovery  that the 
major biochemical feature of NP-C disease is lysosomal accumulation of LDL-derived, 
unesterified (free) cholesterol, and consequently, these patients develop a dysregulated 
sterol biosynthesis, uptake and esterification (94). The estimated incidence of the disease is 
approximately 1:120,000 live births, based on studies performed during the past 20 years 
(95).  
 
1.5.2. Cell biology of cholesterol 
 Cholesterol, which is the major steroid present in animal tissues, stabilizes the 
structure of plasma membranes, regulates membrane permeability, and reinforces the liquid 
ordered phase of lipid bilayers (96). It is essential for myelin formation (97), and during 
development it has a major signalling pathway function, specifically in the hedgehog 
signalling pathway, in which cholesterol covalently modifies the proteins involved in order 
 
 
38 
 
to render them functional (98, 99). Cholesterol binds to the amino terminal peptide arising 
from the autoproteolitic cleavage of the original protein (i.e. those involved in the hedgehog 
pathway), and it is only this N-terminal peptide which has signalling activity, involved for 
example in skeletal (100) and cerebellum development (101). Cholesterol is a precursor of 
corticosteroids, vitamin D, bile acids and steroid hormones. 
 Not all mammalian cells are able to metabolize cholesterol. In fact, only liver and 
steroidogenic tissues do. Nevertheless, other tissues unable to metabolize this molecule are 
capable of modulating its concentration in the membranes by regulating the biosynthesis, 
uptake, and export of cholesterol from the cell through ATP-binding cassette (ABC) 
transporters (102). 
Cholesterol can be obtained by cells through two routes. Firstly, it can be acquired 
from the diet associated with plasma low-density-lipoproteins (LDLs), in which cholesterol 
from the liver can be transported through the circulation to extra-hepatic tissues, being 
initially packaged in very-low-density-lipoproteins (VLDLs). In the circulation, VLDLs are 
converted to LDLs by the action of lipoprotein lipase.  
LDLs are taken up by cells via LDL receptor-mediated endocytosis. The interaction of 
LDLs with LDL receptors requires the presence of apoB-100, the exclusive apolipoprotein of 
LDLs. The endocytosed vesicles (endosomes), derived from the internalization of the 
membrane, then fuse with lysosomes, where the apoproteins (originally contained in LDLs), 
are degraded; subsequently, cholesteryl esters are hydrolysed within the lysosome yielding 
free cholesterol. This cholesterol moiety is then incorporated into the plasma membranes 
where required, predominantly at the cytoplasmic membrane, where LDL-cholesterol 
released from lysosomes can be rapidly detected (103). The caveolae (special region within 
the membrane which is rich in cholesterol and sphingomyelin) are the first destination for 
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the free cholesterol carried by LDL. However, to elicit homeostatic responses and to be 
transformed to cholesteryl esters and bile acids, or indeed incorporated into lipoproteins, 
cholesterol must first reach the endoplasmic reticulum (ER) (103). 
Alternatively, cholesterol can be generated via de novo synthesis in the endoplasmic 
reticulum. LDLs are not able to go through the blood-brain barrier (BBB) and supply the brain; 
furthermore, this de novo pathway is the only and exclusive mechanism for the central 
nervous system (CNS) to obtain cholesterol. Free cholesterol synthesised in the glia and 
complexed with apolipoprotein E is then delivered to neurons (104). Although LDL cannot 
cross the BBB, cholesterol can egress from the CNS as 24-hydroxy-cholesterol. Furthermore, 
27-hydroxy-cholesterol can also cross the BBB in the opposite direction (105). 
 
1.5.3. NPC1 and NPC2 proteins 
 The multivesicular late endosomes accommodate two proteins, NPC1 and NPC2, 
which are crucial for moving cholesterol out from the endosomal system (Figure 1.10). 
Therefore, deficiencies in the levels or activity of these proteins lead to the accumulation of 
LDL-derived unesterified cholesterol in LE (106).  
In NP-C disease, the movement of LDL-derived cholesterol to the endoplasmic 
reticulum and plasma membrane is delayed, resulting in altered regulation of cholesterol 
homeostasis in the ER. Hence, cholesterol and LDL-receptor synthesis is enhanced to 
compensate for the apparent lack of cholesterol detected by the cell; additionally, 
cholesterol esterification is diminished (107). In contrast, intracellular transport of 
cholesterol delivered from exogenously-supplied high-density-lipoproteins (HDLs) seems to 
be unaffected in the disease, and this is presumably ascribable to this source of cholesterol 
not entering late endosome/lysosome via endocytosis (107). 
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Figure 1.10. Potential mechanism for NPC1/NPC2-mediated cholesterol export from late 
endosome/lysosome: CE, cholesteryl ester; FA, unesterified fatty acid; LBPA/BMP, lyso-bis 
phosphatidic acid, also known as bis-(monoacylglycerol)phosphate (108). NPC2 (soluble 
protein) binds unesterified cholesterol in the late endosome/lysosome with the iso-octyl 
chain in the binding pocket, an event that may be enhanced by bis-
(monoacylglycero)phosphate. NPC2 transfers cholesterol to the N-terminal loop of NPC1 (a 
multi-pass membrane protein) which binds cholesterol, accommodating the hydroxyl group 
in the binding pocket. Cholesterol is exported from late endosome/lysosome by an unknown 
mechanism (109). [Figure taken from (108)] 
 
Other biomolecules are also stored within the lysosome in this disease, including 
complex gangliosides such as GM1 and GM2, glucosyl and galactosylcerebrosides (108). NPC1 
and NPC2 proteins have been proposed to be involved in the endosomal/lysosomal 
processing of these lipids, since simple gangliosides (e.g. GM2, GM3) can be delivered to Golgi 
after being endocytosed by the late endosome/lysosome system to generate more complex 
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structures as an alternative to the de novo synthesis pathway (110). Therefore, mutated 
NPC1 and/or NPC2 lead to the accumulation of these gangliosides. 
A sequential process of pathological effects derived from NPC1 gene 
mutation/inactivation has been recently proposed, in which the first consequence of this 
genetic alteration is sphingosine storage, folllowed by deficient calcium homeostasis within 
the lysosome which leads to a reduced calcium release and consequently a block in late 
endosome/lysosome fusion that finally causes unsterified cholesterol storage (111). 
Accordingly, the storage of cholesterol, which was previously thought to be the main 
activator of the molecular disease process, is actually the trigger of all the neurodegenerative 
processes that subsequently occur. 
 
1.5.4. Disease manifestations 
 The manifestation of NP-C1 disease is very heterogeneous, and actually it can vary 
between siblings (95), which leads a delay in in diagnosis of 5–6 years from the onset of 
neurological symptoms (112, 113). Therefore, the individual features illustrated in Figure 
1.11 are not NP-C1-specific, but the conjunction of all of them generates a clinical picture 
which is considered disease-specific. 
Neurological features include abnormal saccadic eye movements, ataxia, dystonia, 
dysarthria and dysphagia. In the cerebellum, Purkinje cells die in a characteristic pattern that 
exacerbates with age and disease state (114). The age of onset of these neurological 
manifestations has a major impact on the severity of the disease; however, the progression 
remains essentially the same (Figure 1.11) (114). 
Systemic symptoms include hepatosplenomegaly and pulmonary failure (115), the 
latter being more associated with the most severe cases of the disease (116); indeed, the 
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strongest visceral hallmark of NP-C1 is splenomegaly, which is a more powerful indicator 
when it presents along with the neurological symptoms delineated above.  
Psychiatric symptoms are also part of the disease process, including cognitive decline, 
psychosis which typically appears in adolescence or early adulthood, and disruptive or 
aggressive behaviour presenting at the same stage (117).   
 
 
Figure 1.11. Major clinical disease manifestations and age at onset of neurological 
symptoms. [Figure adapted from (91)] 
  
1.5.4.1. Hepatic manifestations  
 NP-C1 is mainly a neurodegenerative disease associated with major organic 
manifestations, in which the liver is affected. A percentage of NP-C1 patients (approximately 
50%) suffer from liver disease, and approximately one tenth of these patients die from liver 
failure before the first year of age (118). Moreover, NP-C1 disease is one of the most 
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common disorders responsible for neonatal cholestasis, a disorder in which bilirubin 
excretion is altered, and consequently, bile salt levels are decreased in the gastrointestinal 
tract, causing a decreased or even null absorption of fats and hydrophobic vitamins (i.e., 
vitamins A, D, E and K). In a 20-year investigation conducted at King’s College Hospital 
(London, UK), NP-C disease was found to be the second major cause of neonatal cholestasis, 
only one place below alpha-1-antitrypsin deficiency (119). Another 2-year study, performed 
in the USA revealed that NP-C was the first cause amongst all metabolic/genetic disorders of 
neonatal cholestasis (120).  
The liver controls lipoprotein, glucose and cholesterol homeostasis within the body; 
it has a major synthetic function producing most of the clotting factors, bile, albumin and 
some vitamins. Additionally, the liver has an excretory function (i.e. bilirubin), participates in 
the immune response through Kuppfer cells filtering antigens and damaged cells out of the 
organ, and has a relevant function in the storage of glycogen and certain vitamins. All these 
functions that are performed by this organ, along with the fact that liver disease is one of 
the major pathological symptoms of NP-C1, renders investigations involving this organ as a 
valuable approach to the disease process. 
The majority of investigations on NP-C1 liver have been previously focused on the 
lipid profiles of the hepatic cells (121, 122) or alternatively explore hepatocyte gene 
expression (123). However, to date low-molecular-mass polar compounds present within 
hepatic tissue have not been investigated. Indeed, such metabolites are involved in 
metabolic pathways that may be altered in NP-C1 disease. 
Studies previously performed using an NP-C mouse model (124) indicate that this 
animal model develops a pathological hepatic phenotype similar to that observed in NP-C1 
infants (121, 125), showing cholesterol storage, increased levels of liver damage biomarkers 
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such as alkaline phosphatase, aspartate and alanine aminotransferase, hepatomegaly and 
the presence of apoptotic cells (122). 
1.5.5. Diagnosis 
When a patient is suspected to be suffering from NP-C disease, then a genetic test is 
carried out to check for mutations in either the NPC1 or NPC2 genes. If at least 1 pathogenic 
mutation is detected, then this patient is diagnosed with NP-C (126). Contrarily, if these 
pathogenic mutations are not detected, then the filipin test is performed. This diagnostic 
test involves the staining of cultured skin fibroblasts from a biopsy obtained from patients, 
in order to demonstrate free cholesterol accumulation within lysosomes (127), since this dye 
specifically binds unesterified but not esterified cholesterol.  
The LDL-induced cholesterol esterification rate assay also represents a useful 
complementary evaluation (92). More recently, a preliminary diagnosis of NP-C disease using 
the filipin test in a  blood smear has been proposed (128), but this demonstrated that there 
were no morphological differences between blood samples collected from healthy controls 
and NP-C patients; nevertheless, filipin signal intensities were much higher in NP-C patients 
than those of healthy controls (128). However, the filipin test gives inconclusive results in 
15% of cases (129). If after these tests the NP-C diagnosis is not absolutely clear, further DNA, 
mRNA and protein analyses is required.  
Recently, diagnostic markers for NP-C such as plasma oxysterols (130) have been 
proposed and also the measurement of intracellular acidic compartment volume (mean 
equivalent of fluorescence - MEFL/LysoTracker) (131). However, both are complementary to 
the above diagnostic methods, and they are required to be more focused on the 
development of the disease, its assessment, and its response to treatment. More recently, a 
new blood biomarker has been proposed, specifically lysosphingomyelin-509 (a derivative of 
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lyso-sphingomyelin), which is detectable at higher levels in blood collected from NP-C1 
patients by LC-MS/MS (132). 
 
1.5.6. Treatment  
NP-C presents a complex and wide spectrum of symptoms derived from the 
pathophysiology associated with this disease, and different pharmaceutical approaches have 
been explored in order to ameliorate the disease process. 
 NP-C disease also involves behavioural disturbances, catatonia, psychosis and 
depression (133); indeed, general psychotic symptoms appear in early adulthood in 
approximately 35% of NP-C patients (113). Moreover, in view of the high incidence of 
epilepsy in these patients [seizures are common manifestations of the disease in young 
patients (134)], anti-epileptic drugs are also employed, including sodium valproate (VPA), 
iamotrigin and levetiracetam (135). VPA is also an inhibitor of histone deacetylases (HDACi), 
a process that will be further described as a target. However, VPA is one of the weakest and 
simplest HDACi, and indeed its performance was not recognized until long after preliminary 
studies were performed on its therapeutic properties (136). 
Differing medication strategies have been proposed for the treatment of NP-C 
disease according to the different classes of its clinical development. Disease-induced 
apoptosis has been proposed as one of the targets, so that an inhibitor of protein tyrosine 
kinase, imatinib (Gleevec, STI571), was tested against the c-Abl/p73 system, proteins 
involved in cerebellar neurodegeneration in NP-C (137). By inhibiting these proteins, Alvarez 
et al. reported an increase in Purkinje cell survival, and also a reduction of the apoptotic 
process in the cerebellum of NP-C mice; accordingly, neurological symptoms of this mice 
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model were improved, together with a reduction of weight loss coupled with a longer mean 
lifespan (137).  
A different approach is the therapeutic use of cyclodextrins, which are cyclic 
polysaccharides with a truncated cone shape that has the ability to carry hydrophobic 
molecules inside its crevice whilst having a hydrophilic outer surface that renders this 
polymer soluble in polar solvents and fluids. Cyclodextrin has been proven to ameliorate the 
neurological symptoms in NP-C1 disease in the NP-C1 mouse model (BALBc/NPCnih) (138) in 
view of its ability to remove cholesterol from neurons; although this process remains 
unclear. Furthermore, a cyclodextrin derivative, 2-hydroxypropyl-cyclodextrin has also been 
proven to reduce the activation and influx of macrophages in both liver and brain, together 
with a corresponding improvement in Purkinge cell survival and consequently a longer 
lifespan (139).  
Another group of compounds tested for the treatment of NP-C disease are histone 
deacetylases. These agents increment the expression of some chaperones that allow mutant 
NPC1 proteins to be delivered from the ER to LE/L system. If these NP-C1 mutant proteins 
exhibit sufficient activity to export cholesterol from the lysosome, then its accumulation may 
be ameliorated as well as the clinical manifestations derived therefrom (140). 
In view of the inflammatory processes that take place in the brain of NP-C1 patients 
some treatment strategies targeted on the amelioration of this symptom have also been 
investigated. The activation of microglial cells and macrophages in the NP-C1 mouse brain 
also gives rise to oxidative stress, which has been targeted in combination therapies such as 
ibuprofen/aspirin plus vitamin C (141); indeed, in the work performed by Smith et al., they 
show how the use of an NSAID such as ibuprofen can improve the lifespan of animals in a 
mouse model of NP-C1, based on survival curves (141). Another combined therapy using 
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ibuprofen as an anti-inflammatory agent is its employment with both curcumin and MGS, in 
order to target GSL storage (MGS), inflammation (ibuprofen) and calcium homeostasis 
(curcumin) (142). In this work, the authors showed how a combination therapy comprising 
curcumin and MGS was more efficient than the three drugs together, and then suggested 
how anti-inflammatory treatment can ‘act as a double-edged sword’, ameliorating the 
symptoms in the first instance and then becoming gradually detrimental, as previously 
reported for Sandhoff disease (143), another LSD.  
  
1.5.6.1. Miglustat 
 One sub-group of iminosugars is the N-iminosugars, in which the anomeric carbon 
and the intracyclic oxygen have been replaced by an -NH and a methylene group 
respectively. One of the members of this group is miglustat (MGS).  
MGS (OGT 918, N-butyl-deoxynojirimycin) is a small molecule (MW = 218) derivative 
of a family of polyhydroxylated alkaloids extracted from some plants and micro-organisms, 
specifically, a deoxynojirimicyn derivative.   
This agent inhibits glucosylceramide synthase and the synthesis of all 
glucosylceramide-based GSLs, including lactosylceramide and gangliosides (Figure 1.12), 
since this is the first step in glycosphingolipid synthesis (144). The type of inhibition of this 
drug was determined by using ceramide as an acceptor, and revealed that 
glucosyltransferase activity was competitive for ceramide and non-competitive for UDP-
glucose, confirming that this inhibition was performed by ceramide mimicry (145).  
MGS can effectively pass the blood-brain-barrier (BBB), and has the potential to be 
effective in treating LSD with neurologic manifestations; indeed, the observational cohort 
study carried out by Pineda et al. (115) indicates that MGS stabilizes neurological disease in 
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the majority of patients with NP-C. MGS also provides protection against oxidative stress 
(146), which appears to be part of the pathological cascade of symptoms of the disease (146, 
147). Moreover, beneficial effects on axonal degeneration were also shown in patients 
receiving MGS treatment (148). 
 
 
Figure 1.12. Key steps in the biosynthesis of GSLs: ceramide glucosyltransferase gives rise to 
ceramide glycosylation generating glucosylceramide, a step inhibited by MGS. This 
glycosphingolipid is subsequently converted to lactosylceramide which is the precursor of all 
the glycosphingolipid series shown. 
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Prior to the approval of MGS as a therapeutic agent for NP-C1 disease, it had been 
used to treat other GSL diseases such as Tay-Sachs and Sandhoff diseases (149). Indeed, it 
was approved by the European Medicines Agency (EMA) in 2002, and by the USA Food and 
Drug Administration (FDA) in 2003 for the treatment of type I Gaucher disease (150, 151). 
However, for the treatment of NP-C disease it was only approved in 2009 by the EMA; in 
fact, despite its use being approved in most countries, this has not been accomplished in the 
USA. It was first proposed for the treatment of this condition based on evidence of slower 
disease progression and prolonged survival in animal models (108). Subsequently, clinical 
studies demonstrated the stabilization of neurologic disease in both children and adults 
treated with MGS (152). 
The recommended daily dose is 200 mg 3 x daily in adults, and is adjusted according 
to body surface area in patients under 12 years of age (EMA). It was shown to be rapidly 
absorbed, and maximal plasma concentrations are attained on average 2.0 - 2.5 hr. after 
dosing, on average. Renal clearance is about 150 mL/min (no biotransformations have been 
reported), suggesting that the renal elimination is mainly through filtration and also that the 
risk for interactions with drugs which are eliminated by active secretion is low (EMA).  
MGS was firstly discovered to improve neurological dysfunctions together with an 
increase in lifespan in murine and feline NP-C models after its daily administration (153). 
Saccadic eye movement velocity, a parameter for disease progression exploration, is 
decreased in both the vertical and horizontal direction in NP-C1 patients (154-156); 
nonetheless, when these patients receive MGS treatment, this defect is improved (157). 
Moreover, about 72% of patients treated with this drug over 12 months presented stabilized 
disease status (based on ambulation), swallowing and cognition (158). 
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CHAPTER 2 
 
1H NMR LINKED METABOLOMICS ANALYSIS OF 
URINE COLLECTED FROM NP-C1 PATIENTS, 
MIGLUSTAT-TREATED PATIENTS AND 
HETEROZYGOUS CARRIERS 
 
 
2.1. URINE SAMPLES PREPARATION FOR NMR ANALYSIS 
107 urine samples collected from untreated NP-C1 patients, heterozygote carriers as 
controls and miglustat (MGS)-treated patients were stored at -80oC prior to 1H NMR analysis. 
Urine samples were provided by Prof. Platt and colleagues at the Department of 
Pharmacology, University of Oxford (Oxford, UK); these samples were collected with 
informed consent and approved by the appropriate Research Ethics Committee 
(06/MRE02/85). Samples were thawed at room temperature, and 0.60 mL of each sample 
was centrifuged (5 min., 10,000 x g) in order to remove cells and debris; 0.55 mL of the 
supernatant was collected from each sample and subsequently spiked with 0.05 mL of D2O, 
thoroughly mixed, and 0.60 mL aliquots of the supernatants were then transferred to 5-mm 
diameter NMR tubes (Norell, UK).  
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Disease class NP-C1 Heterozygotes MGS-treated NP-C1 
Samples (male/female) 14 (6/8) 47 (6/26)* 46 (14/32) 
Mean age in years (range) 9.9 (0.5-29.6) 57.8 (42.6 - 64.0)** 18.3 (3.0 - 33.0) 
Table 2.1. General characteristics of participants included in the urinary NP-C1 metabolomics 
investigation. *Information regarding the gender of the remaining participants was 
unavailable. **Mean and range computed only from 8 HET participants in view of a lack of 
information availability. 
 
Urine samples were collected from 21 NP-C1 disease patients at differing time points 
throughout a 4 year period, both prior and subsequent to treatment with MGS, yielding a 
total of 47 samples from patients treated with this therapeutic agent. MGS dose is calculated 
and based on body surface area for children, whilst adult patients typically receive 600 
mg/day. Eight of the patients in the cohort received 3 × 200 mg daily doses, two patients a 
reduced dose of 2 × 200 mg daily, four patients received a single 100 mg dose, and one 
patient received 2 × 200 mg daily doses followed by a 100 mg nightly dose. Unfortunately, 
dosages of valproate received by the relevant NP-C1 disease patients were unavailable to 
the author; however, those for the control of epileptic seizures in adults typically range from 
1 to 2 g daily, and children 10-15 mg/kg/day up to a maximum of 600 mg daily. 
 
Spiking experiments: Standard solutions of authentic biomolecules were prepared in 
the mM range concentrations in 0.10 M phosphate buffer (pH 7.00). In the case of bile acids 
(Sigma-Aldrich, UK), they were firstly dissolved in a pH 7.00 buffer solution to reach a final 
concentration of 10 mM; then, 450 μL of urine samples were spiked with 100 μL of these bile 
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acids, and 50 μL of D2O containing 0.05% wt. d-TSP) as a lock reference. Subsequently, the 
mixture was thoroughly mixed and transferred to a 5-mm diameter NMR tube (Norell, UK). 
 
2.2. NMR ANALYSIS OF NP-C1 URINE SAMPLES 
1D 1H NMR: Single-pulse 1H NMR spectra experiments were acquired at 298 K on a 
Bruker AX 600 MHz spectrometer (Queen Mary University of London facility, London, UK). 
Each spectrum was acquired for 128 scans, 5.6 μs pulses, 32 K (subsequently filled to 65 K) 
data points and a spectral width of 12.00 ppm. The intense residual H2O/HDO signal (δ = 4.80 
ppm) was supressed using Presaturation (Bruker zgpr pulse sequence). Spectra were 
acquired in an automated manner using a sample changer for continuous sample delivery. 
 
1H-1H COSY: These experiment were conducted at 300 K on a Bruker AV 400 MHz 
spectrometer (Leicester School of Pharmacy, De Montfort University). The pulse sequence 
employed was cosygpprqf (Bruker) with presaturation during relaxation delay using gradient 
pulses for selection. The spectral width in the F1 and F2 axes were 4000 Hz, and 2048 data 
points were collected in F2. For the urine samples, 256 increments and 32 scans per 
increment were used. The relaxation delay was 4.5 s for a total acquisition time of ∼ 7 hr. 
Prior to Fourier transformation, a sine function was applied in both time domains.  
 
1H-1H TOCSY: This experiment was carried out at 300 K on a Bruker AV 400 MHz 
spectrometer (Leicester School of Pharmacy, De Montfort University). Spectra of urine were 
acquired using dipsi2esgpph pulse sequence (Bruker) in which 72 transients per increment 
and 256 increments were collected into 2k data points over a spectral width of 12 ppm in 
both dimensions applying the MLEV17 spin-lock scheme with a spin-lock power of 6 kHz. A 
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recycle delay of 1.43 s was used, and water suppression was achieved using excitation 
sculpting with gradients, and DIPSI2 sequence was employed for mixing. The total acquisition 
time per sample was ∼ 18 hr. 
 
1D-TOCSY: 1D TOCSY spectra were acquired using the SELMLGP pulse sequence (1D 
homonuclear Hartman-Hahn transfer using MLEV17 sequence for mixing using selective 
refocusing with a shaped pulse). This experiment was carried out at 300 K on a Bruker AV 
400 MHz spectrometer (Leicester School of Pharmacy, De Montfort University). The mixing 
time was set to 0.2 s, 256 FIDs were acquired. The duration of the selective 180° shaped 
pulse was optimized to 80 ms and the power level Gauss shape to 63 dB. The 1D-TOCSY pulse 
sequence selectively excites only the peak of interest at the specified chemical shift value in 
the spectrum, which corresponds to a particular proton/group of protons in a molecule, for 
a period of time (the mixing time), in order to transfer this magnetization via J-couplings to 
all protons throughout the spin system which it is part of. 
 
2.2.1. 1H NMR Urinary profiles of NP-C1 patients 
The identities of metabolites present in the urinary 1H NMR spectra acquired were 
assigned according to chemical shift values, coupling patterns and coupling constants and 
also from a range of literature sources (45, 159, 160), and then cross-checked with the 
Human Metabolome Database (HMDB) (161). A combination of both 1D and 2D COSY and 
TOCSY techniques were employed to confirm these assignments, as was the ‛spiking’ of these 
biofluids with appropriate small (μL) volumes of solutions of authentic biomolecules 
prepared at mM concentrations.  
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Figure 2.1.  (a), (b) and (c), 0.50-2.75, 2.75-5.50 and 6.00-9.50 ppm regions, respectively, of 
the 600 MHz urinary 1H NMR profile of an NPC1 patient (a typical spectrum is shown): 
Abbreviations: 1, Bile acids-C18-CH3; 2, Ile-CH3; 3, Leu-CH3; 4, Val-CH3; 5, Val-CH3'; 6, Methyl-
succinate-CH3; 7, 2-Oxoisovalerate-CH3's; 8, 3-Aminoisobutyrate-CH3; 9, 3-D-
Hydroxybutyrate-CH3; 10, L-Fucose-CH3; 11, 3-Hydroxyisovalerate-CH3; 12, Lactate-CH3; 13, 
2-Hydroxyisobutyrate-CH3's; 14,  Lysine-C4-CH2; 15, Alanine-CH3; 16, 5-Aminovalerate-C3/4-
CH2; 17, Lysine-C5-CH2; ; 18, Thymine-C5- CH3; 19, 2-Hydroxyglutarate-C3-CHA; 20, Lysine-C3-
CH2; 21, Acetate-CH3; 22, 2-Hydroxyglutarate-C3-CHB; 23, N-acetylaspartate-CH3; 24, N-
acetylneuraminate-CH3; 25, N-acetyl-X-CH3; 26, Glutamine-C2-CH2; 27, Methionine-S-CH3; 
28, Glutamine-C3-CH2; 29, Acetoin-C1-CH3; 30, Acetoacetate-CH3; 31, 2-Hydroxyglutarate-
C4-CH2; 32, Pyruvate-CH3; 33, Glutamate-C3-CH2; 34, Succinate-CH2's; 35, Glutamine-C4-CH2; 
36, Citrate-CH2A/CH2B; 37, 3-Aminoisobutyrate-C2-CH2; 38, Dimethylamine-CH3's; 39, 
Trimethylamine-CH3's; 40, Dimethylglycine-CH3's; 41, Creatinine-CH3/Creatine-CH3; 42, 
Malonate-CH2; 43, Taurine-CH2-NH3+; 44, Trimethylamine-N-oxide-CH3's; 45, Methanol; 46, 
Cystine-C3/C6-CH2; 47, cis-Aconitate-CH2; 48, Taurine-CH2-SO3-; 49, 3-
Hydroxyphenylacetate-CH2; 50, Phenylacetate-CH2; 51, Glycine; 52, Phenylacetylglycine-
CH2; 53, Lysine-C2-CH; 54, Guanidoacetate-CH2; 55, Ethanolamine-CH3; 56, Mannitol; 57, 
Serine-C2/3-CH2; 58, Creatine-CH2; 59, Glycolate-CH2; 60, Hippurate-CH2; 61, Creatinine-CH2; 
62, Lactate-CH; 63, Tartrate-CHOH; 64, Trigonelline-CH3; 65, β-Glucose-C1-CH; 66, α-
Glucose-C1-CH; 67, Allantoate-CH; 68, Sucrose-C1-CH; 69, Allantoin-CH; 70, 2-Furoylglycine-
C3-CH; 71, Tyrosine-C3/C5-CH; 72, 3-(3-hydroxyphenyl)-3-hydroxypropanoate-C1/C6-CH; 
73, Phenol-C2/C4/C6-CH; 74, Histidine-C5-CH; 75, Phenol-C3/C5-CH; 76, Tyrosine-C2/C6-CH; 
77, Indoxyl-sulphate-C8/C7/C2-CH; 78, Indoxyl-sulphate-C6/C9-CH; 79, Indoxyl sulphate-C2-
CH and Phenylalanine-C2/C6-CH; 80, Phenylalanine-C3/C4/C5-CH; 81, Indoxyl sulphate-C6-
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CH and Benzoate-C3/C5-CH; 82, Hippurate-C3/C5-CH: 83, Hippurate-C4-CH; 84, 1-
Methylhistidine-C4-CH; 85, Hippurate-C2/C6-CH; 86, Histidine-C2-CH; 87, 3-Methylhistidine-
C2-CH; 88, Quinolinate-C5-CH; 89, 3-Methylxanthine-C7-CH; 90, Trigonelline-C5-CH; 91, 
Hypoxanthine-C2/C7-CH; 92, 1-Methylnicotinamide-C5-CH; 93, Quinolinate-C6-CH; 94, 
Formate-H; 95, Trigonelline-C4/C6-CH; 96, Trigonelline-C2-CH; 97, N-methylnicotinamide-
C2-CH; 98, N-Ribosylnicotinamide-C2-CH.  
 
 Typical 600 MHz single-pulse 1H NMR spectra of urine samples collected from NP-C1 
disease patients and their heterozygous carrier controls contained a multitude of prominent, 
sharp signals assignable to a wide range of low molecular-mass metabolites (Figure 2.1). 
Indeed, resonances ascribable to a very wide range of amino acids [e.g. glycine (Gly), alanine 
(Ala), leucine (Leu), isoleucine (Ile), valine (Val), tyrosine (Tyr) and taurine, etc.], short-chain 
organic acid anions (e.g., acetate, citrate, formate, fumarate, lactate, pyruvate, succinate, 
etc.), amines such as methyl-, dimethyl- and trimethylamines, and bile acids, together with 
many further classes of biomolecules, were readily observable. Indeed, > 100 different 
metabolites were unambiguously assigned on the basis of the 107 spectra acquired. Some 
resonances present in the spectra required further work in order to confirm assignments in 
addition to the simple acquisition of a 1D spectrum, and therefore correlation spectroscopic 
techniques were applied, such as TOCSY (in both 1D and 2D versions) and COSY. The coupling 
patterns of the metabolites can be explored by performing these correlation spectroscopy 
experiments, as can be observed in Figure 2.2, in which 3-aminoisobutyrate (3-AIB) was 
identified in urine samples using a 1D-TOCSY experiment. 
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Figure 2.2. 400 MHz 1D-TOCSY spectrum of a human urine specimen collected from an NP-
C1 disease patient:  this selective TOCSY experiment confirms couplings between each of the 
3-aminoisobutyrate (3-AIB) resonance assignments. The signal centred at 1.21 ppm was the 
one selectively irradiated in this experiment. 
 
The assignments of some metabolites were not accomplished in view of their low 
concentration or overlap with other resonance peaks in view of the great complexity of the 
urinary 1H NMR profiles explored, since more than 200 compounds are identifiable (45).  
 
2.2.2. Identification of bile acids in urine samples 
The C18-CH3 group of bile acids (BAs) have urinary resonances located within the 0.60 
and 0.75 ppm region of 1H NMR spectra. The importance of the resonances encountered 
therein for further MVA will be detailed in the following sections. Assignments for the bile 
acids’ C18-CH3 group signals were confirmed via the acquisition of 1H NMR spectra on 
selected urine samples which had been ‛spiked’ with authentic bile acid standard solutions 
(Figure 2.3), i.e. chenodeoxycholate, glycocholate, glycochenodeoxycholate, 
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taurochenodeoxycholate, taurodeoxycholate and tauroursodeoxycholate.  Lithocholate 
solubility in water is only ca. 0.05 µM (162), and therefore, it is unobservable by either 400 
MHz or 600 MHz NMR spectrometers; accordingly, its C18-CH3 resonance was not observed 
in Figure 2.3(a).  
 
 
Figure 2.3. (a) 0.4 - 1.1 ppm region from a 400 MHz 1H NMR spectra of a urine sample ‛spiked’ 
with different bile acids (BAs): the C18-CH3 group signal can be clearly observed as a singlet 
between 0.65 and 0.75 ppm. The green shadowed rectangle highlights the 0.66 - 0.69 ppm 
bucket. (b) BAs general chemical structure together with a table listing those BAs arising from 
the different possible substitutions in those groups highlighted.  Glycine or taurine adducts 
resulting from further conjugations are located at R1. 
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BAs that do not present an -OH group in either C7 or C12 [Figure 2.4 (b)] positions 
are responsible for this signal, since BAs that do have a downfield-shifted C18-CH3 resonance 
contain a hydroxyl group. Indeed, the more pronounced effect is ascribed to C12, as 
expected in view of its proximity to C18. The conjugation with either taurine or glycine does 
not exert any major observable effects on the chemical shift value of this C18-CH3 resonance 
[Figure 2.3 (a)]. Additionally, p-values arising from the ANOVA model depicted in Equation 
19 for adjacent regions to the 0.66-0.69 ppm bucket were not significant for the comparison 
between HET and NPC groups [p (0.61 - 0.66 ppm) = 0.211), p (0.69 - 0.72 ppm) = 0.728]. 
 
2.3. DATA PREPROCESSING  
61 urine samples were initially included for statistical analysis: 14 untreated NP-C1 
patients (NPC) and 47 heterozygous carriers as controls (HET). The binning process gave a 
table of 61 rows (samples) x 199 columns (variables), containing the sum-normalised 
intensities of each spectrum. Spectral regions containing resonances arising from ethanol (t, 
1.22 - 1.24 ppm; q, 3.63 - 3.67 ppm), which were detectable in several of the heterozygous 
carrier urine samples and urea (br, 5.59 - 5.99 ppm) were removed from all the urinary 1H 
NMR profiles for further MVA. 
An exponential line-broadening function of 0.30 Hz was routinely applied to the FIDs 
prior to FT for all the spectra that were subsequently phased, baseline corrected and 
referenced to the formate (s, 8.46 ppm) resonance since no internal standard was added to 
the samples. Moreover, the formate-H resonance is readily visible as a singlet in a clear 
region of the urinary  NMR profiles, and therefore it is easily identifiable. The intense δ = 4.65 
- 5.15 ppm residual H2O/HDO signal region was also removed from all the 1H NMR profiles 
acquired prior to the performance of MV data analysis strategies. 
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Spectral data were analysed using NMR Spectrus Processor 2012 (Advanced 
Chemistry Development Inc., ACD/Labs, Toronto, Canada) and binned using the ‘Intelligent 
Bucketing’ procedure implemented in the software noted above. This technique splits the 
spectra into chemical shift buckets, given the position of a particular resonance peak in every 
spectrum, so that the same signal in different spectra always is incorporated into the same 
bucket, even if pH or ionic strength effects have shifted it somewhat. The bucket width 
selected was 0.04 ppm with a 50 % looseness factor (width variation of the bucket in order 
to accommodate the resonance peak). This algorithm for binning the spectra (in different 
integral regions) aims at overcome the problem which arises from setting buckets’ limits in 
the middle of a resonance peak, then yielding inaccurate integral values and biased results 
when the statistical analysis is performed on the dataset obtained. 
 
2.3.1. Creatinine normalisation 
Significant differences between the mean urinary creatinine (Cn) concentrations of 
the two disease classification groups were analysed in order to explore the possibility of 
performing Cn-normalization, since both groups investigated, i.e. NP-C1 patients and 
heterozygous carriers as controls, were not age-matched, and Cn urinary concentration is 
known to increase with age (157). Therefore, a preliminary ANOVA (Equation 19) was carried 
out for Cn only (Figure 2.4); for this purpose, the dataset was sum-normalised, cube-root 
transformed and Pareto scaled prior to this analysis. The bucket selected for this univariate 
analysis was 4.05 - 4.10 ppm, since the Cn resonance peak at 3.03 ppm presents some 
overlap with the creatine (Cr) and phosphocreatine-CH3 resonances.   
 
 
 
61 
 
Figure 2.4. Box plot for Cn signal (4.05 - 4.10 ppm): Cn levels for both disease classification 
groups were compared using the ANOVA model depicted in Equation 19, showing a 
significant difference. p = 4.45 x 10-7 for the disease classification contribution (p < 0.05, *; p 
< 0.01, **; p < 0.001, ***). 
 
In view of the significant differences between both classification groups (NPC and 
HET) for the 4.05 - 4.10 ppm Cn bucket, the dataset was constant sum normalised (the sum 
of all individual integral buckets yields 1 for each spectrum) and not Cn-normalised. After 
this normalisation, the dataset was cube-root transformed and Pareto scaled for all further 
MVA performed.  
The main aim of Cn-normalisation has always been to reduce the potentially large 
intra-and inter-individual differences in diuresis, and therefore, prevent the occurrence of 
false negative or false positive values attributable to very dilute or very concentrated urine 
samples (163). Nevertheless, Cn-normalisation has only been proven to be useful when no 
differences in diet or kidney disease were assumed, or if the kinetics of excretion of the 
selected biomarker(s) is(are) similar to Cn (164); indeed, some authors prefer not to Cn-
normalise their data if the metabolites of interest do not have the same kinetics of excretion 
as Cn. In view of the participants’ age in this study, where the NP-C1 patients are all below 
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32 years of age and the HET participants are the parents of those donors, the expected result 
for Cn levels matches with the one obtained in the ANOVA performed. The p-values obtained 
therefrom indicated significatively higher Cn levels for the HET group, and therefore, Cn-
normalisation was discarded for MVA of the urinary dataset. 
Prior to performing both univariate and MVA, samples were visually checked for any 
major disturbances. One NP-C1 patient was found to be receiving valproate treatment by 
detecting a triplet at 0.84 ppm and its coupling with the remaining valproate-CH2’s resonance 
signals, and 6 heterozygous carriers plus another NP-C1 patient taking acetaminophen, since 
their characteristic resonance signals were identified at 7.13 and 7.35 ppm for its glucuronide 
metabolite, 7.31 and 7.45 ppm for the sulphate one and 2.16 ppm for its acetamido methyl 
group (Figure 2.11). All these samples were removed for the purpose of all further analysis. 
 
2.4. UNIVARIATE AND MULTIVARIATE ANALYSIS OF THE 1H NMR URINARY DATASET  
2.4.1. Univariate data analysis: ANOVA 
 ANOVA analysis of the urinary dataset was performed according to the model 
depicted in Equation 19 to explore any significant differences between the metabolites for 
each disease group, and also to isolate the variance attributable to the disease status, 
removing any further effect attributable to kinship. In this ANOVA model, Yijk represents the 
(univariate) predictor variable value observed, µ is the overall population mean value in the 
absence of any significant, influential sources of variation. Di, Fj and DFij are components of 
variation ascribable to between-disease classifications, family, and the disease classification-
family interaction sources, and eij is the unexplained error (residual) contribution.  
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𝑌𝑖𝑗 =  𝜇 + 𝐷𝑖 + 𝐹𝑗 +  𝐷𝐹𝑖𝑗 +  𝑒𝑖𝑗                                 (19) 
 
2.4.2. Multivariate data analysis 
2.4.2.1 Preliminary data analysis: PCA 
PCA [MetaboAnalyst 3.0 (50), this software was utilised for all the PCA performed in 
this work] was employed in order to explore any underlying classification patterns within the 
urinary NP-C1 dataset. In the PCA 3D scores plot depicted in Figure 2.5, the clustering of 
samples based on their disease status is not readily visible. Although NPC urine samples have 
lower values for PC3 than of the HET group, there is some overlap for that PC. PC1 and PC2 
do not accomplish any clear separation. However, combination of these 3 PCs allows the 
best visualization of the clustering by disease class. 
 
 
Figure 2.5. PCA 3D score plot for the NP-C1 urinary dataset: representation of the 3 first PCs 
in a 3D scores plot with the projections on the 2D planes as the scores plot for each 2 PCs. 
(green circles = HET, yellow diamonds = NPC). 
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2.4.2.2. Classification performance 
Random Forests (RFs): The RFs technique was employed for classification and 
variable selection purposes using the randomForest R package (165) (this software was 
utilised for all the RF analysis performed in this work). 
RFs parameters were tuned in order to improve its performance, so the number of 
trees was set up to 500 and the number of variables selected at each split was 8 based on 
the Out-Of-Bag (OOB) error values obtained. RFs was applied over 100 iterations; at each 
iteration, the OOB and the confusion matrix was stored in order to obtain classification 
performance parameters (Table 2.2). Additionally, variable importance (mean decrease 
accuracy criterion, MDA) values for variable selection were extracted and their mean and 
standard error of the mean (SEM) values computed. For each set of 100 iterations, a column 
of 65 rows (number of samples) was generated containing random numbers from 0 to 1, so 
that samples with values > 0.66 were included in the test-set, whilst samples with values ≤ 
0.66 were included in the training-set. This procedure, also known as Monte Carlo Cross-
Validation (MCCV) was applied to each class (NPC and HET) independently.  
 
Genetic Algorithms (GAs): The GAs strategy was applied using the GALGO R-package 
(166) that allows the selection of different parametric and non-parametric classification 
techniques such as k-nearest-neighbours, discriminant functions (Maximum Likelihood), 
nearest centroid, SVMs, RFs and neural networks. In this work we have used SVMs and 
MLHD. 
For this GAs methodology, the chromosome size was selected to be 10 (maximum 
number of variables in each model/chromosome). These chromosomes evolved generating 
500 solutions (chromosomes/models) with the aim of achieving a fitness value of 0.9. To 
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build up the models, the methods employed were Maximum LikeliHooD (MLHD, a 
modification of LDA that uses Bayes’ rule as the discriminant function assigning a sample to 
the class with highest conditional probability) and SVMs, using a radial Kernel. The 
performance of the models generated using the techniques delineated above was computed 
by using a 5-fold cross validation procedure and the outcomes are listed in Table 2.2. 
 
Correlated Component Regression-Linear Discriminant Analysis (CCR-LDA): CCR-LDA 
was set to a maximum of 1, 2 and 3 components and to a maximum of 5, 10, 15 and 20 
variables for developing the classification models. Each of the combinations was repeated 5 
times, resulting in 60 different models. The validation procedure was a 5-fold cross-
validation over 10 rounds. Results from this CCR-LDA analysis are shown in Table 2.2.  
 
Table 2.2. Classification performance of the techniques employed for the analysis of the NP-
C1 urinary dataset: the OOB error value is also indicated for the RFs approach. Standard error 
of the mean values for each of the parameters computed are provided in brackets. 
 
 All the MVA techniques were able to succesfully classify urine samples regarding their 
disease status (NPC vs. HET); indeed, they all gave very good results for specificity and 
accuracy. However, values obtained for sensitivity were not very efficient, the CCR-LDA 
technique having the lowest sensitivity and the highest variablity, not only for sensitivity, but 
MVA Technique OOB (SEM) Accuracy (SEM) Sensitivity (SEM) Specificity (SEM) 
RFs 0.224 (0.00012) 0.835 (0.001) 0.695 (0.001) 0.831 (0.003) 
GA-MLHD/SVM - 0.827 (0.002) 0.752 (0.002) 0.903 (0.001) 
CCR-LDA - 0.810 (0.013) 0.583 (0.032) 0.926 (0.012) 
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for the remainder of the classification performance parameters computed, as observed for 
the SEM values displayed in Table 2.2. However, these SEM values cannot be considered 
high, since the maximum value accounts for only 5.49% of the averaged sensitivity 
parameter. Nevertheless, the CCR-LDA model gave the highest specificity value (0.926). The 
RFs and CCR-LDA strategies gave the highest accuracy and specificity values respectively 
when applied to the NP-C1 urinary dataset.   
 The limitations introduced for GAs and CCR-LDA classifications technique with regard 
of the number of variables that could be included to the model building process were aimed 
at reducing the neglective effect of overfitting, i.e. the employment of a number of variables 
highly exceeding the number of samples, which results in very accurate models which usually 
fail when new samples are tested. Additionally, cross-validation procedures were 
implemented in the model development process in order to also overcome this issue. 
 
2.4.2.3. Variable Selection 
Random Forests (RFs): Throughout the 100 iterations applied in the RFs analysis 
outlined above, MDA value for variable importance was computed, and consequently, the 
mean value of those 100 MDAs obtained for each variable; so that a variable ranking was 
obtained on completion of the process (Table 2.3). 
 
Genetic Algorithms (GAs): The GALGO package saves the frequency at which each 
variable is selected to generate a successful classification (i.e., reach a fitness of 0.9). The 
variables can then be ranked and averaged for both techniques (SVMs and MHLD) based on 
these frequencies (Table 2.3). 
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Correlated Component Regression-Linear Discriminant Analysis (CCR-LDA): The 
average presence of the variables in the models built by this CCR technique was computed 
in order to generate a ranking. This ranking was based exclusively on the number of times a 
specific variable is included within a model, so their loadings in each component were not 
considered (Table 2.3).  
 
Bucket 
(ppm) 
Assignment 
Multiplicity 
(J, Hz) 
p-value for 
Disease 
Fold 
Change 
RF 
GA-
MLHD/SVM 
CCR-
LDA 
0.66 - 0.69 BAs-C18-CH3 s 9.39 x 10
-5
 8.54 (7) (1) (8) 
0.72 - 0.76 Unknown-1 d (6.6) 2.79 x 10
-5
 -11.86 (3) (2) (2) 
0.81 - 0.83 2-OH-3-MeBu-CH3 d (6.7) 8.47 x 10
-3
 -10.22 (>15) (4) (7) 
0.98 - 1.03 Val-CH3’s/Ile-CH3a 2 x d 1.65 x 10
-2
 5.06 (>15) (>15) (14) 
1.17 - 1.22 3-AIB-CH3 d (7.4) 8.58 x 10
-9
 2.81 (2) (>15) (1) 
1.36 - 1.41 2-HydroxyisoBu-CH3’s s 3.65 x 10
-2
 1.84 (15) (>15) (>15) 
1.50  - 1.56 n-Butyrate-C3-CH2 m 6.18 x 10
-4
 13.00 (13) (>15) (>15) 
1.58 - 1.63 5-Aminovalerate-C3/4-CH2 m 3.87 x 10
-2
 -5.04 (>15) (10) (12) 
2.02 - 2.08 N-acetyl-CH3 s 2.15 x 10
-2
 1.25 (>15) (>15) (10) 
2.08 - 2.12 Gln-C3-CH2 m 2.61 x 10
-2
 1.49 (6) (>15) (>15) 
2.12 - 2.18 Unknown-2 m 2.98 x 10
-1
 -1.09 (>15) (15) (>15) 
2.25 - 2.31 2-Hydroxyglutarate-CH2 m 3.91 x 10
-3
 -1.52 (>15) (12) (>15) 
2.87 - 2.89 TMA-CH3’s s 2.09 x 10
-2
 2.29 (10) (7) (>15) 
3.24 - 3.29 TMA-N-oxide-CH3’s s 1.26 x 10
-3
 -1.51 (8) (3) (12) 
3.29  - 3.33 Methanol s 2.39 x 10
-3
 -1.96 (11) (>15) (15) 
3.46 - 3.48 3-HydroxyPheAc-CH2 s 1.73 x 10
-1
 1.38 (>15) (11) (>15) 
3.63 - 3.67 Glycerol-C1/3-CH2a m 5.21 x 10
-1
 1.06 (>15) (14) (>15) 
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3.67 - 3.71 AAs-α-CHs/3-OH-isoBu-β-CH2 m 7.23 x 10
-2
 1.19 (>15) (13) (>15) 
3.88  - 3.92 Hippurate-CH2 d (5.9) 1.04 x 10
-1
 1.02 (12) (>15) (>15) 
3.92 - 3.95 Cr-CH2 s 1.52 x 10
-5
 1.59 (14) (6) (4) 
4.05 - 4.10 Cn-CH3 s 4.45 x 10
-7
 -1.33 (1) (9) (6) 
8.40 - 8.42 Quinolinate-C6-CH dd 3.83 x 10
-5
 30.32 (9) (>15) (13) 
8.80 - 8.86 Trigonelline-C4/6-CH m 4.96 x 10
-4
 -6.70 (4) (5) (5) 
9.11 - 9.16 Trigonelline-C2-CH s 2.92 x 10
-4
 -5.27 (5) (8) (3) 
Table 2.3. Discriminatory variables for the urinary NP-C1 dataset: top 15 variables selected 
by the three techniques employed for analysis (RFs, CCR, GAs) are listed along with their 
assignment, multiplicity, ANOVA p-value for ‛Disease’, fold change (positive values for 
variables with higher levels in NPC group and negative for those with lower values) and the 
ranking for each MVA technique specified in the last column. The colour codes in the last 3 
columns will serve to correlate the disease related-metabolic pathways discussed in Chapter 
6 with the MVA techniques employed to select the metabolites involved in those pathways. 
Abbreviations: Val, Valine; Ile, Isoleucine; 2-OH-3-MeBu, 2-Hydroxy-3-methylbutyrate; 3-AIB, 
3-aminoisobutyrate; 2-HydroxyisoBu-CH3’s, 2-Hydroxybutyrate-CH3’s; Gln, Glutamine; 3-
HydrohyPheAc, 3-Hydroxyphenylacetate; AAs, amino acids; 3-OH-isoBu-β-CH2, 3-
Hydroxyisobutyrate-β-CH2. 
  
 50% of the variables listed in Table 2.3 were ranked in the top 15 for at least 2 
different techniques, and the 0.66 - 0.69, 0.72 - 0.76, 3.24 - 3.29, 3.92 - 3.95, 4.05 - 4.10, 8.80 
- 8.86 and 9.11 - 9.16 ppm buckets were featured as top variables for all three MVA methods, 
which might indicate that these variables were the more robust features to differentiate 
samples according to their disease status. Indeed, all these variables were ranked as top 10 
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features for all the techniques, and only the 1.17 - 1.22 ppm bucket, despite not being 
selected by the GAs approach, it should be included as a top important variable since it was 
ranked 2nd and 1st by RFs and CCR-LDA respectively. 
 The major discriminatory variables include branched chain amino acids (BCAAs) such 
as Ile and Val, and products of their degradation pathways such as 3-AIB, 2-hydroxy-3-
methylbutyrate and 3-hydroxyisobutyrate; moreover, Gln, 3-hydroxyphenylacetate (a 
tyrosine metabolite) and the α-group resonance signal from amino acids were also selected.   
This bile acid bucket has been highlighted as one of the most important features as 
well, although the exact bile acids species contributing to this signal are somewhat unclear.  
n-Butyrate is a gut microbiota metabolite arising from carbohydrate fermentation. 
Further metabolites listed in Table 2.3 that can also be attributed to gut microflora are TMA 
(choline degradation product) and 5-aminovalerate, the latter a product of lysine catabolism.  
Higher levels of TMA-N-oxide (TMAO), trigonelline and Cn were observed in the HET 
participants; however, these three metabolites are well known age-correlated metabolites 
which may arise from diet (TMAO and trigonelline) and muscle tissue (Cn).  
Three metabolites listed in Table 2.3, could arise from exogenous sources as 2-
hydroxyisobutyrate and methanol (although methanol also arises from microflora 
metabolism), in addition to hippurate, a metabolite of benzoate mainly encountered in plant 
dietary sources and a gut microbial-mammalian co-metabolite generated through the 
conjugation of benzoate with glycine (167).  
The N-acetyl-group signals arise from the acetamido (-NHCOCH3) groups of some 
metabolites as a result of a common chemical modification, frequently encountered in 
amino acids and sugars, mainly occurring in brain.  
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2-Hydroxyglutarate is a hydroxy-acid resulting from the reduction of ketoglutarate, 
an intermediate in the Krebs cycle.  
Quinolinate is a product of kynurenine metabolism and a precursor of niacin 
nucleotides, such as NAD, NADP, etc. that can also act as a neurotransmitter.  
Glycerol is a structural metabolite being the frame for the addition of fatty acids to 
form triacylglycerols (TG), diacylglycerols (DG) and monoacylglycerols (MG).  
One of the most important variables selected was the 0.72 - 0.76 ppm bucket, which 
remains unassigned, although it has been previously reported in urine (168); indeed, the 
coupling constant (J) value of this resonance signal (6.6 Hz) is very similar to that determined 
in (168) (6.8 Hz), and these researchers have suggested that it arises from the -CH3 unit of an 
isopropyl group, which is linked to a magnetically-distinguishable, second -CH3 group doublet 
resonance located at δ = 0.88 ppm. Both these -CH3 units were found to be connected (albeit 
in a MV statistical context) to a suggested asymmetrical carbon atom methine (-CH) 
fragment (centred at δ = 2.18 ppm), although these investigators did not confirm these 
connectivities via the application of  neither 1D or 2D 1H-1H NMR COSY/TOCSY techniques. 
  
2.4.2.4. ROC curve analysis 
Biomarker selection was investigated through ROC curve analysis. This analysis was 
conducted using the ROC curve analysis option included in MetaboAnalyst 3.0 [(169) this 
software was utilised for all the ROC curve analysis performed in this work]. Those 
metabolites selected as discriminatory features for more than 1 of the techniques in Table 
2.3, excluding those likely arising from age differences between both disease-classification 
groups, were subjected to ROC curve analysis in order to explore their ability as NP-C1 
disease urinary biomarkers. The variables selected were those assigned to bile acids (0.66 - 
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0.69 ppm), unknown metabolite (0.72 - 0.76 ppm), 2-hydroxy-3-methylbutyrate-CH3a (0.81 - 
0.83 ppm), 3-AIB-CH3 (1.17 - 1.22 ppm), 5-aminovalerate-C3/4-CH2, (1.58 - 1.63 ppm), 
trimethylamine-CH3’s (2.87 - 2.89 ppm), methanol (3.29 - 3.33 ppm), creatine (3.92 - 3.95 
ppm) and quinolinate (8.40 - 8.42 ppm). However, the presence of methanol must be taken 
cautiously since their higher levels in the HET group could be attributable to the lowest 
exposure to methanol vapours (cleaning products) and alcohol consumption in the younger 
NP-C1 patients (170). 
 
 
Figure 2.6. (a) ROC curves and (b) bubbles diagram for variable importance in the NP-C1 
urinary dataset: different combinations of variables gave different AUC values ranging from 
0.705 for 2 variables, up to 0.918 with 8 variables, as indicated in the table inserted in (a). 
Variable ranking arising from ROC analysis is depicted in the vertical axis in (b), blue bubbles 
indicate metabolites with lower levels in NPC group, and the orange ones, those with higher 
levels. The size of each bubble is correlated with the FC (fold change). Abbreviations: U-1, 
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unknown metabolite; 2-OH-3-MeBu, 2-Hydroxy-3-methylbutyrate; TPR, True Positive Rate; 
FPR, False Positive Rate. 
 
The assessment of model performance is evaluated through MCCV, so that two-
thirds of the samples were utilised in order to generate a RFs classifier which were validated 
on the one-third of the remaining samples excluded from the model building process; the 
sensitivity and specificity of the models developed were computed from the confusion 
matrix arising from the multiple MCCV iterations. 100 rounds of CV were performed, and 
results were depicted in the form of a ROC curve by plotting the sensitivity against 1-
specificity showing the performance of biomarkers subsets. Through this method, the 
models generated combine different features in each case from the maximum number of 
variables entered. 
As expected, mean AUC values were decreasing along with the number of variables 
employed for the model, apart from the model built up with 8 variables that has higher 
values than the 9 variables one. AUC values were all above 0.7, a performance which is 
consider fair, in terms of classification success. The selection frequencies of those 9 variables 
included in the ROC analysis are illustrated in Figure 2.6 along with their fold change (FC). 
Bile acids, an unknown doublet within the δ = 0.72-0.76 ppm bucket, 2-hydroxy-3-
methylbutyrate and 3-AIB were the metabolites most frequently selected for construction 
of the models. 
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2.5. POTENTIAL AGE-CORRELATED URINARY METABOLITES  
One of the limitations of the urine NP-C1 dataset analysis is the difference in age 
amongst the sample donors, so that the NP-C1 patients are all below 32 years of age and the 
heterozygote carriers are the parents of these individuals (Table 2.1). 
Trigonelline, TMAO and Cn were selected as important discriminatory features for all 
the MVA techniques employed to differentiate NP-C1 patients from HETs by their NMR urine 
profile, all showing higher levels for the control group (HET) (Table 2.3). It has been 
previously observed that all these metabolites were elevated in people over 40 years old 
(171). Accordingly, since these three metabolites were elevated in the HET group and these 
samples were collected from the NP-C1 patients´ parents, such a difference is likely to be 
ascribable to the older urine sample donors. Therefore, these metabolites will not be 
considered as possible urinary biomarkers or as indicators of any alteration in the 
metabolism of NP-C1 patients in Chapter 6. 
Trigonelline is a pyridine found in coffee beans amongst some other vegetables, so 
its presence in urine may attributable to differences in dietary habits in the older 
participants, mainly regarding coffee and tea consumption. 
TMAO is the oxidation product of TMA, a reaction that takes place in the liver, when 
either carnitine or choline that are not absorbed are degraded by the flora of the large 
intestine yielding TMA, amongst other metabolites (172). Approximately 75% of the total 
body carnitine originates from food sources of either carnitine or its precursors, such as 
lysine and methionine. Indeed, the primary sources of this metabolite are meat.  
Additionally, increased levels of TMAO in urine have been reported after consumption of fish 
(173) and diets with high salt content (174). 
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Cn is a by-product of muscle metabolism arising from Cr-phosphate breakdown, 
which is subsequently excreted into urine. Urinary excretion of Cn correlates positively with 
body weight, reflecting skeletal muscle mass (175, 176), and therefore, higher 
concentrations are expected in adults. Daily urinary excretion of Cn derived from muscles 
occurs at a ratio of ca. 1 g per 20 kg of muscle mass (177). 
 
2.6. NMR ANALYSIS OF URINE SAMPLES COLLECTED FROM NP-C1 PATIENTS 
UNDERGOING MIGLUSTAT TREATMENT 
 
2.6.1 NMR characterization of miglustat  
 Prior to the detection of MGS in urine, the signals arising from this agent had to be 
assigned for its further identification in urine samples collected from treated patients. NMR 
spectra obtained for the elucidation of MGS assignments samples were acquired at 298 K on 
a Bruker AV 400 MHz spectrometer (Leicester School of Pharmacy facility, DMU, Leicester, 
UK) operating at a frequency of 399.94 MHz. All data were processed in Topspin 2.1 (Bruker, 
UK). MGS was obtained from Monsanto/Searle when used as a standard or via prescription 
of the drug to NP-C1 patients. MGS samples were prepared at a concentration of 20.0 mM 
in 17.0 mM phosphate buffer [pH 7.10, 90% H2O/10% D2O, the latter containing 0.05% (w/w) 
TSP]. 
 
1D 1H NMR: Single-pulse 1H NMR spectra were acquired with 64 scans, 6.5 μs pulses, 
32,768 data points and a spectral width of 4,800 Hz. Water suppression was achieved using 
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the NOESY-presaturation pulse sequence (Bruker noesygppr1d pulse sequence) with 
irradiation at the water frequency during the recycle and mixing time delays.  
 
1H-1H COSY: Bruker cosygpprqf pulse sequence was employed. The spectral width in 
the F1 and F2 axes were 2500 Hz, and 2048 data points were collected in F2. For the urine 
samples, 32 increments and 32 scans per increment were used. The relaxation delay was 2.5 
s for a total acquisition time of ∼ 4 hr. Before the Fourier transformation, a sine function was 
applied in both time domains. 
 
1H-13C HSQC: Bruker hsqcedetgpsp.3 pulse sequence was employed. 64 scans for 128 
increments were acquired for each spectrum. The F2 and F1 spectral widths were 6,340 and 
16,600 Hz, respectively.  1D 13C spectra for displaying along the vertical axis in HSQC spectra 
were acquired using the zgpg30 Bruker pulse sequence with 1024 scans, a spectral width of 
23,980 MHz, and 65,536 data points for a total acquisition time of 1.37 s. 
 
 
Figure 2.7. Assigned 1D 1H-NMR spectrum of MGS 20 mM in 17.0 mM phosphate buffer, pH 
7.10 (90% H2O/10% D2O). 
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There are two distinct regions in the MGS spectrum (Figure 2.7), the more shielded 
resonances attributable to the n-butyl chain [δ = 0.95 (t), 1.39 (m) and 1.68 ppm (m)], and 
the deshielded resonances ascribable to the piperidine ring protons within the 2.8-4.1 ppm 
chemical shift range together with the -CH2-α from the butyl chain. The proximity of this 
group to the piperidine ring nitrogen atom causes its resonances to be deshielded (with two 
magnetically-inequivalent 1H nuclei signals centred at 3.10 and 3.23 ppm).   
 
 In order to confirm the assignments displayed in Figure 3.8, 2D NMR experiments 
were carried out, such as 1H-1H COSY [Figure 2.8(a)] and 1H-13C HSQC [Figure 2.8(b)]. The 
assignments, together with the coupling constants and multiplicities for all the resonances 
observed in the NMR spectra acquired are listed in Table 2.4. 
 
Moiety 1H  13C 
CH3-δ 0.95 (t, J = 7.4 Hz, 3 H) 15.71 
CH2-γ 1.39 (dsext, J = 7.4, 1.8 Hz, 2 H) 22.34 
CH2-β 1.68 (m, 2 H) 27.43 
CH2-αA 
CH2-αB 
3.23 (m, 1 H) 
3.10 (m, 1 H) 
55.25 
- 
CH-1A 
CH-1B 
3.47 (dd, J = 13.4, 4.2 Hz, 1 H) 
2.92 (t, J = 11.7 Hz, 1 H) 
56.25 
- 
CH-2 3.77 (m, 1 H) 69.50 
CH-3 3.47 (t, J = 9.4 Hz, 1 H) 79.25 
CH-4 3.64 (t, J = 9.9 Hz, 1 H) 70.61 
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Table 2.4. Chemical shifts together with the coupling patterns and coupling constants for 1H 
and 13C NMR spectra acquired on MGS in aqueous media. 
 
 
CH-5 2.99 (ddd, J = 10.3, 2.3 Hz, 1 H) 66.08 
CH-6 4.02 (2 x dd, J = 13.4, 3.0, 1.8 Hz, 2 H) 57.42 
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Figure 2.8. (a) 400 MHz 1H-1H COSY and (b) HSQC spectrum of 20 mM MGS in 17.0 mM 
phosphate buffer, pH 7.10 (90%/10% D2O/H2O): 1H resonances along with the assignments 
are displayed in the horizontal axis, whilst 13C ones are displayed in the vertical axis. Red 
cross-peaks indicate either a -CH3 or -CH group, and blue ones represent CH2 functions. 
 
2.6.2. Miglustat detection in urine  
Representative 1H NMR spectral profiles of urine samples collected from an NP-C1 
patient subsequent and prior to treatment with MGS are shown in Figures 2.9 (a) and (b) 
respectively. Resonances corresponding to MGS are detectable in the urinary 1H NMR profile 
of the patient when receiving MGS treatment, predominantly those arising from the butyl 
chain. 
Spiking experiments: The presence of MGS in the urine collected from NP-C1 patients 
undergoing this treatment was further confirmed via the addition of a final concentration of 
1.00 x 10-3 M MGS to additional urine samples collected from untreated NP-C1 patients 
[Figure 2.9(c)]. Following this in vitro treatment, a series of MGS resonances were also clearly 
visible in the 1H NMR urinary profiles, most notably a strong triplet located at 0.95 ppm 
corresponding to the terminal n-butyl chain CH3 group protons of MGS, together with its β- 
and γ-CH2, and piperidine ring-CH-1A/B, -CH-3, -CH2-6, -CH-4, and -CH-5 protons.  
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Figure 2.9. 400 MHz 1D spectra of urine collected from an NP-C1 patient before (b) and after 
(a) MGS treatment; (c) healthy urine sample spiked with MGS (red) and the same urine 
sample untreated (black): MGS assignments are displayed in red. For purposes of clarity only 
selected resonances are labelled. Abbreviations: BA, Bile acids;  Me-Succ, Methylsuccinate; 
PG, Propylene glycol; 3-HB, 3-Hydroxybutyrate; Lac, Lactate; Pyr, Pyruvate; Succ, Succinate; 
DMA, Dimethylamine; TMA, Trimethylamine; Cn/Cr, Creatinine/Creatine. 
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2.6.3. 1H NMR analysis of urine collected from NP-C1 patients undergoing miglustat 
treatment 
 MGS was detected in urine samples through 1D and 2D NMR techniques, together 
with spiking experiments, as previously described. Moreover, valproate, together with its 
major metabolite O-acyl-β-glucuronide was detected in 14 of the samples examined in this 
cohort. The identity of this metabolite was confirmed by the addition of β-glucuronidase to 
urine samples in which the glucuronide adduct was present, and also to untreated samples 
serving as negative controls. 
β-Glucuronidase equilibration: Urine samples were treated with 400 units of β-
glucuronidase (Sigma–Aldrich, UK) in 0.10 M phosphate buffer (pH 7.00), and then incubated 
for a period of 24.0 h. at 37 ◦C prior to 1H NMR analysis.  
 
The shifts experienced by the resonance peaks arising from glucuronate, along with 
the appearance of those from the free drug released, revealed the presence of this 
metabolite (Figure 2.10). Additionally, MGS, acetaminophen along with its glucuronide and 
sulphate metabolites (Figure 2.11), valproate and 1-O-Valproyl-β-glucuronide were 
unambiguously identified in urine samples labelled as MGS-treated utilising both 1D and 2D 
NMR techniques, despite the structural similarities between the n-alkyl chain moieties in the 
structures of MGS, valproate and the latter’s 1-O-valproyl-β-glucuronide metabolite. 
Valproate metabolites have been previously identified in urine samples via application of 
NMR, i.e. 1H-1H TOCSY and 1H-13C HMBC techniques (178, 179).  These results obtained 
complemented previous reports which demonstrate that valproate is largely excreted as the 
1-O-valproyl-β-glucuronide metabolite (178, 180, 181). Quantification of both MGS and 1-O-
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valproyl-glucuronide via the integration of their resonances located at the 0.93 - 0.97 and 
5.53 - 5.57 ppm buckets respectively is described in detail in the Appendix 1. 
 
 
Figure 2.10. 400 MHz 1H-1H TOCSY spectrum of urine collected from an NPC1 patient 
receiving MGS treatment, before (black) and following (red) equilibration with β-
glucuronidase: 1H NMR  signals arising from valproate, the valproate-O-acyl-β-glucuronide 
metabolite and MGS are labelled. A typical spectrum is shown. 
 
MGS concentrations in biological fluids have been previously reported in human 
plasma and cerebrospinal fluid (CSF) (182), and also mouse plasma (183) by LC-MS/MS. 
Lachmann and co-workers quantified MGS using cationic exchange chromatography coupled 
with pulsed amperometric detection (184). Treiber et al. investigated the distribution of this 
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agent, after administration in rats, in different tissues and biofluids, including urine, using 
HPLC and radiolabeled MGS together with a perbutyrated derivative acting as a prodrug 
(185). However, all the techniques mentioned above required previous preprocessing 
(separation) steps. 
  
Analytical 
technique 
Preprocessing steps Sample analysed 
Run 
time 
LOD Ref 
LC-MS/MS SPE Human Plasma <2 min. ca. 60–180 nM (186) 
LC-MS/MS 
Collection of HPLC fractions, evaporation 
(N2) and reconstitution in water followed 
by extraction with ethyl acetate. 
Human liver 
microsomal 
samples 
6 min. ca. 0.10 nM (187) 
UPLC-MS/MS SPE Human Blood 4 min. ca. 600 nM (188) 
HPLC-UV 
Acidification of samples (pH 4.0) and 
extraction with ethyl acetate, followed by 
pre-column derivatization with 2,4 -
dibromoacetophenone 
Human plasma 15 min. 
5 and 0.5 g/ml 
for valproate 
and 2- propyl-
4-pentenoate 
(189) 
Table 2.5. Reported methods for valproate and/or its metabolites quantification and 
detection in biofluids and tissue: techniques listed along with any further preprocessing 
steps and major features of the analysis. Abbreviations: SPE, Solid Phase Extraction; LOD, 
Limit Of Detection; Ref, Reference. 
 
The range values of the urinary excretion levels for both MGS and 1-O-valproyl-β-
glucuronide in this patient cohort was 78 - 680 μmol/mmol Cn and 47 - 1154 μmol/mmol Cn 
respectively. However, such values are, of course, influenced by differences in the dose of 
MGS and valproate administered to the patients involved and by the time-point of urine 
sample collection subsequent to dosing, together with any between patient variations in the 
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renal clearance of these agents. Moreover, valproate is mainly excreted as this glucuronide 
adduct, although some other metabolites have been found in urine (187); therefore, the 
inter-individual variability with regard to valproate biotransformations can be an additional 
source of variation. MGS metabolism is still unclear, since it has been reported that 5% MGS 
is excreted in urine as a glucuronide adduct (190); however, we could not confirm it in a 
recent investigation involving a rat microsomal system and to the best of our knowledge 
there are not any reports published with that regard. 
 As with MGS, previous methods available for the analysis of valproate and its 
metabolites in urine include LC-MS/MS (186, 187), together with UPLC-MS/MS (188) and 
more conventional HPLC-UV analytical approaches (189) (Table 2.5).  
 A further advantage of 1H NMR urinalysis is that 1-O-valproyl-β-glucuronide is 
particularly sensitive to pH value (i.e., it has a limited hydrolytic stability) and elevated 
temperatures (191), and hence the use of techniques which do not require the exposure of 
biofluid samples to such methodological stresses is recommended. 
 
Xenometabolome: NMR analysis provides a holistic view of the urine samples 
analysed, which permits the exploration of the presence of further resonances arising from 
exogenous molecules, such as drugs and their metabolites. These observations encourage 
the use of NMR for the resolution of complex mixtures such as biological fluids, where it is 
likely to find metabolites from exogenous compounds like drugs, the so called 
Xenometabolome (26, 192). The ability of NMR to detect these kind of metabolites will serve 
of tremendous aid when dealing with epidemiological studies where patients are likely to be 
self-medicated (193), exposed to toxic substances or in cases in which patients undergo dual 
or multiple therapies, as notable in the NP-C1 disease cases explored here. It has to be 
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considered that in some countries such as the USA, MGS is not approved, even when this 
drug is the only available therapy worldwide, so the risks of self-medicating patients is high. 
The biofluid profile of an individual is mainly composed for endogenous metabolites; 
nevertheless, the presence of molecules arising from diet or the exposure to hazardous 
compounds offers much valuable information to the investigator, since  metabolomics 
analysis not only reveals the endogenous metabolome, but also how it responds to these 
exogenous compounds, and the behaviour of sample donors, e.g. either passively or through 
self-administration of medicines and drugs, tobacco and alcohol consumption, etc. 
Furthermore, for urine 1H NMR-based metabolomics investigations of NP-C patients, 
the assignment of MGS affords valuable information regarding the empirical removal of such 
potentially interfering xenobiotic relevant spectral bucket regions prior to conducting such 
analyses. 
 
 
Figure 2.11. Aromatic region from a 1H-NMR 400 MHz urine spectra collected from a NP-C1 
MGS-treated patient before (b) and after (a) β-glucuronidase incubation: acetaminophen 
aromatic ring C2/6-CH signals are labelled for its different metabolites detectable in urine.  
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2.6.4. 1H NMR-linked metabolomics investigations of the response to miglustat treatment 
of NP-C1 patients 
 In order to explore the possible changes in the 1H NMR urine profiles of NP-C1 
patients conceivably attributable to MGS treatment, the urine levels of those metabolites 
identified as discriminatory variables in the previous section were analysed in an univariate 
sense using the Tukey’s HSD (Honest Significant Difference) test for pairwise comparisons 
(Figure 2.12).  
However, it should be noted that such MGS as valproate and further glucuronide 
adducts of this agent have chemical shift values very close or even identical to those of the 
selected metabolites listed in Table 2.4. Therefore, some of these biomolecules were not 
employed for this analysis in view of their overlap with those signals attributable to the 
exogenous metabolites previously mentioned. Metabolites labelled as age-correlated in 
section 2.5 were also excluded from this analysis. 
 
Chemical shift bucket (δ, ppm) Assignment Obscuring signal 
0.98 - 1.03 Val-CH3’s/Ile-CH3a MGS-δ-CH3 
1.36 - 1.41 2-HydroxyisoBu-CH3’s MGS-γ-CH3 
1.50 - 1.56 n-Butyrate-C3-CH2 Valp-C3-CH2 
1.58 - 1.63 5-Aminovalerate-C3/4-CH2 Valp-glucuronide-C3-CH2 
2.25 - 2.31 2-Hydroxyglutarate-CH2 Valp-C2-CH2 
2.87 - 2.89 TMA-CH3’s MGS-C5-CH/C1-CHb 
3.46 - 3.48 3-HydrohyPheAc-CH2 MGS-C3-CH 
3.63 - 3.67 Glycerol-C1/3-CH2a MGS-C4-CH 
3.67 - 3.71 AAs-α-CHs/3-OH-isoBu-β-CH2 Valp-glucuronide-C4’-CH 
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3.88 - 3.92 Hippurate-CH2 Valp-glucuronide-C5’-CH 
Table 2.6. List of discriminatory variables with resonances overlapping those arising from 
drugs and corresponding metabolites found in urine samples collected from NP-C1 patients 
receiving MGS treatment: the exogenous metabolite resonances are listed in the third 
column. Chemical shift values employed for assignments are listed in Table 2.3 and Figure 
2.10. Abbreviations: 2-HydroxyisoBu-CH3’s, 2-Hydroxybutyrate-CH3’s; 3-HydrohyPheAc, 3-
Hydroxyphenylacetate; AAs, amino acids; 3-OH-isoBu-β-CH2, 3-Hydroxyisobutyrate-β-CH2. 
 
 
Figure 2.12. Analysis of discriminatory metabolites levels amongst heterozygotes controls 
(HET), NP-C1 patients (NPC) and MGS-treated NP-C1 patients (MGS): box plots for 
discriminatory variables that represent their normalised intensities for each group 
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(heterozygote, NP-C1 and NP-C1 MGS treated). Statistically significant differences obtained 
from the Tukey’s HSD test are indicated by asterisks (p < 0.05, *; p < 0.01, **; p < 0.001, ***). 
Abbreviations: BAs, bile acids; 2-OH-3-Me-Bu, 2-Hydroxy-3-methylbutyarte; 3-AIB, 3-
aminoisobutyrate; Cr, creatine. Unknown-1 corresponds to the 0.77 - 0.80 ppm bucket.  
 
 Bile acids levels remain the same for NP-C1 and MGS-treated patients, their levels 
being higher than those for the HET group, and somewhat lower than that of the NPC group. 
As expected, since MGS has no effect on bile acid synthetic pathways, nor cholesterol 
metabolism. Additionally, the increase in urinary BAs levels is mainly ascribable to hepatic 
problems in NP-C1 patients, and MGS mainly improves their neurologic status, although in 
some Gaucher disease patients the hepatomegaly has been partially resolved after MGS 
treatment (194, 195). 
2-Hydroxy-3-methylbutyrate, 3-AIB, Cr and Gln show similar levels for MGS and HET 
groups, being all 4 metabolites correlating with muscle tissue breakdown as will be discussed 
in section 6.4.  
MGS has been proved to improve the neurological symptoms and concomitantly the 
ability of NP-C1 patients to move and walk. Those functions require muscular activation, 
which may prevent atrophy, and consequently the release of muscle breakdown products 
into the bloodstream, that would be subsequently filtered out into the urine. MGS-treated 
NP-C1 patients are usually studied from a functional point of view, focusing in the 
neurological symptoms, in which common analysis are ambulation, swallowing, acoustic 
response, etc. (115, 196), mainly based in a test originally developed by Iturriaga et al. (197).  
Improvements for the majority of these characteristics have been observed after MGS 
treatment. Therefore, an increase in patients mobility triggered by an improvement in their 
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neurological status caused by MGS treatment would explain these results. Nevertheless, 
these outcomes might contrast with some well-known adverse effects of MGS treatment as 
diarrhoea and weight loss (198, 199); however, diarrhoea is directly related to the loss of 
liquids and the body weight is usually recovered after 24 months of treatment (199, 200). 
Both issues have their source in gastrointestinal problems caused for the intake of this drug 
and not in endogenous protein degradation. 
Higher N-acetylated metabolites levels in urine is a common feature of some LSD 
such as Sandhoff and Tay-Sachs diseases. These biomolecules are mainly gangliosides, the 
degradation pathway of which is affected by mutations in one of the catabolic enzymes 
involved.  Indeed, the accumulation of gangliosides in the brain is the cause of some of the 
neurological symptoms occurring in NP-C1 patients (201, 202). The presence of these N-
acetylated biomolecules can be monitored by 1H NMR analysis of urine (203). The 2.02 - 2.08 
ppm bucket was selected by CCR-LDA and ranked 10th, showing higher levels for the NPC 
group (p = 2.15 x 10-2, FC = 1.25). The well-known effects of MGS in reducing 
glycosphingolipid concentrations in brain can lead to the significant decrease observed in 
this study for urinary N-acetyl-metabolites in NP-C1 patients undergoing MGS treatment. 
Indeed, investigations conducted with animal models of Tay-Sachs and Sandhoff under MGS 
treatment revealed the delayed accumulation of GM2 ganglioside in the brain (149, 204).  
Methanol levels, despite experiencing a slightly increase with regard to NPC group, 
remain significatively lower than the HET group. Hence, MGS has no effect on this 
metabolite. The absence of more resonances available arising from bacterial metabolites 
prevent generalisation of the effect of MGS on microbiota activity/population in NP-C1 
disease. 
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Quinolinate (QUIN) levels are significantly lower for the MGS-treated group than for 
the NPC one, showing a similar pattern to HET participants. Since the source of this 
metabolite is somewhat unclear (macrophages infiltrate, imbalance in NAD+/NADH 
synthesis, muscle wasting, etc.), the results observed here are difficult to attribute to a 
specific physiological change caused by MGS treatment. Nevertheless, recent studies 
suggest that the inflammation process associated to the NP-C pathophysiology is secondary 
to the tissue damage, so it is a response from the body to fight back the disease (205); and 
therefore, as MGS corrects some of the symptoms arising from the disease process, then the 
lower levels of QUIN may reflect the reduced inflammatory process as an indirect 
consequence of the treatment.  
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CHAPTER 3 
 
1H NMR LINKED METABOLOMICS ANALYSIS OF 
PLASMA SAMPLES COLLECTED FROM NP-C1 
PATIENTS, HETEROZYGOUS CARRIERS, HEALTHY 
PARTICIPANTS AND MIGLUSTAT TREATED NP-C1 
PATIENTS 
 
 
3.1. PLASMA SAMPLES COLLECTION AND PREPARATION FOR NMR ANALYSIS  
75 plasma samples collected from NP-C1 patients, 89 from MGS treated NP-C1 
patients, 31 from heterozygous carriers and 30 collected from healthy participants (as 
controls) were stored at -80◦C. NP-C1 patients untreated and MGS treated together with 
heterozygotes were fasted prior to sample collection. However, healthy participants were 
not fasted. Plasma was separated from whole-blood using a histopaque column (gradient 
density column). Samples were thawed on ice and centrifuged for 3.0 min. at 850 x g. 200 μL 
of plasma was diluted with 300 μL Mili-Q H2O and 55 μL D2O (the latter to provide an NMR 
field frequency lock). Samples were transferred to standard 5 mm-diameter NMR tubes 
(Norell, UK) for analysis. 
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Disease class NPC MGS HET WT 
Number (male/female) 75 (42/33) 89 (54 /35) 31 ( 15/13)* 30 (23/6) 
Average age in years (range) 19 (0.3 - 54) 11 (1 – 28) N/A ~15 (0.4 - 18)** 
Table 3.1. Participants’ information included in the NP-C1 plasma dataset: Abbreviations: 
NPC, NP-C1 disease patients; MGS, NP-C1 patients undergoing miglustat treatment; HET, 
heterozygous carriers; WT, healthy participants. *Information relative to the gender of some 
heterozygous carriers was not available; **, the age of all healthy participants was not 
available. 
 
3.2. NMR ANALYSIS OF PLASMA PROFILES 
NMR spectral acquisition was performed on a Bruker AVIII 700 spectrometer 
equipped with a 1H (13C/15N) TCI cryoprobe (Department of Chemistry, University of Oxford) 
with sample temperature stabilised at 310K. 1H NMR spectra were acquired using a 1D 
NOESY presaturation (noesygppr1d pulse sequence, Bruker) scheme for attenuation of the 
water resonance with 2 s presaturation. Low molecular weight metabolite spectra were 
acquired using a spin-echo sequence [Carr-Purcell-Meiboom-Gill (CPMG)] with presaturation 
for water suppression (cpmgpr1d pulse sequence, Bruker) with a τ interval of 0.39 ms, 80 
loops, and echo time of 0.40 ms, 32 scans, an acquisition time of 1.46 s, a relaxation delay of 
2 s, and a fixed receiver gain.  
 
3.2.1. 1H NMR plasma profiles of NP-C1 patients 
 1H NMR resonances were assigned on the basis of chemical shifts, coupling constants 
and literature values (46, 206, 207). Spectra acquired from plasma samples contained 
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different resonance signals ascribable to amino acid, small organic acid anions, glucose, 
lipoproteins and glycoproteins. Additionally, some other signals from exogenous agents 
were observed in the NMR spectra such as Ca-EDTA2- and Mg-EDTA2- complexes resonances 
arising from the chelation of these metal ions by this agent, which was present in the sample 
collection tubes as an anticoagulant (Figure 3.2); resonances arising from the plasma 
separation procedure can also be observed in the spectrum such as a singlet at 2.26 ppm 
and signals around 1.80 ppm. Broad resonances from 3.40 to 4.45 ppm and from 5.40 to 5.62 
ppm are attributable to the polymer (polysucrose-based) contained in the histopaque 
column employed for plasma isolation (Figure 3.1).  
 Histopaque is a method employed to separate the different phases present in blood, 
i.e. those conformed by plasma from that containing lymphocytes, monocytes and platelets, 
and an additional phase conformed of granulocytes and erythrocytes, through a density 
gradient media composed of polysucrose, which is the broad signal observed in Figure 3.1, 
in 3.40 - 4.45 and 5.40 - 5.62 ppm NMR spectral regions. This solution incorporates sodium 
diatrizoate, observable as a singlet at 2.26 ppm. Additional signals were found after running 
a sample of water, as control, ca. 1.80 ppm, which probably arises from the histopaque 
treatment of blood samples. In view of the exogenous NMR-visible signals assignable to the 
sucrose polymer and further agents derived from histopaque treatment that overlayed some 
resonance signals of biological interest, this plasma isolation method presents limitations for 
NMR-based metabolomics studies. 
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Figure 3.1. Stack plot of (a) a plasma sample separated by histopaque and (b) a water 
sample also passed through a histopaque column. 
 
The usual methods employed to avoid anticoagulation during blood sample 
collection include the usage of sample tubes containing lithium-heparin, citrate or the 
sodium salt of EDTA. Both citrate and EDTA give 1H NMR-visible resonance peaks in plasma 
spectra, subsequently acquired, at the concentrations typically used (208), whilst plasma 
samples collected in heparin-Li+ present only a weak and broad spectrum that can be 
removed through CPMG pulse sequences for spectral acquisition. However, the presence of 
EDTA signals in the 1H NMR plasma spectra could offer additional information, since the 
resulting Ca and Mg-EDTA2- resonances are clearly observable, and can be employed to 
monitor both metal ions. Although other metal ions (Zn2+) could be interfering in the complex 
equilibrium that involves Ca-EDTA2-:Ca2+:Mg-EDTA2-:Mg2+:Free-EDTA. Barton et al. (209) 
explored the influence of the differing anticoagulants noted above on NMR metabolomics 
plasma investigations, and concluded that only a few resonances are completely masked by 
EDTA and EDTA-metal ions resonances, such as acetylcarnitine-N(CH3)3 resonance at 3.60 
ppm (Ca-EDTA2--N-CH2CH2-N- peak), carnitine resonances at ca. 3.21 ppm (free EDTA-N-CH2-
CO- peak), ornithine-C4-CH2 resonances at 3.07 ppm (Ca-EDTA2--N-CH2CH2-N- peak) and cis-
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aconitate-CH2 resonance at 3.44 ppm (Ca-EDTA2--N-CH2CH2-N- peak). Their final conclusion 
was that NMR metabolomics investigations utilising plasma samples collected in EDTA tubes 
can be conducted without any major drawbacks.  
 
 
 
Figure 3.2. (a) 0.75 - 4.45 and (expansion of the BCAA region is included as an insert) (b) 5.10 
- 8.50 ppm regions from an NP-C1 patient 1H NMR plasma profile: 1, CH3-VLDL/LDL; 2,-(CH2)n-
VLDL/LDL; 3, Lactate-CH3; 4, Alanine-CH3; 5, TG-CH2CH2CO; 6, Arginine-C4-CH2; 7, Lysine-C5-
CH2; 8, Arginine-C3-CH2; 9, Acetate-CH3; 10, CH2CH2CH=-; 11, N-acetyl-glycoprotein-CH3; 12, 
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Proline-1; 13, Glutamate-C2-CH2; 14, Pyruvate-CH3; 15, Glutamate-C3-CH2; 16, Glutamine-
C4-CH2; 17, Citrate-CH2a; 18, Creatine-CH2; 19, TMAO-CH3’s; 20, Proline-2; 21, 
Phosphocholine-NCH3; 22, Lactate-CH; 23, =C-CH2-C=, -CH=CH-; 24, Tyrosine-C3/5-CH; 25, 
Histidine-C5-CH; 26, Tyrosine-C4/6-CH; 27/28-Phenylalanine; 29, Histidine-C6-CH; 30, 
Formate-H.  
 
3.3. DATA PREPROCESSING 
 Any resonances arising from histopaque contamination, i.e., the 1.80 - 1.86, 2.18 - 
2.31, 3.30 - 4.50, and 5.37 - 5.68 ppm spectral regions were removed. Additionally, the 1.15 
- 1.17 ppm region was excluded in view of ethanol contamination, likely as a result of skin 
disinfection prior to sample collection. Regions containing only noise across all spectra were 
also excluded, so that a dataset containing 38 columns (variables) and 252 rows (samples) 
was obtained. Prior to any statistical analysis, the whole dataset was sum-normalised, Pareto 
scaled and cube-root transformed. 
 
3.4. UNIVARIATE AND MULTIVARIATE ANALYSIS OF THE 1H NMR PLASMA DATASET 
3.4.1. Univariate data analysis: Tukey’s HSD test 
 Since some information concerning the age and gender of participants was not 
available, an ANOVA/ANCOVA model similar to those employed in previous and next 
sections cannot be accurately employed. However, a post-hoc Tukey’s range test (honest 
significant test, HSD) was applied to the sum-normalised, cube-root transformed and Pareto-
scaled plasma dataset. Those variables selected by the RFs technique as discriminatory 
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features are supplemented in Table 3.3 by a ‛*’ sign to indicate the level of significance based 
on their 1H NMR plasma profiles.  
 
3.4.2. Multivariate data analysis 
3.4.2.1. Preliminary analysis: PCA 
 PCA scores plots illustrated in Figure 3.2 reveal that WT is the most distinct 
classification group, since a clear cluster can be observed when plotted against the NPC, HET 
and MGS groups. However, the HET and NPC groups do not form clear clusterings in the 
scores plot, and hence there is no separation between these groups. The influence of 
miglustat (MGS) treatment on the 1H NMR plasma profiles of NP-C1 patients was also 
explored. Scores plot of PC1 vs. PC2 in Figure 3.3 did not show any differences between both 
groups (MGS vs. NPC). Indeed, apart from WT, the MGS plasma profiles were found to be 
very similar to the remaining disease classification groups (NPC and HET). 
 
3.4.2.2. Classification performance 
Random Forests (RFs): The procedure described in section 2.4.3 for RFs analysis was 
also employed for the plasma dataset. Since in this case the number of groups is 4, this 
analysis was applied for each pair of different groups, with the exception of MGS vs. HET 
one, since that comparison was irrelevant for this study (Table 3.2) as heterozygous carriers 
do not present any symptomatology associated to NP-C1 disease, and therefore, they are 
not treated with MGS. 
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(a) (b) 
(c) (d) 
OOB error   Accuracy 
Disease class WT NPC   Disease class WT NPC 
NPC 0.106 (0.003)    NPC 0.904 (0.005)  
HET 0.175 (0.005) 0.226 (0.003)   HET 0.818 (0.007) 0.765 (0.007) 
MGS 0.160 (0.003) 0.353 (0.004)   MGS 0.832 (0.006) 0.646 (0.006) 
 
    
 
  
Sensitivity   Specificity 
Disease class WT NPC   Disease class WT NPC 
NPC 0.926 (0.005)    NPC 0.853 (0.011)  
HET 0.824 (0.011) 0.754 (0.020)   HET 0.823 (0.012) 0.778 (0.007) 
MGS 0.864 (0.007) 0.664 (0.008)   MGS 0.729 (0.015) 0.632 (0.010) 
Table 3.2. RF classification performance for all 4 groups analysed in the plasma dataset: 
tables showing mean and SEM values (the latter between brackets) for OOB error (a), 
accuracy (b), sensitivity (c) and specificity (d) values.  
 
It should be noted that accuracy, sensitivity and specificity show lower values for the 
HET vs. NPC classification comparison, and even lower values for MGS vs. NPC one (Table 
3.2), and this confirms the absence of differences between the 1H NMR profiles of the HET 
and NPC groups, and the unaltered profile of NP-C1 patients despite of being under MGS 
treatment. However, the remaining group pair comparisons were successfully classified by 
RFs as illustrated in the multidimensional scaling plots shown in Figure 3.3, where the 
classification of the test set is exhibited.  
The RFs performance on WT vs. NPC groups resulted in an OOB error value of 0.106 
± 0.003 (mean ± SEM), which reveals a successful classification of the training set. The 
multidimensional scaling plot of the proximity matrix calculated from one of the RFs 
 
 
98 
 
iterations (Figure 3.3) serves as an illustration of this discrimination. Additionally, no 
discrimination was identified in the untreated NP-C1 patient group based on gender or age. 
 
Figure 3.3. PCA scores plots for PC1 vs. PC2 for each pair of comparisons, and 
multidimensional scaling plot from a RFs proximity matrix showing success of discrimination 
from a single RFs iteration for the NP-C1 plasma dataset. 
 
3.4.2.3. Variable selection 
 Table 3.3 summarises the top nine discriminatory variables selected by the RFs 
analysis, for each pair of disease status classifications compared, along with their 
corresponding assignments. HET vs. MGS is not shown as noted above, and RFs analysis of 
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the NPC vs. MGS comparison did not show any classification success, and therefore no 
ranking was extracted from that analysis. 
  
Bucket 
(ppm) 
Assignment 
Multiplicity 
(J, Hz) 
NPC vs. 
WT 
HET vs. 
WT 
MGS vs. 
WT 
NPC vs. 
HET 
0.81 - 0.83 HDL-CH3  br    ↓**(2) 
0.83 - 0.89 VLDL-CH3  br ↑***(6) ↑***(2) ↑***(6)  
0.89 - 0.95 Isoleucine-C5-CH3 t (7.3) ↑***(9)   ↑*(9) 
1.13 - 1.15 2,3-butanediol-(CH3)2 d (6.1)   ↑(9)  
1.21 - 1.23 HDL-(CH2)n  br  ↑***(7)  ↑(8) 
1.23 - 1.25 LDL-(CH2)n  br ↑***(5) ↑***(3) ↑***(4)  
1.25 - 1.31 VLDL-(CH2)n  br ↑***(2) ↑***(5) ↑***(1) ↑*(7) 
1.31 - 1.37 Lactate-CH3 d (6.8) ↑***(7)  ↑***(7)  
1.53 - 1.61 -CH2CH2CO br ↑***(1) ↑**(8) ↑***(3) ↑** (3) 
1.94 - 1.96 Proline 1 m  ↑***(9)   
1.96 - 1.98 Proline 2 m  ↑***(6)   
2.03 - 2.09 N-acetylglycoprotein/CH2-CH2-CH= s/br ↑***(8)    
2.52 - 2.58 Ca-EDTA s   ↑***(8) ↑***(1) 
5.26 - 5.32 Unsaturated lipid 2 br ↑***(3) ↑***(1) ↑***(2)  
5.32 - 5.37 Unsaturated lipid 1 br ↑***(4) ↑***(4) ↑***(5) ↓ (5) 
7.02 - 7.08 Histidine-C2-CH s    ↑*(6) 
7.74 - 7.85 Histidine-C5-CH s    ↓*(4) 
Table 3.3. RFs discriminatory variables for the NP-C1 plasma dataset:  Arrows indicate an 
increase/decrease in the measured metabolite with respect to the WT samples (or with 
respect to the HET samples in the case of the NPC vs. HET comparison).  The results of the 
Tukey’s HSD test for each metabolite identified by RFs analysis are indicated by asterisks (p 
< 0.05, *; p < 0.01, **; p < 0.001, ***). The RFs ranking is based on their MDA value, and is 
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represented in brackets. Unsaturated lipid 1 and 2 refer to =C-CH2-C= and -CH=CH-  protons 
respectively. 
 
 Since some of the variables listed in Table 3.3 were highlighted in more than one 
classification comparison as discriminant features, their levels are then illustrated as box 
plots in Figure 3.5.  
 
3.4.2.4. ROC curve analysis 
 In order to seek those variables that more efficiently contribute to the classification 
of NP-C1 patients when compared to healthy control ones, a ROC curve analysis was 
performed including WT and NPC classes using RFs as a tool for classification. Metabolites 
selected as important features for discrimination listed in Table 3.3 were employed for this 
analysis. 
The majority of variables selected for classification for the NPC vs. WT comparison 
were assignable to lipoprotein-associated TGs, being actually able to successfully classify the 
WT and NPC groups with only 2 variables [AUC (mean) = 0.912; range, 0.772 - 0.982]. 
Isoleucine (Ile) and lactate were also included in the models, being selected in ca. 86% of 
those constructed [Figure 3.4 (b)].  
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Figure 3.4. (a) ROC curves and (b) bubble diagram for variable importance for the NP-C1 
blood plasma dataset: different combinations of variables gave different AUC values, ranging 
from 0.912 for 2 variables, and up to 0.946 with 9 variables, as indicated in the Table inserted 
in (a). (b) Variable rankings arising from ROC analysis (depicted in the vertical axis in); blue 
bubbles indicate metabolites with lower levels in the NPC group, and orange ones those with 
higher levels. The size of each bubble is correlated with the fold change (FC). Abbreviations: 
N-AGP, N-acetylglycoproteins; TPR, True Positive Rate; FPR, False Positive Rate. 
 
 
3.5. 1H NMR PLASMA PROFILES OF NP-C1 PATIENTS, HETROZYGOUS CARRIERS, HEALTHY 
PARTICIPANTS AND MIGLUSTAT TREATED NP-C1 PATIENTS  
Fasting at least 8 hours prior to lipid determination in blood or plasma is a common 
requirement in order to prevent increased lipid levels ascribable to food intake, specifically 
TGs. Although samples collected from healthy participants are not fasting samples, levels of 
several lipidic species for NPC, HET and MGS groups are higher than those for this WT group 
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(Figure 3.5) and recent studies have reported only a low correlation between fasting times 
and plasma lipid levels (210). However, the results shown herein present some limitations. 
  
 
Figure 3.5. Box plots for metabolites selected in more than one classification problem for the 
NP-C1 plasma dataset: those metabolites selected by the RFs models and also showing 
significant differences are indicated by asterisks (p < 0.05, *; p < 0.01, **; p < 0.001, ***).  
 
NP-C1 is a disorder mainly affecting lipid and cholesterol trafficking. Table 3.3 reveals 
that differences in such lipid resonances were selected as important features for 
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discrimination between untreated NPC patients and the WT participants. Most notably, NP-
C1 patients exhibit an increase in both VLDL lipid signals [i.e. VLDL-CH3 and VLDL-(CH2)n-], 
LDL-(CH2)n-, HDL-(CH2)n-, lipid -CH2CH2CO, and vinylic TGs spectral regions. In addition, 
lactate is significantly increased for all the groups when expressed relative to the WT one. 
The N-acetylglycoproteins and lactate spectral regions were also highlighted as important 
variables for discrimination in view of their higher levels in the NP-C1 group. 
The MGS group’s 1H NMR plasma profiles show a very similar pattern to the NPC one 
for those spectral regions assignable to lipids, except for the -CH2CH2CO and unsaturated 
lipids-1, for which the MGS group has lower levels (Table 3.3). Interestingly, the isoleucine 
bucket was neither selected as a discriminatory variable for MGS-treated samples, nor did it 
attain any statistical significance (showing very similar levels to the NPC group). However, 
some additional variables were required for discrimination between MGS-treated patients 
and the healthy controls (WT group), including increases in the Ca-EDTA2- and 2,3-butanediol 
buckets. 
 The HET group exhibited an intermediary phenotype for plasma lipoproteins 
between the MGS/NPC and WT ones, since the pattern for VLDL-CH3, Ile, VLDL-(CH2)n-, TG-
CH2CH2CO and unsaturated lipid-1 in the 1H NMR plasma spectra is NPC > MGS > HET >> WT, 
similar to WT although the unsaturated lipid 2 resonance signal is of higher intensity than 
that of the MGS group. Similar to the NP-C1 patients, the key variables responsible for 
discrimination between the HET and WT groups are dominated by lipid resonances. Two 
variables responsible for discrimination between NPC and control spectra were not 
identified in the HET vs. WT analysis (N-acetyl glycoprotein/CH2-CH2-CH= and lactate), whilst 
an increase in proline resonances is observed only for the HET samples. This HET group was 
successfully classified when compared to the WT one, but the profiles exhibited were closer 
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to the NPC group; RFs analysis for this pair (HET vs. NPC) of groups gave fair values for 
accuracy, specificity and sensitivity. Additionally, both histidine buckets contributed to the 
discrimination between the NPC and HET classes, this being the only case in which this amino 
acid resonances were featured as discriminatory variables.  
 These similarities between the HET and NPC groups are somewhat surprising, since 
heterozygous carriers do not manifest any pathological symptoms, and this may indicate an 
irrelevant role of lipoprotein metabolism in the disease process. 
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CHAPTER 4 
 
1H NMR LINKED METABOLOMICS ANALYSIS OF 
LIVER SAMPLES COLLECTED FROM AN NP-C1 
MOUSE MODEL 
 
 
4.1. LIVER AQUOEUS METABOLITES EXTRACTION FOR NMR ANALYSIS 
NP-C1 mutant (BALB/cNctr-Npc1m1N/J, Npc1-/-; NP-C1), control (Npc1+/+; WT) and 
NP-C1 heterozygous mice (Npc1+/-; HET), were generated from heterozygote matings and 
the genotype of offspring was determined by polymerase chain reaction (PCR), as described 
previously (211). Mice were bred and housed under standard non-sterile conditions at the 
University of Oxford. All animal procedures were conducted using protocols approved by the 
UK Animals (Scientific Procedures) Act (1986). In total, 65 liver samples from gender-
matched heterozygous carrier (HET), NP-C1 disease (NPC) and wild type (WT) mice were 
collected at 3, 6, 9 and 11 weeks. 
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 Collection Time Point (weeks) 
Disease Class 3 6 9 11 
Wild type (WT) 4 (3/1) 3 (0/3) 7 (5/2) 8 (5/3) 
Heterozygotes (HET) 0 (0/0) 0 (0/0) 9 (5/4) 10 (5/5) 
NP-C1 (NPC) 4 (2/2) 6 (4/2) 11 (6/5) 3 (0/3) 
 Number (male/female) 
Table 4.1. Liver samples available for 1H NMR-linked metabolomics analysis at time-points of 
3, 6, 9 and 11 weeks. 
 
Aqueous metabolites extraction for NMR analysis: The extraction protocol 
employed was based on the procedure described by Waters et al. (212) with slight 
modifications. A portion of hepatic tissue (ca. 80 mg) was taken, for each piece of liver 0.02 
mL of ice-cold extraction solvent (H2O/CH3CN, 1:1) per mg of tissue were added. The sample 
was then mechanically homogenized using an electric pestle rotor (Sigma-Aldrich UK, UK). 
The homogenates were centrifuged at 10,000 × g for 10 min at 4 °C. Supernatants 
(hydrophilic metabolites) were freeze-dried and reconstituted in 500 µL of D2O containing 
0.05 % wt. TSP, and 50 µL of pH 7 phosphate buffer to reach a final concentration of 0.01 M, 
then vortexed and centrifuged at 5,000 x g for 10 min. at room temperature. Supernatants 
were transferred into 5-mm NMR glass tubes (Norell, UK) for NMR analysis.  
 
4.2. NMR ANALYSIS OF LIVER EXTRACTS 
1D 1H NMR:  Single-pulse 1H NMR spectra experiments were carried out on a Bruker 
Avance AM-400 spectrometer (Leicester School of Pharmacy facility, DMU, Leicester, UK) 
operating at a frequency of 399.94 MHz and a probe temperature of 298 K. Spectra were 
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acquired using noesygppr1d (Bruker) pulse sequence for water suppression. For each 
spectrum 128 scans were acquired, a relaxation delay of 3 s, spectral width of 4,800 Hz and 
a time domain of 32 K points. Spectra were acquired in an automated manner using a sample 
changer for continuous sample delivery. 
 
1H-1H COSY: This experiment was carried out at 27 °C on a Bruker AV 400 MHz 
(Leicester School of Pharmacy, DMU, Leicester, UK) using the same parameters as those 
delineated above for urine samples.  
 
13C-1H HSQC: Heteronuclear Single Quantum Coherence (HSQC) spectra were 
acquired on a Bruker Avance AM-400 spectrometer (Leicester School of Pharmacy, DMU, 
Leicester, UK). For the HSQC experiments, hsqcedetgpsp.3 pulse sequence (Bruker) was 
employed, and 256 scans for 128 increments were acquired for each spectrum. The F2 and 
F1 spectral widths were 6,340 and 16,600 Hz, respectively.   
 
4.2.1. 1H NMR hepatic profiles of NP-C1 mice 
Typical 400 MHz single-pulse 1H NMR spectra of liver samples (Figure 4.1) collected 
from NP-C1 disease mice and their heterozygous carrier, plus wild type specimens controls 
contained a large number of different types of polar low molecular weight metabolites, 
including amino acids [alanine (Ala), isoleucine (Ile), lysine (Lys), tyrosine (Tyr), phenylalanine 
(Phe)] and derivatives such as sarcosine, small organic acids (2-aminobutyrate, 2-
hydroxybutyrate, lactate), carbohydrates (glucose, glycogen), nucleotides (GMP,GTP), etc. 
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Figure 4.1. 1H NMR spectrum of an NP-C1 mouse liver aqueous extract: 1, Unassigned-1; 2, 
Leu-CH3/Ile-C5-CH3/Val-CH3a; 3, 2-Aminobutyrate-CH3; 4, Val-CH3b; 5, Propylene glycol-CH3; 
6, Lactate-CH3; 7, Ala-CH3; 8, Lys-C5-CH2/Orn-C4-CH2; 9, Acetate-CH3; 10, Acetonitrile; 11, 
Met-CH3; 12, GSSH-Glu-C3-CH2/Gln-C3-CH2; 13, Glu-C4-CH2; 14, Oxalacetate-CH2; 15, 
Succinate-CH2; 16, Gln-C4-CH2; 17, Met-C4-CH2/Hypotaurine-C4-CH2; 18, Asp-CH2a; 19, 
Sarcosine-CH3; 20, Asp-CH2b; 21, TMA-CH3’s; 22, Dimethylglycine-CH3’s; 23, GSSH-Cys-C3-CH2; 
24, Creatine-CH3; 25, Lys-C6-CH2; 26, Orn-C5-CH2; 27, Choline/Phosphocholine-CH3’s; 28, 
Glycerophosphocholine-CH3’s; 29, Taurine-S-CH2/β-Glucose-C2-CH; 30, Methanol; 31, β/α-
Glucose-C4-CH; 32, Taurine-N-CH2; 33, β-Glucose-C3/5-CH; 34, Glycine; 35, Glycerol-C1/3-
CH2; 36, β-Glucose-C6-CHa/α-Glucose-C3-CH/6-CH2; 37, β-Glucose-C6-CHb; 38, Betaine-CH2; 
39, Lactate-CH2; 40, Thr-CH2; 41, Ascorbate; 42, GSH-Cys-CH; 43, β-Glucose/Glucose-6P-C1-
CH; 44, Phosphoenolpyruvate-CH2a; 45, α-Glucose/Glucose-6P-C1-CH; 46, 
Phosphoenolpyruvate-CH2b/Glycogen; 47, Uracil-CO-CH; 48, GTP-C1’-CH; 49, 3-
Hydroxyphenylacetate-CH2; 50, Tyr-C2/6-CH; 51, Tyr-C3/5-CH; 52, 3-Hydroxyphenylacetate-
C4/6-CH; 53, Phenylalanine; 54, Uracil-NH-CH; 55, Niacinamide-C5-CH; 56, Guanosine-C8-
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CH; 57, GTP/GMP-C8-CH; 58, GMP-C8-CH/Hypoxanthyne-C2-CH; 59, Hypoxanthine-C8-CH; 
60, Nicotinate-C4-CH; 61, Nicotinate/Niacinamide-C6-CH; 62, Nicotinate/Niacinamide-C2-
CH. 
 
4.3. DATA PREPROCESSING 
After 1D spectral acquisition, an LB = 0.30 Hz was applied to all spectra prior FT and 
subsequent baseline and phase corrections were carried out using NMR Spectrus processor. 
The intelligent bucketing procedure applied gave a dataset of 65 rows (samples) and 207 
columns (variables). The integral intensity values for each bucket were normalised and 
referenced to the TSP signal (s, δ = 0.00 ppm). Spectral regions which did not contain any 
resonances were removed, so that a final dataset of 65 samples x 143 variables was obtained 
for further analysis.  
Prior to further analysis, NMR spectra were visually checked for any major 
disturbances. None of the spectra was excluded for subsequent statistical analysis.  
 
4.4. UNIVARIATE AND MULTIVARIATE ANALYSIS OF THE 1H NMR MURINE HEPATIC 
DATASET 
4.4.1. Univariate data analysis: ANCOVA 
The experimental design for univariate analysis of the 1H NMR buckets from the NP-
C1 liver dataset involved an ANCOVA model that incorporates 3 factors and 6 primary 
sources of variation: (1) ‛between-disease classifications’ (qualitative NPC disease-active vs. 
the combined HET/WT control group), fixed effect (Di); (2) ‛between-genders’ fixed effect 
(qualitative) ‛nested’ within ‛disease classifications’ (Gj); (3) experimental sampling time-
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point fixed effect (quantitative, Tk); (4, 5 and 6) disease classification x gender, disease 
classification x time-point and gender x time-point first-order interaction components (DGij, 
DTik and GTjk) respectively. This experimental design is represented by Equation 20, in which 
Yijk represents the (univariate) predictor variable value observed, μ its overall population 
mean value in the absence of any significant, influential sources of variation, and e ijk the 
unexplained error (residual) contribution. 
 
Yijk = μ + Di + Gj + Tk + DGij + DTik + GTjk + eijk                                                                                             (20)              
                                                                                         
4.4.2. Multivariate data analysis 
4.4.2.1. Preliminary analysis: PCA 
PCA was employed in order to explore any clustering present within the data 
regarding the 3 groups initially studied. PCA analysis revealed that there was a significant 
clustering of the NP-C1 disease classification which was distinct from both the HET and WT 
groups; however, no discrimination between the latter two disease status classifications was 
found. Indeed, PC 4 vs. PC 3 vs. PC 2 score plot obtained with the unsupervised PCA approach 
(Figure 4.2) provided the best visualisation of this NPC vs. the combined HET/WT group 
discrimination. The NPC cluster exhibited significantly higher and lower scores vectors than 
those of the combined HET/WT ones for components 2 and 4 respectively; there appeared 
to be no ‘between-classification’ differences between these scores vectors for component 3 
as can be observed in the projections of the 3D plot on the 2D planes.  
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Figure 4.2. (a) Three-Dimensional (3D) PC4 vs. PC3 vs. PC2 scores plot arising from PCA of the 
liver NP-C1 dataset (yellow diamonds, NPC; red squares, WT; green circles, HET). (b) 
Multidimensional scaling plot of a random forests proximity matrix from HET/WT vs. NPC 
analysis: this plot demonstrates the success of discrimination from a single RFs iteration. 
 
4.4.2.2. Classification performance 
 Random Forests (RFs): The RFs classification methodology for these liver samples 
was performed in the same way as described previously for the urinary and plasma datasets, 
but in this case the RFs tuning gave optimised values of 1,000 for the number of trees and 
12 variables selected at each split.  Initially, 3 groups were analysed using RFs: HET, WT and 
NPC mice. RFs performed on HET vs. WT gave OOB = 0.428, meaning a 57.2% out of sample 
accuracy. However, lower values for OOB error were obtained when RFs was employed with 
NPC vs. HET (OOB = 0.175) and NPC vs. WT (OOB = 0.190). In view of this situation, HET and 
WT were merged in one group (HET/WT) for further analysis. This analysis gave OOB error 
mean values of 0.190 ± 0.00041. For prediction performance, the values for sensitivity, 
specificity and accuracy were 0.799 ± 0.0013, 0.843 ± 0.0034 and 0.810 ± 0.00084 
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respectively. A plot representing the classification performance of RFs for the test set is 
depicted in Figure 4.2 (b). 
 
4.4.2.3. Variable selection 
The variable importance values for the 143 variables were computed in the same way 
as previous datasets (urine and plasma) using the mean decrease accuracy value (MDA). This 
value is computed from permuting OOB data, so that for each tree the prediction error on 
the OOB portion of the data is recorded as an error rate for classification. Subsequently, the 
procedure is repeated after permuting each feature. The difference is then averaged over 
the ensemble of trees, and normalized by the standard deviation of the differences (165). 
The top 15 variables, together with their respective ranking, p-values and assignments are 
presented in Table 4.2. 
 
Variable 
Ranking 
Bucket 
(ppm) 
Assignment Multiplicity 
ANCOVA p-value 
for disease 
Fold change 
1 7.30 - 7.35 Phenylalanine-C1/C2-CH d (6.8) 1.60 x 10-4 +1.56 
2 7.17 - 7.23 Tyrosine-C3/C5-CH d (8.6) 1.70 x 10-4 +1.38 
3 6.88 - 6.93 Tyrosine-C2/C6-CH d (8.2) 1.45 x 10-3 +2.25 
4 8.92 - 8.97 Nicotinate-C2-CH d (2.1) 1.30 x 10-3 -1.49 
5 2.99 - 3.05 Lysine-C6-CH2/Ornithine-C5-CH2 t/t 2.00 x 10-4 +1.51 
6 2.62 - 2.67 Hypotaurine-C4-CH2SO2-/Methionine-C4-CH2 m 2.40 x 10-3 +1.96 
7 6.78 - 6.81 3-Hydroxyphenylacetate-C4-CH m 3.80 x 10-4 -3.45 
8 0.94 - 0.99 Valine-CH3 d (7.1) 1.49 x 10-2 +1.35 
9 4.24 - 4.27 Threonine-C3-CH m 3.40 x 10-4 +1.30 
10 8.69 - 8.74 Niacinamide-C6-CH dd (4.4, 1.7) 0.26 -1.01 
11 8.23 - 8.29 Nicotinate/Niacinamide-C4-CH m/dd 8.11 x 10-2 -1.37 
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12 7.35 - 7.41 Phenylalanine-C3/4/5-CH m 1.22 x 10-2 +3.21 
13 0.77 - 0.80 Unassigned t (7.5) 0.20 -1.27 
14 8.90 - 8.92 Niacinamide-C2-CH s 0.25 -1.79 
15 2.67 - 2.72 Aspartate-C2-CH2a dd (8.9) 3.90 x 10-3 +2.06 
Table 4.2. Key 1H NMR variables derived from the application of the RFs strategy to the liver 
NP-C1 dataset: variables are ranked from 1 to 15 based on their MDA value. ‛Between-
disease classifications’ ANCOVA p-values are provided, along with their fold changes. 1H NMR 
resonances, their coupling patterns and assignments were confirmed via the methods 
outlined in section 4.2. Fold changes for TSP-normalised hepatic metabolite concentrations 
are expressed relative to NP-C1 disease group, so that a positive value indicates upregulation 
in NP-C1 disease, whereas a negative value indicates a higher level in the HET/WT group.  
 
The acquisition of 2D 1H-13C HSQC and 1H-1H COSY NMR techniques confirmed the 
structural identities of those metabolites selected as discriminatory features. Thus, the 
assignment of phenylalanine, tyrosine, nicotinate and niacinamide was facile since their 1H 
NMR signals are clearly visible in unobscured regions of the 1D 1H NMR spectra acquired, 
and in some cases further supporting evidence for such assignments was obtained, since two 
or more resonances arising from individual metabolites were indicated as discriminatory 
variables. Although, both nicotinate and niacinamide presented low concentrations so their 
13C resonances were unobserved in the HSQC spectra acquired. However, application of 2D-
NMR experiments was required to confirm assignments of the valine resonances since they 
are located at chemical shift values close to those of leucine and isoleucine. Additionally, 
both methionine and hypotaurine have triplet resonances located at ca. 2.65 ppm, coupled 
to a multiplet located at 2.15 ppm for the former, and a triplet at 3.35 ppm for the latter; 
both these linkages were observed in the 2D COSY NMR experiments conducted (Figure 4.4) 
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and their respective 13C resonances were also observed in the HSQC experiments performed 
[Figure 4.3 (a)]. The 3-hydroxyphenylacetate resonance was detectable, at low intensity, in 
17 of the HET and WT liver samples, but only in 2 of the NP-C1 samples, specifically the 6.78-
6.81 ppm bucket (generally, an uncrowded region for all the tissue spectra acquired). 
Assignments for aspartate resonances were also confirmed by such 2D-NMR experiments. 
The ABX coupling system of the C2-CHb proton resonance of this amino acid lies within the 
2.79-2.81 ppm bucket. For the combined lysine-C5-CH2/ornithine-C4-CH2 resonances (δ = 
1.70-1.74 ppm), 1H-13C HSQC spectra acquired confirmed the identities of these amino acids, 
and hence this 1H NMR bucket did not arise from further metabolites with similar δ values 
(for example, putrescine and spermidine).  
These variables included significantly elevated hepatic spectral intensities of amino 
acids (Phe, Tyr, Asp, Lys/Orn, Met, Thr and Val, and also the β-amino acid hypotaurine), along 
with reduced ones for nicotinate and nicotinamide, 3-hydroxyphenylacatate and an 
unassigned species with a triplet resonance located within the 0.77-0.80 ppm bucket. Whilst 
this latter resonance remains unassigned, 1H-1H COSY NMR (Figure 4.4) analysis 
demonstrated that this triplet signal was linked to a multiplet centred at δ = 1.99 ppm, an 
observation indicating that the latter is attributable to a proton located α- to a carboxylate 
function, i.e. these coupled resonances appear to arise from a carboxylic acid anion species. 
Additionally, its 13C chemical shift value is 10.98 ppm. 
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Figure 4.3. 400 MHz 1H-13C HSQC spectrum of an NP-C1 mouse liver aqueous extract: only 
those resonances that were selected as discriminatory features and observable in a 1H-13C 
HSQC spectrum (low concentrated metabolites are not visible in view of the low natural 
abundance of 13C) are assigned in this Figure for purposes of clarity. Red cross-peaks indicate 
either a -CH3 or -CH group, and blue ones represent -CH2- functions. 
 
 
Figure 4.4. 400 MHz 1H-1H COSY spectrum, of an aqueous extract of an NP-C1 liver sample. 
Typical spectra is shown (aromatic region expanded). Only the cross-peaks for the selected 
metabolites are indicated in the spectrum. Abbreviations: Phe-C1/C2, Phenylalanine-C1/C2-
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CH; Tyr-C3/C5, Tyrosine-C3/C5-CH; Tyr-C2/C6, Tyrosine-C2/C6-CH; Nic-C2, Nicotinate-C2-CH; 
Lys/Orn, Lysine-C6-CH2/Ornithine-C5-CH2; Hypotau, Hypotaurine-C4-CH2SO2-; Met, 
Methionine-C4-CH2; Val, Valine-CH¬3; Thr, Threonine-C3-CH; Nic/Nia-C4, 
Nicotinate/Niacinamide-C4-H; Nia-C6, Niacinamide-C6-CH; Phe-C3/4/5, Phenylalanine-
C3/4/5-CH; Nia-C2, Niacinamide-C2-CH; Asp, Aspartate-C2-CH2a. 
 
4.4.2.4. ROC curve analysis 
In order to evaluate the ability of RFs to classify and predict using these variables, a 
ROC analysis was carried out, using the corresponding option in MetaboAnalyst 3.0. Only 
those variables detailed in the previous section were retained to perform the analysis 
outlined above. Then, with only 11 variables (out of 143 initial variables) attributable to Phe, 
Tyr, Val, Met/Hypotaurine, Niacinamide, Nicotinate, Lys/Orn, Thr, Asp, 3-
hydroxyphenylacetate and the unassigned bucket (0.77 - 0.80), RFs gave a maximum AUC 
value of 0.939 (range = 0.823 - 1.000) (Figure 4.5). 
 In the ROC analysis observed in Figure 4.5, the number of variables is permuted to 
generate different RF models containing different sets of variables from those previously 
selected; furthermore, the number of features employed also changes. In this case, 2, 3, 5, 
7, 10 and 11 variables were used for developing the models. For each model the respective 
AUC value together with the range is stored and depicted in Figure 4.5. 
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Figure 4.5. (a) ROC curves analysis for the liver NP-C1 dataset and (b) blue bubbles indicate 
metabolites with lower levels in NPC group and orange ones, those with higher levels. The 
size of each bubble is correlated with the FC (fold change): different combination of variables 
gave different AUC values ranging from 0.754 for 2 variables, up to 1 with 7, 10 and 11 
variables, as indicated in the table inserted in the left plot. Abbreviations: TPR, True Positive 
Rate; FPR, False Positive Rate; AUC, Area Under the Curve; U, unknown; 3-OH-PheAc, 3-
hydroxyphenylacetate. 
 
 ROC curve analysis revealed that the buckets attributable to 3-hydroxyphenylacetate 
and tyrosine were the variables with higher frequency of selection for building up the 
classification RFs models, additionally the models involving only 2 variables accomplished an 
AUC range of 0.579 - 0.951 showing a good extent of success. These facts together with the 
phenylalanine frequency of selection (0.96, ranked the 4th) indicate that the most affected 
pathway in NP-C1 liver disease, and therefore the one with higher value as a discriminant 
feature, is that involving aromatic amino acids.  
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4.4.3. Time-dependency of 1H NMR NP-C1 hepatic profiles 
As the samples were collected at different time points, ASCA was performed using 
the MetaboAnalyst 3.0 option for Time Series Analysis. ASCA splits the total variance into 
different parts due to the factors involved in the experiment, and extracts the variance 
arising from the interaction of these factors (213). No significant differences were found for 
sampling time; indeed, ‛between-time-points’ component gave a p-value = 0.185, revealing 
no correlation with metabolite levels. Furthermore, the ‛disease x time-point’ interaction 
component of variance was also found not to be significant for the first two (major) PCs 
explored (p = 0.530). Partial redundancy analysis performed focused on the collection time-
point variable revealed no significant differences (p = 0.069) attributable to this variables 
regarding the levels of the hepatic metabolites monitored.  
Since some variables selected were ascribable to the same metabolite, only those 
with the highest MDA values arising from that biomolecule were retained in order to explore 
the time dependency of the variables. Therefore, the top 15 features were attributed to 11 
metabolites. Plots of normalised intensity values v. collection time-point for those 11 
discriminatory metabolites selected by RFs are shown in Figure 4.6.  
Lower intensity values for Val, Asp, Thr, Tyr, Lys/Orn and the unassigned δ = 0.77-
0.80 ppm resonance were observed at the week 3 time-point than those for NP-C1, and 
these observations appear to be consistent with the pre-symptomatic nature of this time-
point, i.e. elevated levels of these biomolecules appear at the early (6 week) and late (≥ 9 
week) symptomatic points. Indeed ‛time point’ x ‛disease classification’ interaction effect 
was found to be marginally significant for Val (p = 0.025) and the bucket 0.92 - 0.94 ppm was 
also found significant (p = 0.042), which is ascribable to the other methyl group of Val. 
Interestingly, other regions showing statistical significance for ‛time point’ x ‛disease 
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classification’ interaction effect were 1.70 - 1.74 and 1.74 - 1.79 ppm (p = 0.030 and 0.039) 
which are ascribable to Lys-C5-CH2/Orn-C4-CH2 and 7.41 - 7.47 ppm (part of Phe multiplet, 
p = 0.031). Nevertheless, those values may be considered marginally significant due to their 
proximity to the threshold 0.05. 
However, there appeared to be no time-dependence of the 3-hydroxyphenylacetate, 
phenylalanine and nicotinate levels, although Val, Asp, Thr, Tyr and Phe NP-C1 hepatic levels 
were higher than those of HET/WT group at all the post-symptomatic time-points, together 
with lower ones for 3-hydroxyphenylacetate and nicotinate in this group. Although 
niacinamide shows some descending tendency over time, such differences are clearly not 
significant. Moreover, with the exception of 3-hydroxyphenylacetate, the liver content of all 
metabolites appeared to be time-independent in the combined HET/WT group.    
Performance of the above RF procedure, but excluding the pre-symptomatic week 3 
samples, gave rise to a slight improvement compared to that achieved without removal, 
specifically a mean OOB error of 0.13 ± 0.003, and prediction performance values for 
sensitivity, specificity and accuracy of 0.86 ± 0.0014, 0.89 ± 0.0016 and 0.865 ± 0.00082 
respectively. These results are consistent with the pre-symptomatic nature of samples 
collected at the week 3 time-point in NP-C1 mice. 
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Figure 4.6. Box plots of the 11 metabolites identified as discriminatory variables for the NP-
C1 liver dataset by RFs analysis vs. time-point (weeks) for the NPC (grey) and HET/WT (white) 
classifications. 
 
 The ANCOVA model revealed some regions attaining statistical significance for the 
‛Time point’ effect, such as 3.44 - 3.50 (p = 0.023), 3.39 - 3.44 (p = 0.026), 5.22 - 5.28 (p = 
0.017), 8.44 - 8.47 (p = 0.034) and 3.69 - 3.71 ppm (p = 0.046) ascribable to glucose moieties 
and formate (8.44 - 8.47 ppm). These values may arise from a differential energetic 
metabolism over time for mice, although these values were very close to 0.05, the threshold 
for statistical significance. 
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4.4.4. Gender contribution to 1H NMR NP-C1 hepatic profiles  
The same RF procedure described above was applied to the dataset, but in this case 
the y response variable was gender. This analysis was performed to check that the variables 
selected were not conditioned by gender differences and hence represent a true separation 
between NP-C1 and healthy mice (WT/HET). The OOB obtained was 0.461 which reveals no 
differences attributable to gender. Corresponding partial redundancy analysis-based 
permutation testing analysis focused on the gender variable revealed that gender was not 
significantly related to any of the discriminatory variables (p = 0.100). The only signals that 
gave significant p-values for ‛gender’ contributions were 3.35 - 3.37 (p = 0.0065) , 5.17 - 5.20 
(p = 0.0083), 3.44 - 3.50 (p = 0.024), 8.44 - 8.47 (p = 0.029), 5.88 - 5.93 (p = 0.035), 5.22 - 5.28 
(p = 0.035) and 1.45 - 1.51 ppm (p = 0.040), ascribable to methanol, phosphoenolpyruvate-
CH2a (PEP), β-Glucose-C3/5-CH, formate-H, GTP-C1’-CH and  α-glucose/glucose-6P-C1-CH 
and alanine-CH3 respectively. Most of these metabolites are correlated with the glycolysis 
pathway, since glucose subsequent transformed to glucose-6P yields PEP prior to the final 
product, i.e. pyruvate, which can also arise from alanine in the alanine-pyruvate cycle. The 
same variables shown significant p-values in the ANCOVA model for the factor ‛time point’ x 
‛gender’, revealing no effect of the collection time point in those variables gender-
dependent. None of the variables presented a significant p-value for the interaction factor 
‛disease’ x ‛gender’.  
The variables listed in Table 4.2 failed to attain statistical significance for the ‛gender’ 
factor or any of the combinations with others, such as ‛disease’ and ‛time-point’, which 
indicates that gender is not conditioning the classification of mice liver extracts according to 
their disease class. 
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4.5. HEPATOCYTE REDOX STATUS BASED ON GSH:GSSG RATIO  
Although not featuring as significant biomolecule variables in the RF and further MV 
analysis models developed, we also explored differences between the mean hepatic 
concentrations of glutathione (GSH) and its corresponding disulphide oxidation product 
(GSSG), and in particular that of the [GSH]:[GSSG] concentration ratio between the NP-C1 
and HET/WT classifications investigated. [GSH]:[GSSG] ratio is a valuable and reliable 
indicator of the REDOX status of tissue, mainly in the liver, since this organ is the site of GSH 
synthesis (214). GSH provides reducing equivalents to cells, and the GSH/GSSG couple is 
recognised as a major thiol-disulfide cellular ‘redox buffering system’, since the combined 
cellular concentrations of these biomolecules are much higher than those of the other two 
major redox-active systems, i.e. NADP+/NAPH and thioredoxin (215). The levels of both 
correlated metabolites can be utilised as indicator for the redox environment of the cell 
(215). Glutathione is a tripeptide conformed for Glu-Cys-Gly, in which Cys is the key 
component, since its reactive thiol group is the one involved in the formation of a disulphide 
linkage with an additional GSH molecule to yield GSSG (Equations 21 and 22). 
 
GSH + •OH     GS• + H2O                                 (21) 
GS• + GS•   GSSG                       (22) 
 
The buckets selected to explore the levels of GSH and GSSG were 4.55 - 4.61 ppm and 
3.31 - 3.35 ppm (Figure 4.7), attributable to GSH-Cys-CH and GSSG-Cys-CH2a respectively, 
according to the chemical shift values provided in (216) and (217) respectively. 
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Figure 4.7. Typical spectra from an aqueous liver tissue extract from 3.15 ppm to 4.62 ppm 
showing the resonance signals employed for the [GSH]:[GSSG] computation. 
 
Primarily, it was found that hepatic GSH levels were significantly reduced in NP-C1 
patients (p = 0.036), although no such differences were noted for GSSG (ANCOVA model 
depicted in Equation 20) for the ‛between-disease classifications’ factor However, there was 
a much more highly significant decrease in the mean [GSH]:[GSSG] ratio of the NP-C1 group 
when compared to that of the HET/WT control one (p = 8.65 x 10-4).    
 
 
Figure 4.8. (a) Box plot for hepatic mice GSH:GSSG  ratio [4.55 - 4.61]:[3.31 - 3.35] and (b) for 
hepatic mice GSH levels for both disease classification groups: Both GSH and GSH:GSSG ratio 
were analysed using the ANCOVA model depicted in Equation 20, showing a significant 
difference  (p < 0.05, *; p < 0.01, **; p < 0.001, ***). 
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CHAPTER 5 
 
CLASSIFICATION AND VARIABLE SELECTION BY 
RANDOM FORESTS AND CORRELATED 
COMPONENT REGRESSION IN A METABOLOMICS 
CONTEXT 
 
 
5.1. RANDOM FORESTS RANKING FOR VARIABLE SELCTION vs. RANDOM FORESTS-
RECURSIVE FEATURE ELIMINATION 
NP-C1 Disease Urinary dataset: In order to identify the variables which were more 
important for the discrimination of samples according to their disease classification, MDA 
values for each variable were saved at each iteration and finally averaged to obtain final 
rankings. Additionally, it was possible to track the ranking and MDA value of any variable 
along all those 100 repetitions (Figure 5.1) in order to explore their variability. At each 
iteration the whole sample set was partitioned as 2/3 for training and 1/3 for test sets, and 
hence 100 different sub-sets of training and test sets were employed.  
 An alternative methodology for variable selection is Recursive Feature Elimination 
(RFE), an approach which is linked to the RFs technique (RFs-RFE). RFs-RFE is a strategy 
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proposed by Diaz-Uriarte (218) in which 20% of variables with lowest ranking are removed 
after RFs performance, and then the classification is performed again without those 
variables. The ability of this process is assessed by the OOB error value, i.e. variables with 
lowest contribution for classification will be removed until this value (OOB error) increases 
or becomes unstable. 
 
 
 
Figure 5.1. (a) MDA values for top-5 variables ranked by RFs over 100 iterations in which the 
black line represents the MDA mean value (0.88) of the 15th variable selected by RFs for the 
urinary NP-C1 dataset, and this acts as a threshold for variable selection. (b) Recursive 
Feature Elimination (RFE) for the urinary NP-C1 dataset showing changes in the OOB error 
value as a function of the number of variables employed by the RFs analysis. 
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 Creatinine-N-CH3 (4.05 - 4.10 ppm), 3-aminoisobutyrate-CH3 (1.17 - 1.22 ppm), 
unknown-1 (0.72 - 0.76 ppm), and both trigonelline signals [-C4/6-CH (8.80 - 8.86 ppm) and 
-C2-CH (9.11 - 9.16 ppm)] were selected below the mean MDA value obtained for the 15th 
top variable (2-Hydroxyisobutyrate-CH3’s, 1.36 - 1.41 ppm) 7%, 10%, 13%, 19% and 20% 
respectively. The 16th ranked variable was the 1.58 - 1.63 ppm bucket assignable to 5-
aminovalerate-C3/4-CH2, with an MDA value of 0.79. This metabolite was selected by the 
CCR and GAs techniques as the 12th and 10th most important variable respectively. 
In Figure 5.1 (b) the OOB error value decreases until the number of variables is 23, 
then it becomes stable and then starts to fluctuate as the number of variables further 
decreases. However, even with only 3 variables, the OOB error value obtained was 0.149, a 
value below 0.220 which is the starting OOB value with 219 variables. These last 3 variables 
were the 0.72 - 0.75 ppm, 1.17 - 1.22 ppm and 4.05 - 4.10 ppm buckets, the latter two 
assigned to 3-AIB and Cn respectively.  
 
Mice hepatic dataset: The variability of the variables ranking, and consequently, the 
features selected after the full cross-validated process was also explored for the NP-C1 liver 
dataset. The combined top-5 ranked variables’ MDA value was explored over each of those 
100 repetitions, and is depicted in Figure 5.2. The performance of RFs-RFE was also explored 
to compare with the RFs variable selection procedure. 
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Figure 5.2. (a) Mean decrease in accuracy (MDA) values computed for the 5 most effective 
discriminatory variables throughout 100 iterations. The black pointed line represents the 
mean MDA value for the 15th most important selected variable (aspartate), which acts as a 
threshold for variable selection. (b) Recursive Feature Elimination (RFE) for the mice liver NP-
C1 dataset showing the changes in the OOB value as a function of the number of variables 
employed by RFs. 
 
 MDA computations indicated that the top 5 variables selected would not have been 
selected in 7, 11, 12, 16 and 19% for the first, second, third, fourth and fifth of these 
respectively in the CV testing cases. As expected, this percentage increases for those 
variables selected with lower rankings. The 2.67 - 2.72 ppm bucket attributable to a proton 
from the ABX system of aspartate (Asp) was the threshold for this dataset, with an MDA 
value of 4.11, with the next one being the 2.79 - 2.81 ppm bucket assignable to the other 
Asp proton from that coupling system, which gave an MDA value of 3.94. 
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In this study, the RFs strategy was applied for the classification of human urine and 
plasma, together with mice liver samples according to their disease status. In this case, RFs 
was employed with the major aim of determining the variables that can group samples based 
on their disease class; in this manner, we can enhance our knowledge of disturbances in 
metabolic pathways arising from the NP-C1 disease process, and moreover propose some of 
these metabolites as biomarkers.  
A wide range of different MVA techniques are available for variable selection (219), 
but RFs attain effective results when dealing with outliers, it does not overfit and provides 
excellent results even if some variables are noise (220). Several MVA strategies have been 
successfully utilised for the analysis of datasets in which the number of possible predictor 
variables (P) exceeds the number of samples (n) available, i.e. P > n situations; one of these 
techniques is the RFs approach, which has been successfully applied throughout a range of 
metabolomics studies (221, 222). 
Our RFs model was primarily tuned in order to improve its performance, and this 
approach has been previously investigated by Diaz-Uriarte et al. (218), in which the 
investigators demonstrated that both the number of variables included in the generation of 
each individual tree, and the maximum number of trees included in the final RFs model can 
be tuned separately since they are independent parameters. Moreover, the computational 
time required proportionally increases with the number of trees, and selecting a very large 
number does not necessarily provide an improved performance, as reported in (218) and 
explored in this investigation. The number of variables selected for tree partitioning  has 
been shown to be the most critical parameter to tune; nevertheless, the default value was 
found to be an effective choice for the liver and plasma NP-C1 datasets, in which it was set 
at a value of (143)1/2 ≈ 12 for liver, and 7 for plasma, given the presence of a total of 39 
 
 
131 
 
variables in the latter dataset (for this model, 6 or 7 variables for tree partitioning would 
have matched the √𝑛 rule). Nevertheless, when RFs strategy was applied to the urinary NP-
C1 dataset, the optimal value for tree partitioning was 8, a very low value considering the 
total number of variables in the original dataset (199 variables).  
The variable selection process has been performed based on the MDA values, since 
this has been suggested to be the most reliable metric (79, 223), and therefore it is more 
robust than the other available metric, the Gini index (224). In view of the random sub-
sampling procedure conducted by RFs for classification purposes, the variables with 
selectively higher MDA values can, of course, vary when this classification technique is 
repetitively applied to MV analysis of the same dataset; moreover, in order to explore as 
many combinations of samples in the training and test sets as possible, an iterative process 
was implemented here, although the OOB error term computation already involves a cross-
validation (CV) procedure (225).  
An assessment of the performance of this iterative cross-validated process was also 
conducted in order to test the reliabilities of the selected metabolite variables, and this 
revealed that with the employment of the MDA value of the 15th-ranked variable as a 
threshold, the top 1-, 2-, 3-, 4- and 5-ranked variables selected would not have been selected 
in 7, 11, 12, 16 and 19% respectively of the CV testing cases (Figure 5.2) for the liver dataset, 
and 7, 10, 13, 19 and 20% respectively for the NP-C1 urinary one (Figure 5.1), which shows 
how the variables selected change with different test and training sub-sample sets. 
Therefore, studies in which CV with random sub-sampling is only performed once or a few 
times can experience this limiting effect, since the results can be biased by the sub-sample 
selected. However, the robustness of this ensemble technique was confirmed by the 
computation of SEM values for the MDAs, which were very small.  
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Additionally, a further major methodology available for variable selection, the so-
called Random Feature Elimination, serves as another iterative process which was first 
proposed by Diaz-Uriarte (218). When combined with RFs, the variable importance is 
primarily computed, and this process then repeated with removal of the 20% of less 
important variables until the OOB decreases to a stable value.  This strategy was also 
explored herein employing our urine and hepatic datasets, which revealed how the OOB 
value initially decreases with the reduction of the number of variables (20% at each 
repetition), an observation predominantly ascribable to the removal of noisy variables that 
generate unsuccessful trees, and that are further averaged when computing the OOB. 
Additionally, this procedure has been investigated in detail in (226). 
In the datasets investigated, the OOB error value reached a minimum and then 
became unstable, i.e. a high variability of OOB error values following the removal of certain 
variables; however, even using only 3 variables, the OOB error  value was lower than the 
initial one containing the complete set of features, indicating an improved classification 
performance. The main issue arising from this RFE approach is that the final goal of this 
strategy is to reduce the number of variables to the minimum, whilst maintaining reasonably 
good classification performance; nevertheless, in a metabolomics context, where the 
selected features might be related to disorders caused by the disease and not by the disease 
itself, reductions in the number of variables can be detrimental, since information about 
affected pathways may be lost, and the reduced number of variables may represent common 
metabolites that usually are non-disease-specific, and therefore their value as biomarkers is 
severely limited. 
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5.2. CORRELATED COMPONENT REGRESSION: A NEW TOOL FOR METABOLOMICS 
ANALYSIS 
5.2.1. CCR-LDA performance  
 Correlated Component Regression-Linear Discriminant Analysis (CCR-LDA) was 
applied to the urinary and liver NP-C1 datasets to evaluate its ability to classify those samples 
with regard to their disease status, and also to compare its performance against other well-
established MVA techniques employed in metabolomics investigations. The results arising 
from both these classification problems are depicted in the table below. 
Table 5.1.  MVA performance of all the technique employed for the urinary and liver NP-C1 
datasets: the top part of the Table is a copy of Table 3.2. The bottom part includes the 
analysis outlined in section 4.4.2.2 plus the results of the CCR-LDA applied to the hepatic 
dataset. The OOB error value is also indicated for the RFs approach (the standard error of 
the mean for each of the parameters computed is shown in brackets). 
 
 CCR-LDA only out-performs the other techniques in term of specificity, although it 
presents higher SEM values for all the parameters computed. The main difference, however, 
is the low value obtained for sensitivity. This dataset is somewhat complicated, since the 2 
Dataset MVA Technique OOB (SEM) Accuracy (SEM) Sensitivity (SEM) Specificity (SEM) 
U
R
IN
E
 
RFs 0.224 (0.00012) 0.835 (0.001) 0.695 (0.001) 0.831 (0.003) 
GA-MLHD/SVM - 0.827 (0.002) 0.752 (0.002) 0.903 (0.001) 
CCR-LDA - 0.810 (0.013) 0.583 (0.032) 0.926 (0.012) 
      
LI
V
ER
 RFs 0.190 (0.0004) 0.810 (0.001) 0.799 (0.001) 0.843 (0.003) 
CCR-LDA - 0.824 (0.014) 0.719 (0.029) 0.887 (0.016) 
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classes are not balanced, and the control group is almost 4 times larger than the disease one. 
Therefore, the CCR strategy could be more sensitive to that issue.   
 The main feature that CCR-LDA has when compared to alternative parametric MVA 
techniques is the correlation of the components, so that these are not selected with the 
restriction of having to be orthogonal to each other, but with the aim of improving the 
performance of the model, increasing the ability of the component previously selected for 
classification (in the case of the combination with LDA, it can be employed for regression 
purposes in addition). Those components contributing to the overall performance via 
enhancements of the predictive ability of the pre-built model are known as proxy 
components, and those variables with higher loading on those components and lower on the 
prior ones are denominated proxy (suppressor) variables. 
   
5.2.2. CCR-LDA dependency of the number of components and variables employed 
 In order to explore the ability of the CCR-LDA technique to classify samples 
independently of the number of variables and/or components employed to construct the 
model, the number of variables was limited to 5, 10, 15 and 20, and the number of 
components to 1, 2 and 3 for both urinary and hepatic mouse datasets; selecting each of 
these combinations 5 times yields a final set of 60 different models. Specificity, sensitivity, 
accuracy and AUC values were computed for each of these models. For each of those 12 
possible combinations of maximum number of components x maximum number of variables, 
the classification performance parameters were averaged.  
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Figure 5.3. CCR-LDA results for the NP-C1 urinary dataset. (a) Scatter plot of the number of 
variables vs. the parameters employed for the 60 models generated utilising from 1 to 20 
variables. (b) Mean values for specificity (Spec), sensitivity (Sen), accuracy (Acc) and area 
under the curve (AUC), along with their SEM values for the models generated with 1, 2 and 
3 components. (c) Individual density plots for specificity, sensitivity, accuracy and AUC as a 
function of the total number of variables employed by the CCR-LDA strategy. 
 
No significant correlations (linear, logarithmic or quadratic) were found between the 
number of variables employed for the model and their classification performance (Figure 
5.3). Indeed, analysis of the classification performance as a function of the number of 
components did not show any tendency for sensitivity and accuracy to increase; however, it 
should be considered that specificity decreases as the number of components increase, and 
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also the opposite effect is observed for AUC values in Figure 5.3(c). In the density plots it can 
be observed that neither sensitivity nor accuracy show a tendency (decreasing or increasing 
values as the number of components increases); however, sensitivity values appear to 
increase with the number of variables, and for the AUC, these values increase with only a 
few variables, and then they remain at a high level when more variables are introduced into 
the model. 
 
 
Figure 5.4. CCR-LDA results for the NP-C1 mice hepatic dataset. (a) Scatter plot of the number 
of variables vs. the parameters employed for the 60 models generated utilising from 1 to 20 
variables. (b) Mean values for specificity (Spec), sensitivity (Sen), accuracy (Acc) and area 
under the curve (AUC), along with their SEM values for the models generated with a 
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maximum of 1, 2 and 3 components. (c) Individual density plots for specificity, sensitivity, 
accuracy and AUC as a function of the number of variables employed by CCR-LDA. 
 
 Values for specificity, sensitivity, accuracy and AUC in the NP-C1 mice liver CCR 
analysis of the 1H NMR spectral buckets reveals a clear dependency of the number of 
components, these parameters increasing with the number of components involved (Figure 
5.4). Nevertheless, no tendency or dependency is observed regarding the number of 
variables employed, although lower values for these parameters are obtained when the 
number of variables is less than 10, except for that of sensitivity which reaches its minimum 
value when the number of features employed are close to 15.  
 The variable selection process in CCR is analogous to the RFE one described in section 
5.1, since the ‛step-down’ procedure incorporated in the CCR algorithm starts with the whole 
set of variables and they are then sequentially removed until the CV process performance 
decays. With regard to classification problems, the minimum number of variables is always 
desired for a model, so that a low number of variables can be set as an initial parameter for 
CCR, and then researchers may check to determine if a successful classification rate is 
accomplished. In this case, a limitation to only 5 variables out of 219 and 143 for the urinary 
and hepatic datasets, respectively, were set, and results arising from CCR-LDA model gave 
very promising results. Nevertheless, the lowest values for sensitivity, accuracy and AUC 
were obtained using 5 variables [Figure 5.3 (c)] for the urinary dataset. The same results 
were observed in the hepatic dataset [Figure 5.4 (c)]. However, there is not a very high 
density of points in Figures 5.2 (c) and 5.3 (c), an observation that may indicate that limitation 
of variables affects the results for these datasets, as expected. 
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CHAPTER 6 
 
INTEGRATIVE METABOLOMICS: URINE, PLASMA 
AND LIVER 1H NMR METABOLOMICS ANALYSIS 
TO ASSESS THE METABOLISM OF NP-C1 
PATIENTS 
 
 
6.1. NICOTINATE/NIACINAMIDE PATHWAY  
Elevated levels of quinolinate (p = 3.83 x 10-5, FC = 30.32) were found in urine 
specimens collected from NP-C1 patients, and the 1H NMR analysis of liver samples collected 
from NP-C1 mice model also showed lower levels of nicotinate (p = 1.30 x 10-3, FC = -1.49) 
and niacinamide (p = 0.26, FC = -1.01) than in healthy controls. These findings suggest an 
imbalance in the nicotinate/niacinamide pathway that may, in turn, lead to a depletion in 
NAD/NADP levels.  
Dietary nicotinamide is absorbed in the intestines, and it is then converted in the 
intestinal lumen by bacterial nicotinamidase to nicotinate. Both nicotinamide and nicotinate 
are major precursors of NAD synthesis in humans (salvage pathway), even though they are 
required to be incorporated through the diet. Moreover, human cells have the ability to 
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synthesise NAD from tryptophan (Trp) (Figure 6.1).  Hara and co-workers have suggested 
that NAD biosynthesis is tissue-specific based on the expression pattern of the enzymes 
involved in its metabolism (227). Hence, it occurs predominantly from nicotinate in the small 
intestine and from nicotinamide in skeletal muscle, whereas in the liver and kidney, both 
metabolites, along with Trp, contribute to the synthesis of NAD (227). Moreover, NADP is 
synthetised through the phosphorylation of NAD, and particularly noteworthy is the 
diminished mean hepatic concentration of GSH present in the NP-C1 mouse classification (p 
= 0.036), which may reflect a disease-mediated imbalance in hepatocyte [NADP+]:[NADPH+] 
concentration ratios, since GSH is required for the conversion of NADP to NADPH (228).  
The first step in NAD synthesis from nicotinamide is the generation of its 
mononucleotide, a reaction mediated by the enzyme nicotinamide 
phosphoribosyltransferase (Nampt). A recent investigation has reported an upregulation of 
Nampt mRNA, and increased levels of NAD in the liver of mice fed with a high-fat diet (229), 
and also in non-alcoholic fatty liver disease (NAFLD) (230). Additionally, Nampt mRNA 
expression levels were also found to be higher in fibrotic human livers (231), fibrosis being a 
major feature of the development of NP-C1 mice liver pathophysiology (122). Therefore, the 
hepatic stress experienced by the NP-C1 mice could lead to an increase in NAD production 
in order to load enzymatic reactions that require this cofactor, such as β-oxidation and 
tricarboxylic acid metabolism which are enhanced in other hepatic disorders such as NAFLD 
(232). Indeed, in NAFLD liver tissue, there is an imbalance in bile acid duct transporters (233), 
a complication also observed in NP-C1 mice liver as discussed below. This enhanced 
requirement of NAD may be responsible for the low nicotinate/nicotinamide levels observed 
in NP-C1 mice liver extracts, since they appear to be overutilised to generate NAD.  
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Moreover, the increased levels of quinolinate (QUIN) found in urine collected from 
NP-C1 patients, together with the lower levels of both nicotinate and niacinamide in NP-C1 
mice hepatic tissue, could indicate an imbalance between de novo and salvage pathways, 
i.e., an overloading of the latter in NP-C1 liver. The synthesis of NAD from Trp via QUIN 
mainly occurs in the liver (234); therefore, a defect in the QUIN to nicotinate mononucleotide 
stage may lead to an increased activity of the salvage pathways enzymes, hence reducing 
the levels of nicotinate/niacinamide and therefore the accumulation of QUIN that is then 
released from hepatocytes. Healthy individuals, with sufficient dietary levels of 
nicotinamide, present relatively low levels of QUIN production in the liver, and consequently 
its levels, together with those of further kynurenine pathway metabolites in other tissues 
and the systemic circulation are relatively low (235).  
 
 
Figure 6.1. NAD metabolism: schematic representation of NAD synthesis highlighting those 
metabolites selected as discriminatory variables, and indicating the tissue/biofluid where 
they were found, and their levels in NP-C1 samples expressed relative to those from healthy 
controls. Urinary metabolites selected by the different strategies applied are indicated by 
coloured boxes (red = RFs; green = GAs-SVMs/MLHD; blue = CCR-LDA). Metabolites 
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highlighted in orange refer to those selected in mice liver samples analysis.  Arrows illustrate 
higher (↑) or lower (↓) levels in the NPC group. 
 
 Quinolinate (QUIN) is generated and released by infiltrating macrophages and 
activated microglia in the brain (236). It is produced through the kynureine pathway, which 
is the route involved in the degradation of Trp and the production of NAD (Figure 6.1). QUIN 
acts as an agonist of the N-methyl-D-aspartate (NMDA) receptors, mainly in the forebrain, 
and as such is considered to be an endogenous brain excitotoxin. This gives rise to a wide 
range of deleterious processes within the brain through its triggering of ionic imbalances in 
neurons via a Ca2+ influx which activates a NMDA-receptor (237). Moreover, activation of 
neuronal nitric oxide synthase and nitric oxide activity (238), together with and cytoskeleton 
destabilization (239), may also lead to cell death. Since QUIN does not have a specific 
transporter to cross the BBB (240), the increased levels of this metabolite found in NP-C1 
urine samples presumably arise from other tissues, since macrophages have a 20-fold higher 
ability to generate QUIN than that of microglial cells (241). Additionally, the liver also has the 
ability to generate QUIN (242). 
The increase of QUIN levels in biofluids has been previously reported, with elevated 
concentrations in blood serum and cerebrospinal fluid (CSF) being correlated to early renal 
insufficiency (243).  Indeed, a method to quantify QUIN in urine using LC-MS/MS (244) has 
recently been proposed for the diagnosis of renal cell carcinoma, i.e., urinary QUIN may serve 
as a biomarker (245). Furthermore, its levels have been also observed to be elevated in sepsis 
processes (246), such levels being linked to an immune system response mainly dominated 
by macrophage activation. Elevated levels of QUIN in urine could arise from a macrophage 
infiltration, which has been observed in several tissues such as lungs (247) and liver (120) in 
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both human and mice afflicted with NP-C1 disease. Indeed, more recently increased serum 
levels of QUIN have also been observed in hepatic dysfunction (248). 
 
6.2. BLOOD PLASMA LIPOPROTEIN PROFILES 
 A major cellular process in NP-C1 disease is the disruption of cholesterol transport 
from the lysosome. This cholesterol arises from LDL particles that are transported via the 
bloodstream. Given these pathological features, it may be expected that significant changes 
occur in lipoprotein homeostasis in NP-C1 patients. Indeed, recent studies have revealed 
that the plasma lipoprotein profile of NP-C1 patients is characterised by low HDL, LDL and 
total cholesterol levels, and higher TG levels (249). It has also been observed that a reduction 
in HDL-cholesterol levels is correlated with the impairment of cholesterol trafficking within 
the cell (249, 250). 
Intriguingly, in this work, the LDL-(CH2)n spectral region presented a similar pattern 
following the NPC ≈ MGS ≈ HET >> WT classifications. The 1H NMR plasma profiles of NP-C1 
patients revealed higher levels for both VLDL signals than the WT one (Figure 4.4). Since the 
-(CH2)n, -CH2CH2CO, and N-acetyl glycoprotein/CH2-CH2-CH= mobile lipid regions of the NMR 
spectra acquired have been previously shown to be strongly correlated with plasma 
triglyceride levels in both humans and mice (251, 252), this is consistent with elevated 
lipoprotein-associated TG levels in the NP-C1, MGS and HET groups over those of the WT 
one observed in this study, even though the WT samples were collected under non-fasting 
conditions. 
Interestingly, nicotinate is an inhibitor of hepatocyte microsomal diacylglycerol 
acyltransferase 2 (DGAT2), an enzyme involved in the synthesis of TGs from DGs (253). When 
this metabolite inhibits hepatic DGAT2, TG synthesis is decreased, and concomitantly, its 
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availability for VLDL assembly; as a consequence, apoB degradation is increased and the 
secretion of VLDL/LDL particles is diminished (254). Therefore, in cases of diminished 
nicotinate levels, VLDL particles should be increased in plasma, as   observed in this work. 
Intriguingly, a study performed by Beltroy et al. (122) showed that TGs levels in the hepatic 
tissue of NP-C1 mice are lower than those of corresponding healthy controls. In contrast, in 
another study performed by Garver and co-workers, lipid levels in both NP-C1 and WT mice 
were found to be not significatively different, with surprisingly elevated levels of TGs in a 
HET mice group (121). In this work, the HET  group involved also exhibited enhanced levels 
for the VLDL-CH3 and -(CH2)n spectral regions when expressed relative to those of the WT 
group, indicating that heterozygotes may also present increased plasma TGs levels, and 
suggesting that this increase is not directly linked to disease pathology [which is consistent 
with the lack of correlation between TGs and age of death in previous reports (249)] or that 
they present an intermediate phenotype for VLDL metabolism.  
 The HDL-(CH2)n- variable exhibits a pattern in the classification order HET > MGS  > 
NPC >> WT, and this was selected by RFs analysis as the 2nd most important variable when 
determining differences between the NPC and HET groups. The higher levels of this 
lipoprotein contrast with those found in other cholesterol storage disorders (besides NP-C1), 
such as Tangier disease (255) and cholesterol ester storage disease (256). HDL levels in 
heterozygotes have been previously reported as not generally affected (250), an observation 
contrary to the results reported here. MGS-treated patients show a slight increase in their 
HDL levels when compared to those from the NPC group, which is in accordance with 
investigations using MGS with Gaucher patients (257); in contrast, this improvement in HDL 
metabolism was not observed when treating Tangier disease patients with this agent (258). 
This effect on HDL levels is potentially attributable to the imbalance in ABCA1 protein 
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activation that occurs in NP-C1 cells, since ABCA1 is the central protein involved in HDL 
metabolism (250).  
  
6.3. BILE ACID METABOLISM 
Increased levels of bile acids (BAs) were observed in the urinary profiles of NP-C1 
patients (p = 9.39 x 10-5, FC = 8.54); indeed, the variable 0.66-0.69 ppm was selected within 
the top 8 features for classification by all the MVA techniques employed for the urinary 
dataset analysis employed. This bucket contains resonances ascribable to the C18-CH3 group 
of glycochenodeoxycholate, chenodeoxycholate, taurochenodeoxycholate, 
taurodeoxycholate and tauroursodeoxycholate, the latter being a BA encountered in 
humans at very low levels (259); indeed, about 4% of total bile is ascribable to this BA (260). 
The primary bile acids are cholate and chenodeoxycholate, since they are synthetized in the 
liver by the action of human enzymes; subsequently, further biotransformations carried out 
by human microbiota lead to the formation of lithocholate, deoxycholate and 
ursodeoxycholate. 
As previously noted, urinary concentrations of BAs are increased in pathological 
situations where the hepatobilary system is compromised. These increased urinary levels of 
BAs could arise from the cholestasis and liver disease that are features of NP-C1 disease (91). 
Erickson et al. have shown how mRNA levels for the BA transporters Mrp1, 2, 3, 5 (multi-
drug resistance proteins) and Ntcp (Na+-taurocholic co-transporting polypeptide) were 
elevated in NP-C1 mice, an observation suggesting that this transcriptional upregulation is a 
compensatory mechanism in hepatic stress situations, and is required to potentiate the 
excretion of any  potentially toxic agents (125). The increased expression of these sinusoidal 
excretion transporters may cause an enhancement in BA excretion from the liver into the 
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bloodstream, and consequently, urinary levels of these metabolites are elevated. 
Additionally, the enhanced excretion levels of cheno, urso and lithocholate may indicate an 
imbalance between both synthetic pathways (Figure 6.2), since BAs generated through the 
neutral pathway, involving ER enzymes, did not contribute to the signal located within the 
0.66 - 0.69 ppm bucket. 
 
 
Figure 6.2. Bile acid synthesis pathway: Synthesis route for bile acids from cholesterol. Note 
that in view of the overlay of the C18-CH3 group resonance in the urinary 1H NMR profiles 
obtained, the main bile acids highlighted in this Figure are undistinguishable, so they have 
all been selected. Metabolites selected as urinary discriminatory variables in this work are 
shown within a coloured box, indicating that the technique selected that variable (red = RFs; 
green = GAs-SVMs/LDA; blue = CCR-LDA). Arrows illustrate higher (↑) or lower (↓) levels in 
the NP-C1 group. 
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Increased BA levels observed in the urinary profiles of NP-C1 patients may also (or 
alternatively) arise from the unusual bile acid 3β,7β-dihydroxy-5-cholen-24-oate (which is 
doubly-conjugated with sulphate at C-3, and N-acetylglucosamine at C-7), and/or its glycine 
and taurine C-24 position adducts (261), agents which may serve as valuable urinary 
biomarkers for this disease and perhaps reflect associated liver trauma in these patients 
(262). Moreover, in the work published by Alvelius et al. (263), higher urinary levels of C24 
3b-sulfooxy-7b-N-acetylglucosaminyl-5-cholen-24-oic bile acid (SNAG-D5-CA), together with 
its glycine and taurine-conjugates, were found to be elevated for NP-C1 patients when 
compared with healthy controls, and a LC-MS/MS methodology has been recently reported 
for the measurement of this BA in urine (262). Based on the chemical structures of both BAs 
in which the position 12 is not hydroxylated, they may contribute towards the signal located 
within the 0.66 - 0.69 ppm bucket. 
 
6.4. MUSCLE BIOMASS WASTING 
Common clinical features of NP-C1 disease are weight loss and loss of muscle biomass 
(264, 265). Consequently, the release of muscle breakdown products, such as branched-
chain amino acids (BCAAs) and correlated metabolites into the bloodstream, which can then 
be filtered out into urine may serve as an indicator of this process.  
BCAAs can be neither stored nor biosynthesised in the human body; therefore, their 
levels are conditioned by the diet, the proteolysis of endogenous proteins and the 
degradation that takes place in mitochondria. BCAA catabolism occurs in skeletal muscle, 
liver, kidney, heart, brain and adipose tissue. Although they cannot be synthetized de novo, 
their degradation products can be incorporated into other biomolecules such as lipids, since 
Val, Leu and Ile ultimately yield propionyl-CoA and/or acetyl-CoA from their catabolism. 
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Muscle protein contains a higher proportion of BCAAs than that of proteins in other 
tissues, and muscle is the predominant site of their degradation. Indeed, a urinary 1H NMR-
based metabolomics study on muscle wasting revealed that the concentrations of BCAAs, 
together with their oxidation products, are increased in urine collected from patients 
suffering from this debilitating condition (266).  
 In this study, the Val-CH3’s/Ile-CH3a bucket (0.98 - 1.03 ppm) was selected as a 
discriminant feature by the CCR-LDA approach in view of its higher level in the NP-C1 1H NMR 
urinary profiles (p = 1.65 x 10-2, FC = 5.06), and Ile was also highlighted in plasma, having 
considerably higher levels in NP-C1 patients (p = 5.51 x 10-11, FC = 1.47), along with those of 
the HET and MGS groups. Additionally, 3-AIB (p = 8.58 x 10-9, FC = 2.81) was selected by the 
RFs and CCR techniques with very high rankings (2nd for RFs, 1st for CCR-LDA), this being a 
common metabolite for the valine and thymine degradation pathways. Therefore, this may 
serve as a hallmark of muscle wasting, since increased BCAA levels have been previously 
reported to be correlated to rises in muscle protein deterioration (267). Another two BCAA 
metabolites were selected as discriminatory features in our urinary dataset, specifically 2-
hydroxy-3-methylbutyrate (p = 8.47 x 10-3, FC = -10.22) and 3-hydroxyisobutyrate (p = 7.23 x 
10-2, FC = 1.19). 2-hydroxy-3-methylbutyrate is generated through the reduction of 2-
oxoisovalerate, a catabolite of Val, and 3-hydroxyisobutyrate is a further metabolite in the 
same pathway (Figure 6.3). The lower levels of this metabolite, together with those higher 
values for 3-AIB urinary concentrations, may indicate an increased activity of the enzymatic 
system that yields isobutyryl-CoA from 2-oxoisovalerate (Figure 6.3). Nevertheless, the 
spectral region to which 3-hydroxyisobutyrate was assigned may indeed contain other 
resonances arising from the α-CH group of amino acids, which may represent a confounding 
factor. 
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Figure 6.3. BCAA degradation metabolic pathway: this route, as part of the BCAA catabolism 
process, was indicated as one of the major pathways affected in the disease (leucine 
catabolism is not included). The thymine catabolism route is also incorporated into this 
diagram since its final product is common to that of the valine degradation pathway. Urinary 
metabolites selected as discriminatory variables are visible within a coloured box, which also 
indicates the technique that selected that variable (red = RFs; green = GA-SVM/LDA; blue = 
CCR). Plasma discriminatory features for the NP-C1 vs. WT comparison are indicated by a red 
coloured circle. Arrows illustrate higher (↑) or lower (↓) levels in the NPC group.  
 
Intriguingly, loading evaluations with both thymine and L-Val have revealed that 
urinary 3-AIB predominantly arises from thymine catabolism, with ≤ 10% generated from L-
Val degradation (268, 269). High 3-AIB urinary levels have also been observed in cases of 
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methylmalonic semialdehyde dehydrogenase deficiency (268), an enzyme involved in the 
catabolic breakdown of both Val and thymine. Metabolism of valine produces the 
intermediate (S)-3-hydroxyisobutyric acid, a metabolite that may be elevated in urine from 
NP-C1 patients (p = 7.23 x 10-2, FC = 1.19), although its 1H NMR signal at 3.67 - 3.71 ppm 
overlaps with that from the α-CH group of amino acids, so this assignment remains tentative. 
3-Hydroxyisobtyrate is then oxidized to (S)-methylmalonate semialdehyde by 3-
hydroxyisobutyrate dehydrogenase. Thymine metabolism generates 3-AIB, which is then 
deaminated to (R)-methylmalonate semialdehyde. These two enantiomers are substrates 
for methylmalonate semialdehyde dehydrogenase, which catalyses their oxidative 
decarboxylation to propionyl-CoA (Figure 6.3).  
Glutamine (Gln) was also selected as a urinary discriminatory feature, but only by the 
RFs approach (and ranked as the 6th most important), having higher levels for NP-C1 patients 
(p = 2.61 x 10-2, FC = 1.49). The plasma pool of Gln has been proposed to arise from its release 
from skeletal muscle (270, 271), which may be another indicator of muscle wastage. Indeed, 
increased levels of the Gln bucket were also found in our plasma dataset (p = 7.95 x 10-7; FC 
= 1.23) for the NP-C1 group when expressed relative to those of the WT classification.  
Moreover, increased urinary levels of Cr (p = 1.52 x 10-5, FC = 1.59), a distinctive 
metabolite of muscular tissue, were also increased in the urine collected from NP-C1 patients 
(the 3.92 - 3.95 ppm bucket was selected for all three MVA techniques employed), which 
may serve as another indicator of muscle tissue breakdown in view of the debilitating 
process which is characteristic of the disease. Nevertheless, a limiting factor could be the 
increased levels of Cn in HET participants in view of their age differences, and also the link 
between Cn generation from Cr-phosphate arising from muscle tissue. Gu et al. reported 
increasing levels of Cr in urine collected from children from 0 to 3 years of age, followed by 
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a decrease (272). Despite there are only 2 NP-C1 patients below 3 years, out of 12 in the 
cohort investigated herein, this may be an additional limiting factor for the consideration of 
Cr as an specific NP-C1 biomarker. 
Interestingly, in a metabolomics study of muscle wasting through 1H NMR 
urinanalysis, QUIN was selected as the 3rd most important variable (266), showing increased 
levels in those patients suffering from this condition. This was also observed in urine samples 
collected from NP-C1 patients (p = 3.83 x 10-5, FC = 30.32). 
  
6.5. GUT MICROFLORA IN NP-C1 DISEASE 
 Several metabolites arising from microbial activity within the human body (i.e., co-
metabolites) were highlighted as discriminatory features in the urinary (n-butyrate acid: p = 
6.18 x 10-4, FC = 13.00; TMA: p = 2.09 x 10-2, FC = 2.29, methanol: p = 2.39 x 10-3, FC = -1.96, 
and 5-aminovalerate: p = 3.87 x 10-2, FC = -5.04); the liver (3-hydroxyphenylacetate: p = 3.80 
x 10-4, FC = -3.45) and plasma datasets (2,3-butanediol: p = 0.38, FC = 1.73 for MGS). 
However, the latest was only relevant for the discrimination between the 1H NMR plasma 
profiles of MGS-treated patients vs. the WT ones, and did not attain statistical significance. 
Accordingly, an imbalance in gut microbiota population/activity in NP-C1 patients may be 
implicated in this disease. 
 n-Butyrate is a by-product of complex carbohydrate degradation by bacteria under 
anaerobic conditions in the intestines. n-Butyrate, acetate and propionate are also 
generated in this degradation process (273); however, these metabolites can be also 
produced through human metabolism as hydrolysis products of acetylCoA, or in FA 
oxidation. Therefore, n-butyrate is a gut bacterial status biomarker, and  hence increased 
levels observed in urine may indicate an increased gut permeability (274) since n-butyrate is 
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converted to ketone bodies and CO2 in colon cells (275), and no α-keto-acids have been 
highlighted as discriminatory metabolites in either plasma or urine herein.  
TMA is generated exclusively from the metabolic activity of the gut microbiome using 
choline, carnitine and mainly TMA-N-oxide (TMAO) as substrates (276). TMA is then oxidized 
in the liver by the hepatic enzyme FMAO3 (flavin-dependent monooxygenase 3) yielding 
TMAO; this connection between microbial and human host metabolism has been correlated 
with NAFLD, with increased levels of urinary methylamines in a NAFLD high-fat diet-induced 
mouse model (277). Dumas and co-workers (277) found a correlation of higher urinary TMA 
excretion and a lower phosphatidylcholine level circulating in plasma; however, in view of 
the problems caused by the histopaque separation of plasma involved in this study, 
phosphatidylcholine could not be accurately determined in plasma. Nevertheless, this may 
not be the case, since the proposed mechanism of this limitation in choline availability by 
gut microbiota can lead to a decrease in the synthesis of phosphatidylcholine, which is 
necessary for the secretion of VLDLs (278), contrary to our observations of higher VLDL levels 
in NPC/MGS/HET patients’ plasma levels when compared to those of the WT group.  
Methanol can also arise from pectin degradation in the colon by microflora (279). 
Pectin is a biomolecule of vegetable origin, present in fruits, jellies, etc (280). Moreover, it 
has been proposed as a urinary marker of Crohn’s disease and ulcerative colitis in view of its 
higher levels in the urine collected from these patients in a recent metabolomics 
investigation (281).    
5-Aminovalerate is produced by metabolism of the polyamine cadaverine, which is 
synthesised by bacteria via decarboxylation of lysine (282). Increased levels of this amino 
acid derivative, and lower ones of urinary 2-hydroxyglutarate, were proposed as part of a 
battery of biomarkers for Crohn’s disease in a metabolomics study (283). Intriguingly, lower 
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urinary levels of 2-hydroxyglutarate have also been observed in NP-C1 patients herein. 
Interestingly, this similarity between Crohn’s disease and NP-C disease has become more 
plausible in view of the recent publication by Schwerd and co-workers (284), in which they 
report a direct correlation between Crohn’s disease and NP-C1 gut pathophysiology based 
on the higher predominance in NP-C1 patients of a mutation in the NOD2 gene involved in 
bacterial handling. Deleterious variants in NOD2 are the strongest genetic risk factor for 
Crohn’s disease (285, 286). In their cohort of 150 NP-C1 patients based in Manchester (UK), 
these authors estimated a 3 - 7% occurrence of intestinal bowel disease in patients with NP-
C1, an observation contrasting with values obtained for the general carrying population, in 
which one of the three most common NOD2 mutations (homozygous and compound 
heterozygous) is only about 1.5% (287). Both NPC1 and NOD2 genes were found to be 
correlated to a defective response of macrophages against bacteria, specifically in the 
autophagic process.  
3-Hydroxyphenylacetate can arise either form dietary sources (288) or from gut 
microflora (289), i.e. from quercetin degradation, through a prior conversion of 3,7-
dihydroxyphenylacetate from the C-ring fission of a de-glycosylated quercetin derivative 
(290). Therefore, imbalances in the activity of such microflora in mutant NP-C1 disease mice 
may also account for the significantly lower hepatic levels of this metabolite found in this 
group. Furthermore, this metabolite has been proposed as a marker of dysbiosis (291), which 
is discussed in the following section. 
Interestingly, in a very recent study, Mardinoglu et al. (292) found that gut microbiota 
modulates host amino acids and GSH metabolism in mice, both featured as discriminatory 
hepatic metabolites herein.  
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6.6. HEPATIC STATUS IN NP-C1 DISEASE 
Liver dysfunction/disease is a major feature of the NP-C1 condition, and this hepatic 
damage is exacerbated with the disease progress, since the liver accumulates more lipids 
and unesterified cholesterol. The mouse model of NP-C1 disease serves as a valuable tool 
for studying the hepatic damage caused. Indeed, several investigations in NP-C1 mouse 
models have reported hepatic cell death associated with cholesterol-rich diets (122), and 
increased levels of oxidation products (293). Interestingly, a reduction in the antioxidant 
capacity of liver NP-C1 in humans has also been reported (147), findings linked with the 
diminished GSH levels observed herein. Additional investigations reported a decrease in 
hepatic GSH concentration in Npc1-/- mice (294), these values correlating with an excessive 
level of oxidative stress within hepatic tissue.  
These results are also supported by our finding regarding the GSH:GSSG molar 
concentration ratio, which is very significatively reduced in the liver extracts analysed here 
(Figure 4.8). Additionally, rats treated with CCl4, an agent that induces cirrhosis, showed a 
decrease in the liver levels of this critical antioxidant (295), and this was also observed in 
patients suffering from non-alcoholic steatohepatitis (296). N-acetylcysteine (NAC) has been 
employed therapeutically in a NP-C1 mouse model (297) based on its ability to replenish GSH 
levels (as a cysteine precursor), and also as a ROS (reactive oxygen species) scavenger (298); 
accordingly, it has been recently employed in clinical trials (297). Hepatic GSH levels were 
found to be restored after NAC treatment in these mice, a phenomenon offering protection 
against oxidative stress, results matching those obtained in investigations focused on the 
cerebellum (294) and primary neurons (299). Also particularly noteworthy is the correlation 
between GSH and NAD/NADP pathways, since GSH is required for the reconversion of NADP 
to NADPH (228). Therefore, the results obtained in this study (lower levels of GSH, nicotinate 
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and niacinamide in NP-C1 mouse liver) may reflect a disease-mediated imbalance in 
hepatocyte [NADP+]:[NADPH] concentration ratios. 
The role of hypotaurine as a potential biomarker for NP-C1 disease-associated liver 
dysfunction is complicated in view of the partial overlap of its C4-CH2SO2- resonance with 
that of methionine’s-C4-CH2 one, as noted in section 4.4.2.3. Hypotaurine serves as a key 
antioxidant defence in mitochondria and other intracellular environments, and it is oxidised 
by ROS to yield taurine, which is subsequently excreted through its transporter into 
extracellular media (300). The production of ROS has been indicated as one of the pathogenic 
effects arising from NP-C1 disease pathogenesis, and consistent with this hypothesis, 
elevated levels of cholesterol oxidation products have been reported in the blood plasma of 
NP-C1 disease patients, and also in the liver of NP-C1 mutant mice (301). In view of the 
involvement of oxidative stress in this disease process (146), the increased hepatic 
generation of hypotaurine noted here may arise as an essential metabolic response 
stimulated to combat against it (302).  
Several previous studies performed in NP-C1 mice indicate that hepatocyte apoptosis 
may serve as a primary cause of progressive liver degeneration and failure in this animal 
model (122, 303), and/or an increased activation of macrophages (139); such considerations 
may also be applicable to human NP-C1 patients. If confirmed, higher hepatic hypotaurine 
levels observed here in NP-C1 mutant mice may be consistent with an enhanced metabolism 
of cysteine by the hepatic cysteine dioxygenase/cysteine sulphinate decarboxylase pathway, 
which is stimulated by an upregulation of oxidative stress episodes, which in turn, serve as 
key mediators of hepatocyte apoptosis. However, with regard to macrophage activation, we 
found no evidence for NP-C1 disease-mediated increases in levels of nitric oxide (NO•)-
producing arginine in the NP-C1 mouse group, although quinolinate (macrophage activation-
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related metabolite) was found to be elevated (p = 3.83 x 10-5, FC = 30.32) in the urine samples 
collected from NP-C1 patients when compared to the HET carrier group. 
In addition to symptoms described above, livers from NP-C1 mice exhibit an elevated 
level of fibrosis and proliferation of hepatic stellate cells (122, 303, 304). Of these processes, 
fibrosis plays a predominant role. It is characterised by the replacement of liver tissue by 
fibrous scar tissue, in addition to regenerative nodules (cirrhosis, which is responsible for 
major alterations to liver tissue, represents the irreversible end-stage of these 
developments). Hence, fibrosis gives rise to a progressive loss of liver function, and to a 
modified liver metabolism (305-308). Taken together, collagen and hydroxyproline levels 
serve as valuable hallmarks for liver fibrosis, the latter as an index of collagen metabolism 
(309). However, hydroxyproline was not selected as a significant biomarker by the MVA 
strategies in this study, and nor was it by similar NMR-linked metabolomics investigations of 
fibrosis-cirrhosis referenced in this section.  
    Several amino acids were found to be elevated in the aqueous extracts obtained 
from NP-C1 mice liver samples, i.e. Phe (p = 1.60 x 10-4, FC = 1.56), Tyr (p = 1.70 x 10-4, FC = 
1.38), Lys/Orn (p = 2.00 x 10-4, FC = 1.51), Met (p = 2.40 x 10-3, FC = 1.96), Val (p = 1.49 x 10-
3, FC = 1.35), Thr (p = 3.40 x 10-4, FC = 1.30) and Asp (p = 3.90 x 10-5, FC = 2.06). Higher hepatic 
levels of Phe, Tyr and Met were also increased in a metabolomics investigation conducted 
by Waters et al., in which they employed 1H NMR analysis to explore liver samples collected 
from rats undergoing thioacetamide treatment (310), a fibrosis/cirrhosis-inducting agent 
that causes liver damage, including lipid oxidation and apoptosis (311, 312); both these 
processes are also involved in NP-C1-associated liver dysfunction/disease. These researchers 
suggested that necrosis of liver parenchyma and necrosis-induced protein degradation are 
the main causes of this upregulation in hepatic amino acids levels. An additional 1H NMR-
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linked metabolomics study on rats treated with this agent revealed elevated levels of Val, 
but only after 3 months of treatment (313). Both these investigations showed common 
features to our study, such as the upregulations of hepatic Phe, Thr, Tyr, Met and Val.  
In a further study, Rajendraa et al. (314) explored modifications to the hepatic 
concentrations of free amino acids induced by repeated administration of hexachlorophene 
(HCP) to male adult mice; this agent exerts pathological modifications to liver structure and 
morphology (315). These researchers found that Phe, Tyr, Leu, Ile, Val, Thr, Asn (asparagine), 
Glu (glutamate) and Gln levels were significantly elevated following HCP treatment, whereas 
that of aspartate was markedly decreased. Moreover, reductions in the specific activity 
patterns of enzymes involved in amino acid metabolism, i.e. those featuring 
aminotransferases and glutamate dehydrogenase, indicated a suppression of liver amino 
acid oxidation. The abnormal upregulations in BCAAs and AAAs observed were ascribed to a 
reduced catabolism in view of a depleted skeletal muscle mass and hepatic dysfunction 
respectively; these phenomena may also account for the upregulated liver valine and 
phenylalanine/tyrosine concentrations observed in this study. 
In humans, valine degradation, together with that of BCAAs in general, have been 
previously shown to be disturbed in a microarray expression analysis of serum biomarkers 
(123), and also in our analysis performed on the urinary NP-C1 dataset. The upregulated 
hepatic valine levels observed in NP-C1 disease mice here, however, may be consistent with 
those of Ishigure et al. (316), who found that human liver disease (specifically cirrhosis or 
hepatocellular carcinoma) diminishes the activities of methacrylyl-CoA hydratase and β-
hydroxyisobutyryl-CoA hydrolase (enzymes involved in valine catabolism), and that 
decreased levels of these hepatic enzyme activities are derived from post-transcriptional 
regulation in the damaged liver.  
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Previous investigations have revealed that the application of treatments comprising 
selected methionine metabolites in experimental animal models of liver disease exhibit 
striking hepatoprotective effects (317). However, since the Met-C4-CH2 resonance signal 
observed here (2.62 - 2.67 ppm) overlapped somewhat with the more intense hypotaurine-
CH2SO2- resonance, and therefore additional experiments are required to explore this. 
The accumulation of aspartate, along with increased plasma concentrations of this 
amino acid have been observed in patients with liver disease (170), and this has been 
suggested to arise from the downregulation of urea cycle enzymes. Interestingly, our 1H 
NMR-based dataset provided some evidence for upregulated hepatic ornithine in mutant 
NP-C1 disease mice, a key intermediate of this cycle. However, this pathway has not been 
highlighted as a significantly affected feature in any previous studies focused on liver 
dysfunctions/diseases. 
In NP-C1 disease mice, decreases in the hepatic 1H NMR bucket intensities of both 
nicotinate and niacinamide were observed. Indeed, FCs of -1.49 and -1.79 respectively were 
noted for these metabolites, and as noted above, that this pathway may indeed be affected 
in NP-C1 patients. In view of their roles as NAD+/NADH and NADP+/NADPH precursors, which 
are employed in a wide range of metabolic redox processes, these observations may be 
linked to highly significant biochemical and hepatocellular effects. For example, cytochrome 
P450 activity featured in microsomal oxidation systems are critically dependent on the 
NADP+/NADPH coenzyme system. Similarly, the NADP+/NADPH system is involved in the 
phenylalanine hydroxylase-mediated oxidative transformation of phenylalanine to tyrosine.  
A further example from BCAA catabolism involves the oxidative, irreversible 
decarboxylation of substrates to form branched-chain acyl-CoA adducts (a reaction catalysed 
by mitochondrial branched-chain α-keto acid dehydrogenase), which features the 
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NAD+/NADH cofactor system (318). The investigation conducted by Waters et al. (310) found 
a down regulation of hepatic niacinamide in their 1H NMR-linked metabolomics study of 
thioacetamide-driven fibrosis/cirrhosis in experimental animals, and this was ascribed to an 
enhanced level of this metabolite’s methylation to 1-methylnicotinamide in cirrhotic liver. 
Furthermore, Varela-Rey et al. (319)  found that orally-administered niacinamide 
ameliorated fatty liver and fibrosis in glycine N-methyltransferase knockout mice, and 
concluded that this agent acted through the prevention of hepatic fat accumulation and 
apoptosis via reductions in liver S-adenosylmethionine content. 
Intriguingly, the intensity of the 3-hydroxyphenylacetate bucket was found to be 
significantly lower in the NP-C1 group than that of the HET/WT one. 3-Hydroxyphenylacetate 
is involved in the human tyrosine metabolism pathway, in which it is transformed to 3,4-
dihydroxyphenylacetate (Figure 6.4). This reaction also requires NAD+/NADH as a coenzyme 
system, which is synthesised through the nicotinate/niacinamide pathway, metabolites of 
which were also identified as discriminatory variables here. Furthermore, this metabolite can 
also arise from gut microbiota activity, and is a biomarker of dysbiosis, an alteration found 
in other cases of liver damage (320). 
 
 
Figure 6.4. Enzymatic biotransformation of 3-hydroxyphenylacetate to 3,4-
dihydroxyphenylacetate. 
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6.7. BIOMARKERS FOR NP-C1 DISEASE  
A biomarker must be a metabolite in a biofluid or tissue biopsy sample ideally 
collected by a non-/minimally-invasively technique, and that is found at highly significantly 
elevated or reduced levels in the disease investigated. Then it may be employed to diagnose 
the disease, predict patient response towards therapies, and also monitor the evolution of 
the patient throughout the disease process. Biomarkers may only be validated if such 
alterations are found to be reversible via the actions of an approved therapeutic agent for 
the disease concerned. 
As mentioned in the introductory section, the only one available for NP-C disease is 
the filipin staining of unesterified cholesterol in cultured fibroblasts obtained from a skin 
biopsy; however, this test carries some limitations regarding the detection of NP-C patients 
with ‛variant’ phenotypes (>1/3 NP-C cases) (112), and fails in 15% of the tests performed. 
Additionally, genetic sequencing of NPC1 and NPC2 genes detects mutations on both alleles 
in only 85% cases, and is confounded by the highly polymorphic nature of NPC1 (> 400 known 
mutations) (112). Both tests are time-consuming and expensive; therefore, the discovery of 
new biomarkers for the disease that can improve on these limitations is a major focus in this 
research area. 
Efforts are currently being made in order to find valuable biomarkers for NP-C1 
disease which might out-perform those currently available. Indeed, cholesterol oxidation 
products present in plasma and detected by LC-MS/MS have been proposed as biomarkers 
(301) for this disease, and tested in different centres (321, 322), in addition to comparisons 
of results acquired to additional samples collected from patients afflicted with other lipid 
storage disorders (323). Although cholestane-3β,5α,6β-triol (triol) and 7-ketocholesterol 
(7KC) have been proposed as biomarkers to assess the diagnosis of NP-C1, and have been 
 
 
160 
 
incorporated to the battery of clinical tests for diagnosis in some centres, a recent 
investigation conducted by Polo and co-workers (324) have revealed that these increases in 
both cholesterol oxidation products are common to cholestasis in new-born children, and 
hence their specificity for NP-C disease should be re-evaluated.  Additionally, 
lysosphingomyelin and glucosylsphingosine, were recently proposed as biomarkers in view 
of their elevated levels in plasma samples collected from NP-C1 patients observed via LC-
MS/MS (325).  
Additional biomarkers have been reported in a microarray analysis of blood serum, 
including the pro-inflammatory protein galectin-3 (LGALS3) and lysosomal aspartic protease 
cathepsin D (CTSD) (123).   
A chitriosidase assay has been also included as a possible screening test for NP-C1 
disease. This enzyme is secreted by activated macrophages, and presents an enhanced 
activity in a wide variety of LSDs (326-329). Nevertheless, it has been proven to deliver 
normal (as healthy) results in NP-C1 patients (126), and 10% of the population carry a 
mutation showing similar levels to those of such patients, making this test inconclusive (330). 
Moreover, serum levels of this biomarker are also elevated in some other disorders (331). 
In addition, 3β-sulfooxy-7β-N-acetylglucosaminyl-5-cholen-24-oate acid, along with 
its glycine and taurine amides, have been highlighted as potential biomarkers in urine, 
although the endogenous synthesis pathway of this BA was not confirmed (263). 
Furthermore, an additional bile acid has also been proposed as a urinary biomarker of NP-
C1, specifically 3β,7β-dihydroxy-5-cholen-24-oate and its glycine or taurine conjugates (261). 
The lysotracker assay was also proposed as a valid assay system for the diagnosis of 
NP-C1 disease. This test involves the fluorescent probe Lysotracker, which measures the 
relative acidic compartment volume in live cells (184), and shows higher levels for NP-C1 
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patients when expressed relative to those of healthy controls, and also suggesting a 
correlation with responses to MGS treatment (131). 
More recently, lyso-SM-509, a compound related to lyso-sphingomyelin (lyso-SM), 
has been proposed as an NP-C1 biomarker, and its specificity has been tested against similar 
diseases such as NP-A and NP-B, yielding 95.5, 91.0 and 100.0% values for accuracy, 
specificity and sensitivity respectively (132).  
In this work, we have explored the potential of NMR-linked metabolomics 
technologies as diagnostically-valid methodologies for NP-C1 diagnosis, in view of its ability 
to provide information on wide a range of metabolites simultaneously, and without the need 
for lengthy time-consuming sample preparation processes. Data arising from the NMR 
measurements of the different biofluids and tissue investigated herein were then subjected 
to MVA in order to highlight those metabolites which were efficient for classifying samples 
according to their disease status (NPC vs. HET vs. WT). By applying ROC curve analysis to the 
variables selected, their ability to serve as NP-C1 biomarkers was evaluated. 
 Metabolic evidence which demonstrates that the metabolites highlighted in section 
6.4 serve as indicators of muscle wasting in NP-C1 is presented; however, most of these have 
already been identified as biomarkers in other diseases, or are very common metabolites 
such as amino acids, and hence their specificity for NP-C1 disease is compromised. 
Nevertheless, 3-AIB has only been proposed as urinary biomarker of methylmalonic 
semialdehyde dehydrogenase deficiency, an alteration never observed in NP-C1 to date; 
additionally, the urinary levels of this metabolite are reduced in those samples obtained from 
MGS-treated NP-C patients analysed herein, showing similar values to the HET group; 
accordingly, I propose 3-AIB as a specific biomarker of BCAA degradation/muscle wasting in 
NP-C1.  
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The increased levels of quinolinate (QUIN) in urine have been suggested herein to 
arise from the inflammatory process, hepatic damage and/or deregulation of the NAD/NADP 
synthesis pathway. These increased levels were resolved after MGS treatment, as shown in 
Figure 2.13. Indeed, the first and second of these processes are typical clinical features of 
NP-C1 disease. This metabolite has been proposed as a biomarker for renal failure, a feature 
not previously reported in NP-C1 disease; hence, this Trp metabolite can be considered as a 
specific urinary biomarker for inflammation, specifically macrophage activity, or it may arise 
from a defect/imbalance in the conversion of QUIN to nicotinate mononucleotide in these 
patients.  
Higher levels of bile acids were also found in urine collected from NP-C1 patients. 
Such increases are correlated to liver damage, a common feature in young NP-C1 patients. 
The NMR analyses performed here were not, however, able to distinguish between the 
specific bile acid anion species responsible for the higher intensity 0.66 - 0.69 ppm spectral 
bucket region, although chenodeoxycholate and/or its taurine and glycine conjugates are 
presumably the predominant bile acid species contributing to that bucket. However, some 
other bile acids that may contribute to this signal have already been proposed for the 
diagnosis of NP-C1 (section 6.3).  
Metabolites arising from imbalances in gut microflora activity/populations were 
highlighted in this work as important discriminatory features. 5-Aminovalerate, TMA, 
methanol and n-butyrate were detectable in urine with differential levels when expressed 
relative to our control group. Although these biomolecules may have a diagnostic utility, 
their origins are unclear since they may arise either from a direct enhanced/diminished 
activity of selected microbial strains, or their differential levels between healthy individuals 
and disease patients could be attributable to a physiological defect that leads to an 
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increase/decrease in their urinary levels, as may indeed be the case of intestinal permeability 
and related increased levels of n-butyrate in urine. Moreover, the value of these metabolites 
as biomarkers has to be considered cautiously, since gut microbiota in childhood evolves to 
a more complex population of microorganisms with age (332, 333), and our urinary dataset 
is not age-matched. Gut microflora also present some inter-individual variability that may 
affect these results, and considering the limited number of NP-C1 patients included in our 
urine NP-C1 cohort, this may be another limitation. Despite considerations that these 
microbial metabolites lack specificity in view of the complex variations in gut microflora 
populations, the elevated number of biomolecules featuring as discriminatory variables 
reveals disease-related imbalances in these metabolites. 
Whilst defects in lipid distribution are key clinical manifestations of NP-C1 disease, 
the extent of these changes are not correlated with disease severity, and are not unique to 
NP-C1 disease; indeed, high TG plasma levels are a common feature in many diseases such 
as cardiovascular disorders, obesity, renal failure, excess alcohol consumption, etc., and this 
is an additionally characteristic in another lysosomal cholesterol-related disorder such as 
lysosomal acid lipase deficiency. Therefore, these biomarkers may have limited diagnostic 
value, although they may also serve as complementary tools for NP-C1 diagnosis. 
A comparison of hepatic metabolites highlighted in this study as discriminatory 
features for the classification of NP-C1 mice liver samples with the combined HET/WT group 
revealed an imbalance in the nicotinate/niacinamide pathway that can lead to the 
generation of NAD+/NADP. Therefore, monitoring of the metabolites involved therein can 
provide disease-related information for the progression of liver dysfunction in mice, and if 
these results are confirmed in humans, the translation to applicable clinical tests may be 
possible. However, further metabolites selected in the analysis of the 1H NMR mice hepatic 
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dataset are very common (amino acids), together with well-known liver disorder-related 
metabolites, specifically BCAAs and AAAs, and hence their utility as biomarkers is again 
somewhat limited. A further hepatic metabolite selected was 3-hydroxyphenylacetate; 
although not being highlighted before in any NP-C1 investigation focused on liver 
dysfunction, its source is difficult to determine (i.e. endogenous, bacterial or food), and 
therefore, its employment as biomarker is also limited.  
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CHAPTER 7 
CONCLUSIONS 
  
 
This research programme demonstrates that the 1H NMR- linked metabolomics 
analysis of human urine and plasma samples, together with hepatic aqueous extracts 
obtained from a mouse model of NP-C1 disease, provided valuable information regarding 
potential metabolism dysfunctions in NP-C1 patients, and also yielded valuable information 
regarding a battery of potential biomarkers to aid  disease diagnosis. Moreover, we have 
identified (and quantified, Appendix 1) MGS in urine samples collected from NP-C1 patients 
treated with this therapeutic agent, and employing the same multivariate approach, 
resolved the resonances arising from multiple drug therapy/therapies in these patients. 
NMR-linked metabolomics analysis of urine samples collected from NP-C1 patients 
and heterozygous carriers (as controls) revealed differences in the 1H NMR urinary profiles 
of these patients which were successfully classified according to their disease class using 
different MVA techniques. Variables with higher rankings in the models developed were 
proposed as urinary biomarkers of the disease, and evaluated via a ROC test, which showed 
very good AUC values even with the employment of only 2 metabolites [AUC (mean, range) 
= 0.705, 0.484 - 0.898]. The highest-ranked urinary metabolites in the MVA performed are 
therefore proposed as urinary biomarkers, and also as indicators of differences in the NP-C1 
patients’ metabolism profiles, so that the increased bile acid concentrations in the NP-C1 
group may be an indicator of hepatic damage and imbalanced BA biosynthesis; however, 
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further experiments are required to specify the particular bile acids excreted in urine by 
these patients, and consequently, to employ them as a validated biomarkers.  
Additional metabolites were found to have differing levels in both groups studied 
(NPC and HET), such as QUIN (involved in macrophage activation and NAD synthesis), gut 
microflora metabolites (methanol, TMA and 5-aminovalerate), and muscle wasting by-
products such as 3-aminoisobutyrate and 2-hydroxy-3-methylbutyrate, both arising from 
BCAA degradation pathways. Since the sample set was not conformed for age-matched 
patients, metabolite concentration differences arising from such age-dependent processes 
were removed from biomarker evaluation. An additional confounding factor may be the 
imbalanced sample set, so that only 12 NP-C1 patients were part of the disease class sub-
set, and 41 for the control (HET) one; nevertheless, the MVA methods employed were able 
to successfully classify the samples, and cross-validation methodologies were implemented 
in the analysis to overcome this issue. Another limitation could be the use of heterozygotes 
as controls, since they have some genetic similarities that could be reflected in the 
phenotype, and therefore also perhaps in their 1H NMR urinary profiles. However, these 
participants have the closest healthy genotype, so the ability of our models to classify such 
samples serves as an improvement in diagnosis. Moreover, using age-matched healthy 
participants should facilitate the analyses.  
Urine collected from NP-C1 patients undergoing MGS treatment were analysed by 
high-resolution NMR analysis, identifying this drug in urine together with some other 
pharmaceutical agents, such as valproate and acetaminophen along with their metabolites, 
and hence providing an insight in the urinary profiling of patients undergoing several 
treatments in addition to the introduction of a new validated method for MGS detection in 
urine (and quantification, Appendix 1). Additionally, a series of modifications to the urinary 
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profiles of these patients undergoing MGS treatment (i.e., those of metabolites previously 
highlighted as discriminatory features) were investigated. These studies revealed substantial 
MGS therapy-associated changes in the urinary concentrations of N-acetylated metabolites 
such as N-acetylsugars and saccharides, i.e. reversals. Moreover, metabolites arising from 
the loss of muscle biomass (3-AIB and 2-hydroxy-3-methylbutyrate) and QUIN showed 
similar urinary levels to those from HETs, suggesting a recovery of normal levels for those 
metabolites after MGS treatment. However, this analysis presented some limitations in view 
of the overlap of drug/drug metabolite resonances with those of potential biomarkers, and 
hence not all the discriminatory features selected by the MVA could be evaluated in this 
manner. 
1H NMR-linked metabolomics analysis of plasma samples revealed major changes in 
plasma lipids, in addition to those of some other common metabolites. However, the 
specificity of these metabolites as NP-C1 plasma biomarkers is limited in view of the common 
lipid profile shared with other cholesterol/lipid storage diseases and the employment of non-
fasting WT samples. Therefore, further analysis is required, and such investigations should 
include samples collected from patients with related or similar diseases. Moreover, 
specification of the lipoprotein subclasses should also be a major requirement, since 
recently-developed NMR methods are now able to distinguish many different lipoprotein 
subclasses, and this information should be employed for NP-C1 diagnostic purposes. Higher 
levels of some amino acids, such as glutamine and isoleucine in NP-C1 plasma samples, 
supported the results acquired from MVA of the urinary dataset, i.e. those relating to the 
muscle biomass degradation experienced by these patients, and therefore indicating a 
further complication of the disease that could assist in employing new therapies to overcome 
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this problem, and also potentially adding a new methodology to monitor this debilitating 
process. 
For these plasma samples, a technical issue was faced regarding the employment of 
a polysucrose-based separation column (histopaque) for plasma, which generated additional 
resonance signals which overlapped those arising from endogenous metabolites. Moreover, 
free and metal ion-complexed EDTA resonances were also observable in our 1H NMR plasma 
spectra, since this agent was an anticoagulant present in the blood collection tubes utilised. 
Although the use of this EDTA anticoagulant only presents minor problems, the histopaque 
protocol did present some major problems, particularly with the overlap of many 
histopaque-derived 1H NMR signals with those of a range of potential endogenous 
biomarkers. However, major differences between the 1H NMR profiles of NP-C1 patients, 
heterozygous carriers, healthy controls and MGS-treated NP-C1 patients were observed 
despite these complications, and therefore valuable information regarding the metabolic 
status of NP-C1 disease patients. 
The hepatic levels of small polar metabolites contained in aqueous extracts obtained 
from NP-C1 disease, heterozygous carrier and healthy mice were investigated by 1H NMR-
linked metabolomics analysis. The NP-C1 mouse model studied presented common features 
related to other cases of liver damage, such as fibrosis leading to cirrhosis; fibrosis being a 
feature included in the pathophysiology of the disease, although some discriminatory 
metabolites were unique, such as nicotinate and 3-hydroxyphenylacetate. These findings 
provide support for the higher levels of QUIN observed in urine collected from NP-C1 
patients, together with the lower levels of hepatic niacinamide, and these metabolic 
modifications suggest an imbalance in NAD/NADP synthesis, and therefore, a possible target 
for pharmaceutical strategies aimed at ameliorating the disease process and an additional 
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pathway to be monitored in order to assess the disease progression, specifically that 
involving associated liver dysfunctions. Moreover, the oxidative stress process putatively 
involved in this disease was also investigated by an analysis of GSH:GSSG molar 
concentration ratios, and the results acquired were consistent with those of previous 
investigations. 
With regard to those metabolites arising from microbiota activity, and also found to 
be important discriminatory features in urine (5-aminovalerate, TMA and methanol) and 
liver aqueous extracts (3-hydroxyphenylacetate), further work is proposed to investigate the 
correlation between gut microbiota and NP-C1, since this approach is developing as a very 
useful methodology in metabolomics investigations, and reveal how the microbiota 
modulates some metabolic pathways, and how this modulation is modified in a range of 
human diseases. 1H NMR-linked metabolomics studies of faeces provide a reliable insight 
into the gut microbiota status; accordingly, a further investigation of such samples may shed 
light on our findings. 
The biomarkers proposed herein and discussed in section 6.7 should, in principle, be 
confirmed in further investigations and by other techniques in order to validate our findings. 
Urinary metabolites should be confirmed, including more NP-C1 urine samples and healthy 
individuals as controls. As noted above, plasma lipoprotein profiles can be investigated more 
extensively in order to check for further differences in lipoprotein sub-classes. Furthermore, 
newly-developed methods for 1H NMR-linked metabolomics analysis of plasma samples such 
as methanol precipitation of plasma, followed by drying and reconstitution of the sample 
has revealed an increase in the number of metabolites detected, and consequently, 
broadens the spectrum of biomolecules, including that of putative biomarkers. With regard 
to the investigation of mouse liver samples, further work focused on explorations of the NAD 
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pathway in NP-C1 mouse liver should also be performed, since this metabolic route may 
reveal therapeutic points of action which may improve the pharmacological treatment of 
these patients. 
In addition to the above valuable metabolic information provided, this work also 
evaluated a new method for MVA (CCR-LDA) and the accuracy of RFs when employed for 
variable selection purposes. 
The CCR-LDA approach applied to our urinary and hepatic datasets showed excellent 
results for the classification of 1H NMR urinary and hepatic tissue profiles according to their 
disease class, and values for accuracy, sensitivity and specificity derived therefrom were 
equivalent to those obtained by alternative techniques such as RFs, GAs and SVMs. These 
results encourage the use of this technique for MVA and its inclusion in appropriate data 
analysis ‘toolboxes’ by metabolomics investigators. 
The combined RFs-RFE technique was evaluated as a strategy for variable selection 
and classification in a metabolomics context, as was previously performed for a microarray 
genetic analysis, and results acquired therefrom were compared with the variable selection 
method employed in our RFs model. We observed that despite being successful in 
classification tasks, it can reduce the number of variables to an extent where no relevant 
information can be extracted. Notwithstanding, the classification performance delivers high 
values for accuracy, and therefore with the whole ranking of variables after the completion 
of an appropriate number rounds of cross-validation, offers more information; furthermore, 
the ability of making decisions regarding the cut-off point for the number of variables lies 
with the investigator, and not on the performance of the variable selection algorithm. 
In summary, these 1H NMR-based metabolomics investigations have enabled the 
characterization of metabolites related to NP-C1 disease, providing a functional readout of 
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cellular disease biochemistry and possible biomarkers for its diagnosis. This metabolite 
profiling study has also revealed new discoveries linking cellular pathways to biological 
mechanisms, and hence increases our understanding of the pathophysiology associated with 
NP-C1 disease. 
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APENDIX 1: QUANTIFICATION OF MIGLUSTAT AND 1-O-VALPROIL-β-GLUCURONATE IN 
URINE SAMPLES COLLECTED FROM NP-C1 PATIENTS UNDERGOING MIGLUSTAT 
TREATMENT 
 
 MGS was quantified in those urine samples collected from NP-C1 patients undergoing 
treatment with this therapeutic agent via integration of the 0.93 - 0.97 ppm bucket intensity, 
which contains the resonance peak attributable to the MGS-CH3 (t, 0.95 ppm), and for 1-O-
valproyl-β-glucuronide quantification, the 5.53 - 5.57 (d, 0.55 ppm) ppm bucket was 
employed; the latter encompasses its CH-1 group from the glucuronide moiety. MGS integral 
values were expressed relative to either that of the TSP-(CH3)3 resonance (s, 0.00 ppm) 
bucket, i.e. -0.03 - 0.03 ppm, the concentration of which is known since it was added as an 
internal standard, or to that of Cn-CH2 (s, 4.04 ppm), for which the 4.02 - 4.10 ppm bucket 
was utilised. Calibration curves were constructed in the range of 0.00 - 5.00 mM MGS in 0.10 
M phosphate buffer (pH 7.10) as MGS-CH3:TSP-(CH3)3 ratios. Since 1-O-valproyl-β-
glucuronide standard was not commercially available, we could not construct a calibration 
curve for that agent. Lower limit of quantification (LLOQ) values for the 1H NMR analysis of 
MGS were estimated on the 400 MHz Leicester School of Pharmacy spectrometer via the 
repeated analysis of phosphate-buffered (pH 7.10) standard solutions of this drug, which 
ranged in concentration from 10.0 - 80.0 μM.  
 
Assay selectivity and matrix effects  
 To evaluate the accuracy of our quantification methodology based on the integration 
of selected resonance intensities, we investigated the matrix effects ascribable to those 
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resonances very close to the buckets employed for quantification. These resonances can 
interfere with those quantified, and therefore, generate inaccurate results. For this purpose, 
both blank or MGS-containing urine samples (collected from MGS-treated patients), were 
spiked with increasing concentrations of MGS (i.e. standard addition experiments involving 
the addition of final 0.16 - 0.83 and 1.13 - 5.00 mM levels of this agent), and then subjected 
to 1H NMR analysis. Matrix effects on the intensity of the 0.93 - 0.97 ppm bucket were 
investigated by comparisons of the integral value of this bucket expressed relative to that of 
a pre-added TSP internal standard and/or internal urinary Cn, to those of ‛neat’ MGS 
solutions prepared in 0.10 M phosphate buffer (pH 7.10) at corresponding concentrations. 
These effects were monitored via determinations of variabilities of the concentration values 
attained. A series of 12 urine samples were investigated in this manner. The 1H NMR 
resonance intensities of the 1-O-valproyl-β-glucuronide and Cn buckets selected were found 
not to be influenced by any such endogenous matrix effects. 
 
Precision and accuracy  
The within-, between-run precision (WRP and BRP respectively) and accuracy 
estimates of methods for the determination of MGS and 1-O-valproyl-β-glucuronide were 
evaluated on three separate days and five different quality control (QC) urine samples 
collected from NP-C1 patients treated with both MGS and valproate. An estimate of the BRP 
was obtained via the performance of a one-way (completely randomised design) ANOVA 
model for each sample tested, and employing analysis run (day) as the classification variable.  
 
𝑊𝑅𝑃 = 100% 𝑥 
√𝑀𝑆𝑤𝑖𝑡ℎ𝑖𝑛
𝑂𝑀
                                (A1) 
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Where MSwithin and OM represent the within-run mean square and overall mean 
values respectively. In order to estimate the BRP, 5 separate NP-C1 disease urine samples 
containing both 1H NMR-detectable MGS and 1-O-valproyl-β-glucuronide were selected and 
analysed in triplicate on each of 3 separate runs (days), and for each sample examined, the 
between-days and within-days mean square (MS) values were estimated.  
 
𝐵𝑅𝑃 = 100% 𝑥 
√
𝑀𝑆𝑏𝑒𝑡𝑤𝑒𝑒𝑛− 𝑀𝑆𝑤𝑖𝑡ℎ𝑖𝑛
𝑛
𝑂𝑀
                   (A2) 
 
Where MSbetween and n are the between-groups mean square value and the number 
of replicate observations within each daily run (n = 3) respectively. These parameters were 
computed using XLSTAT 2015 software (Addinsoft). For such ANOVA estimates, the 
‛between-run’ component of variance was found not to be statistically significant when 
tested against the ‛within-run’ one for each analyte and each sample analysed. The accuracy 
of analytical measurements was expressed as follows 
 
𝐴𝐶𝐶 = 100% 𝑥 
𝑚𝑒𝑎𝑛 𝑣𝑎𝑙𝑢𝑒−𝑛𝑜𝑚𝑖𝑛𝑎𝑙 𝑣𝑎𝑙𝑢𝑒
𝑛𝑜𝑚𝑖𝑛𝑎𝑙 𝑣𝑎𝑙𝑢𝑒
                  (A3) 
 
Quantification results 
MGS present in urine samples of patients treated with the standard dose of 200 mg 
(3 × daily) was quantified, yielding 208 ± 30 μmol MGS/mmol creatinine (mean ± SE, range 
78 - 680 μmol MGS/mmol Cn; n = 25). In view of a potential minor interfering matrix effect, 
these levels only include values >70 μmol MGS/mmol Cn.  
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The concentration of 1-O-valproyl-β-glucuronide in these patient’s samples was 
quantified, giving a value of 470 ± 61 μmol/mmol creatinine (mean ± SE, range 47 - 1,154 
μmol/mmol Cn, n = 14). 
 
Assay validation  
MGS and 1-O-valproyl-β-glucuronide assay selectivities, and investigations of the 
influence of matrix effects: Matrix effects arising from resonances close or overlaying those 
selected for MGS and 1-O-valproyl-β-glucuronide quantification did not affect the 
computation of these agents’ concentrations, although this effect presented some minor 
interferences at the lower urinary MGS concentrations. Non-MGS-treated urine samples to 
which 1.00, 2.00, 3.00, 4.00 and 5.00 mM was added (Figure A1) gave increased MGS 
concentration values of 4.4 - 8.8, 3.0 - 6.8, 2.2 - 5.5, 1.5 - 3.4 and 0.9 - 2.6% respectively 
(Table A1). 
 
 
Figure A1. Non-treated urine samples spiked with MGS: plot of 4 urine samples after being 
spiked with MGS displaying their integral ratio MGS-CH3:TSP-(CH3)3 vs. MGS final 
concentration. 
 
 
176 
 
 
Sample M30 Sample F28 Sample F29 Sample D 
8.86% 4.37% 2.21% 5.16% 
6.84% 2.99% 1.35% 3.80% 
5.30% 2.20% 1.21% 2.57% 
3.43% 1.51% 0.83% 1.81% 
2.59% 0.86% 0.55% 1.05% 
 
Table A1. Background contribution (matrix effect) to MGS concentration calculations on 
selected urine samples. 
 
Linearity of calibration curves and lower limit of quantification (LLOQ): Calibration 
curves were generated with (1/concentration) regression weightings via least-squares linear 
regression analysis of MGS/TSP buckets intensity ratios vs. MGS concentration. Standard 
curves exhibited excellent linearity throughout the Cn-normalised MGS concentration range 
of 0 - 5.00 mM for phosphate-buffered (urine-free) standards. For the standard addition 
calibrations, MGS/Cn intensity ratios v. added MGS concentration plots (Figure A2) also 
demonstrated excellent linearity (r = 0.985 - 0.990). The estimated regression coefficient 
(calibration gradient) of these linear relationships was 1.72 ± 0.17 (estimated value ± 95% 
CIs) for plots of the above ratio versus added MGS concentration. For the y intercept, such 
95% CIs always encompassed the zero concentration calibration point for plots obtained 
both with and without the inclusion of corresponding zero (blank) drug concentration data-
points for both analytes, despite the presence of the minor matrix effect for urinary MGS 
determinations. The limit of detection (LOD) value was determined as 10.0 μM for the 400 
MHz spectrometer utilised here; however, the achievement of a satisfactory signal-to-noise 
ratio for this concentration of MGS required 4096 spectral scans. Therefore, for a typical 
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bioanalytical 1H NMR run performed on a typical NP-C1 disease urine sample, which involves 
128 scans, a value of ca. 30 μM for this LOD value was determined. Absolute LLOQ values for 
the determination of MGS in phosphate-buffered aqueous solution and human urine 
samples were 50 and 80 μM respectively, and 80 M for that of 1-O-valproyl-β-glucuronide in 
human urine when analysed at an NMR operating frequency of 400 MHz.  
 
 
Figure A2. Standard addition experiments for 2 MGS-treated urine samples. 
 
Assay precision and accuracies: Corresponding assay precision parameters for 
determinations of MGS and 1-O-valproyl-β-glucuronide are provided in Table A2; these 
values were determined by 1H NMR analysis of the QC validation samples. The WRP of the 
assays were less than 6% and 4% for MGS and 1-O-valproyl-β-glucuronide respectively, and 
the BRP was less than 3% for both analytes on 5 QC samples. Assay accuracy was within the 
range of 95.3 - 107.4% for absolute urinary MGS concentrations which were > 0.10 mM, and 
95.0 - 108.9% for urinary Cn-normalised ones for values >70 μmol/mmol Cn.  
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MGS  
1-O-valproyl-β-
glucuronide 
Sample  WRP BRP  WRP BRP 
1  5.49% 2.31%  3.15% 1.18% 
2  2.26% 1.31%  3.11% 0.43% 
3  3.96% 0.65%  0.17% 0.96% 
4  2.71% 0.98%  0.20% 1.09% 
5  2.87% 2.02%  1.45% 2.48% 
Mean  3.46% 1.45%  1.62% 1.23% 
Table A2. Within-run (WRP) and between-run precision (BRP) estimates (%) for 1H NMR 
determinations of miglustat (MGS) and 1-O-valproyl-β-glucuronide. The buckets employed 
for these analytes were (a) 0.93 - 0.97 and (b) 5.53 - 5.57 ppm.  
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